

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
23 August 2001 (23.08.2001)

PCT

(10) International Publication Number
WO 01/60992 A2(51) International Patent Classification⁷: C12N 9/14, C07K 16/40, G01N 33/50, C12Q 1/42, C12N 5/10, 15/55, C12Q 1/68

(21) International Application Number: PCT/US01/04432

(22) International Filing Date: 12 February 2001 (12.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/182,194 14 February 2000 (14.02.2000) US
09/685,853 11 October 2000 (11.10.2000) US

(71) Applicant: PE CORPORATION (NY) [US/US]; Millman, Robert, A., 761 Main Avenue, Norwalk, CT 06859 (US).

(72) Inventors: WEI, Ming-Hui; Celera, 45 West Gude Drive, Rockville, MD 20850 (US). KETCHUM, Karen, A.; Celera, 45 West Gude Drive, Rockville, MD 20850 (US). DI FRANCESCO, Valentina; Celera, 45 West Gude Drive, Rockville, MD 20850 (US). BEASLEY, Ellen, M.; Celera, 45 West Gude Drive, Rockville, MD 20850 (US).

(74) Agent: MILLMAN, Robert, A.; Celera Genomics Corp., 45 West Gude Drive C2-4, Rockville, MD 20850 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: ISOLATED HUMAN PHOSPHATASE PROTEINS, NUCLEIC ACID MOLECULES ENCODING HUMAN PHOSPHATASE PROTEINS, AND USES THEREOF

1 MENVKLFPPS LPOCKEDAEVW YTYPPRREHQ KILPGFLFLGP-YSSAMKSLP
51 VLGKQGITHI1 ICRGQNEAMK FPKPFLQFLF KFLVLCIADP PVCHI1RFP
101 MTKREFIDGSL QMGGSVVLVHG MACISRSAAF VYAYIMTIG KYRDAPAYV
151 QKARFCINP AGCIVHQLEQY EASYLAKLTQ QMSPLOIQR SLVHSQTCG
201 SLMYRHEEED DFGTVHQVATA QNG

FEATURES:
Functional domains and key regions:

(1) P00C30005 PS00005 PKC_PHOSPHO_SITE
Protein kinase C phosphorylation site
201-203 SLK

(2) P00C00006 PS00006 CK2_PHOSPHO_SITE
Caspase kinase II phosphorylation site
205-208 TTKK

(3) P00C00007 PS00007 TTK_PPHOSPHO_SITE
Tyrosine kinase phosphorylation site
Number of matches: 2 1 15-23 KEDAKENTY 2 142-149 KYRDAPAY

(4) P00C30008 PS00008 MYRISTYL
N-myristoylation site
Number of matches: 2 1 123-128 GISRSA 2 197-202 GTTGS

Membrane spanning structure and domains:

Solex Begin End Score Certainty
1 123 143 0.626 Putative

BLAST Alignment to Top Hit:

Query: 1 MENVKLFPPS LPOCKEDAEVW YTYPPRREHQ KILPGFLFLGP-YSSAMKSLP VLONGCITHI 60
Subject: 1 MENVKLFPPS LPOCKEDAEVW YTYPPRREHQ KILPGFLFLGP-YSSAMKSLP VLONGCITHI 60

Query: 61 ICRGQNEAMK FPKPFLQFLF KFLVLCIADP PVCHI1RFP
Subject: 61 ICRGQNEAMK FPKPFLQFLF KFLVLCIADP PVCHI1RFP

Query: 121 MACISRSAAFVIAVIMETFQYRDAFATVQKARFCICMVAQEVWYQLOEYEAIYLAKLT 180
Subject: 121 MACISRSAAFVIAVIMETFQYRDAFATVQKARFCICMVAQEVWYQLOEYEAIYLAKLT 180

Query: 181 QMSPLOIQRSLVHSQTCG KARFCICMVAQEVWYQLOEYEAIYLAKLT 223
Subject: 181 QMSPLOIQRSLVHSQTCG KARFCICMVAQEVWYQLOEYEAIYLAKLT 223

Recent search results (Pfrag):
Scores for sequence family classification (score includes all domains):
Model Description Score E-value N

PF00782 Dual specificity phosphatase, catalytic doma 221.5 1.2e-62 1

WO 01/60992 A2



patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*

**ISOLATED HUMAN PHOSPHATASE PROTEINS, NUCLEIC ACID MOLECULES
ENCODING HUMAN PHOSPHATASE PROTEINS, AND USES THEREOF**

RELATED APPLICATIONS

5 The present application claims priority to provisional application U.S. Serial No. 60/182,194, filed February 14, 2000 (Atty. Docket CL000259-PROV) and U.S. Serial No. 09/685,853, filed October 11, 2000 (Atty. Docket CL000871).

FIELD OF THE INVENTION

10 The present invention is in the field of phosphatase proteins that are related to the protein tyrosine phosphatase subfamily, recombinant DNA molecules and protein production. The present invention specifically provides novel protein tyrosine phosphatase peptides and proteins and nucleic acid molecules encoding such peptide and protein molecules, all of which are useful in the development of human therapeutics and diagnostic compositions and
15 methods.

BACKGROUND OF THE INVENTION

Phosphatase proteins, especially the member of protein tyrosine phosphatase subfamily, are a major target for drug action and development. Accordingly, it is valuable to the field of
20 pharmaceutical development to identify and characterize previously unknown members protein tyrosine phosphatase subfamily. The present invention advances the state of the art by providing a previously unidentified human phosphatase proteins that have homology to members of the protein tyrosine phosphatase subfamily.

Protein Phosphatase

25 Cellular signal transduction is a fundamental mechanism whereby external stimuli that regulate diverse cellular processes are relayed to the interior of cells. The biochemical pathways through which signals are transmitted within cells comprise a circuitry of directly or functionally connected interactive proteins. One of the key biochemical mechanisms of signal transduction involves the reversible phosphorylation of certain residues on proteins.
30 The phosphorylation state of a protein may affect its conformation and/or enzymic activity as

well as its cellular location. The phosphorylation state of a protein is modified through the reciprocal actions of protein phosphatases (PKs) and protein phosphatases (PPs) at various specific amino acid residues.

Protein phosphorylation is the ubiquitous strategy used to control the activities of eukaryotic cells. It is estimated that 10% of the proteins active in a typical mammalian cell are phosphorylated. The high-energy phosphate that confers activation and is transferred from adenosine triphosphate molecules to protein-by-protein phosphatases is subsequently removed from the protein-by-protein phosphatases. In this way, the phosphatases control most cellular signaling events that regulate cell growth and differentiation, cell-to-cell contacts, the cell cycle, and oncogenesis.

The protein phosphorylation/dephosphorylation cycle is one of the major regulatory mechanisms employed by eukaryotic cells to control cellular activities. It is estimated that more than 10% of the active proteins in a typical mammalian cell are phosphorylated. During protein phosphorylation/dephosphorylation, phosphate groups are transferred from adenosine triphosphate molecules to protein-by-protein phosphatases and are removed from the protein-by-protein phosphatases.

Protein phosphatases function in cellular signaling events that regulate cell growth and differentiation, cell-to-cell contacts, the cell cycle, and oncogenesis. Three protein phosphatase families have been identified as evolutionarily distinct. These include the serine/threonine phosphatases, the protein tyrosine phosphatases, and the acid/alkaline phosphatases (Carboneau H. and Tonks N. K. (1992) *Annu. Rev. Cell Biol.* 8:463-93).

The serine/threonine phosphatases are either cytosolic or associated with a receptor. On the basis of their sensitivity to two thermostable proteins, inhibitors 1 and 2, and their divalent cation requirements, the serine/threonine phosphatases can be separated into four distinct groups, PP-I, PP-IIA, PP-IIB, and PP-IIC.

PP-I dephosphorylates many of the proteins phosphorylated by cyclic AMP-dependent protein phosphatase and is therefore an important regulator of many cyclic AMP mediated, hormone responses in cells. PP-IIA has broad specificity for control of cell cycle, growth and proliferation, and DNA replication and is the main phosphatase responsible for reversing the phosphorylations of serine/threonine phosphatases. PP-IIB, or calcineurin (Cn), is a Ca²⁺-activated phosphatase; it is involved in the regulation of such diverse cellular functions as ion channel regulation, neuronal transmission, gene transcription, muscle glycogen metabolism, and lymphocyte activation.

PP- IIC is a Mg^{++} -dependent phosphatase which participates in a wide variety of functions including regulating cyclic AMP-activated protein-phosphatase activity, Ca^{++} -dependent signal transduction, tRNA splicing, and signal transmission related to heat shock responses. PP- IIC is a monomeric protein with a molecular mass of about 40-45 kDa. One .alpha. and several .beta. isoforms of PP- IIC have been identified (Wenk, J. et al. (1992) FEBS Lett. 297: 135-138; Terasawa, T. et al. (1993) Arch. Biochem. Biophys. 307: 342-349; and Kato, S. et al. (1995) Arch. Biochem. Biophys. 318: 387-393).

The levels of protein phosphorylation required for normal cell growth and differentiation at any time are achieved through the coordinated action of PTKs and PPs. Depending on the cellular context, these two types of enzymes may either antagonize or cooperate with each other during signal transduction. An imbalance between these enzymes may impair normal cell functions leading to metabolic disorders and cellular transformation.

For example, insulin binding to the insulin receptor, which is a PTK, triggers a variety of metabolic and growth promoting effects such as glucose transport, biosynthesis of glycogen and fats, DNA synthesis, cell division and differentiation. Diabetes mellitus, which is characterized by insufficient or a lack of insulin signal transduction, can be caused by any abnormality at any step along the insulin signaling pathway. (Olefsky, 1988, in "Cecil Textbook of Medicine," 18th Ed., 2:1360-81).

It is also well known, for example, that the overexpression of PTKs, such as HER2, can play a decisive role in the development of cancer (Slamon et al., 1987, Science 235:77-82) and that antibodies capable of blocking the activity of this enzyme can abrogate tumor growth (Drebin et al., 1988, Oncogene 2:387-394). Blocking the signal transduction capability of tyrosine phosphatases such as Flk-1 and the PDGF receptor have been shown to block tumor growth in animal models (Millauer et al., 1994, Nature 367:577; Ueno et al., Science, 252:844-848).

Relatively less is known with respect to the direct role of phosphatases in signal transduction; PPs may play a role in human diseases. For example, ectopic expression of RPTP.alpha. produces a transformed phenotype in embryonic fibroblasts (Zheng et al., Nature 359:336-339), and overexpression of RPTP.alpha. in embryonal carcinoma cells causes the cells to differentiate into a cell type with neuronal phenotype (den Hertog et al., EMBO J 12:3789-3798). The gene for human RPTP.gamma. has been localized to chromosome 3p21 which is a segment frequently altered in renal and small lung carcinoma. Mutations may occur in the extracellular segment of RPTP.gamma. which renders a RPTP that no longer respond to external signals (LaForgia et al., Wary et al., 1993, Cancer Res

52:478-482). Mutations in the gene encoding PTP1C (also known as HCP, SHP) are the cause of the moth-eaten phenotype in mice that suffer severe immunodeficiency, and systemic autoimmune disease accompanied by hyperproliferation of macrophages (Schultz et al., 1993, *Cell* 73:1445-1454). PTP1D (also known as Syp or PTP2C) has been shown to bind 5 through SH2 domains to sites of phosphorylation in PDGFR, EGFR and insulin receptor substrate 1 (IRS-1). Reducing the activity of PTP1D by microinjection of anti-PTP1D antibody has been shown to block insulin or EGF-induced mitogenesis (Xiao et al., 1994, *J Biol Chem* 269:21244-21248).

10 The discovery of a new human protein phosphatase and the polynucleotides encoding it satisfies a need in the art by providing new compositions that are useful in the diagnosis, prevention and treatment of biological processes associated with abnormal or unwanted protein phosphorylation.

15 The phosphatase gene of the present invention can be expressed in yeast to identify possible interactors and substrates; this can be done by means of a complementation assay or a two-hybrid experiment. Artificially synthesized enzyme as well as derived peptides can be used to activate or inhibit cellular processes modulated by this phosphatase. Immunoassay or PCR may be used to measure the concentration of this protein and detect abnormally developing tissue or cancerous growth.

20 For a review of the phosphatase associated with the present invention see Wishart et al., *J Biol Chem* 1995 Nov 10;270(45):26782-5, Bjorge et al., *J Biol Chem* 2000 Sep 27; Harroch et al., *Mol Cell Biol* 2000 Oct;20(20):7706-15, Beghini et al., *Hum Mol Genet* 2000 Sep 22;9(15):2297-2304, Waddleton et al., *Anal Biochem* 2000 Oct 1;285(1):58-63.

SUMMARY OF THE INVENTION

25 The present invention is based in part on the identification of amino acid sequences of human phosphatase peptides and proteins that are related to the protein tyrosine phosphatase subfamily, as well as allelic variants and other mammalian orthologs thereof. These unique peptide sequences, and nucleic acid sequences that encode these peptides, can be used as models for the development of human therapeutic targets, aid in the identification of 30 therapeutic proteins, and serve as targets for the development of human therapeutic agents that modulate phosphatase activity in cells and tissues that express the phosphatase. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as

well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues.

DESCRIPTION OF THE FIGURE SHEETS

5 FIGURE 1 provides the nucleotide sequence of a cDNA molecule or transcript sequence that encodes the phosphatase protein of the present invention. (SEQ ID NO:1) In addition, structure and functional information is provided, such as ATG start, stop and tissue distribution, where available, that allows one to readily determine specific uses of inventions based on this molecular sequence. Experimental data as provided in Figure 1 indicates
10 expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues.

15 FIGURE 2 provides the predicted amino acid sequence of the phosphatase of the present invention. (SEQ ID NO:2) In addition structure and functional information such as protein family, function, and modification sites is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence.

20 FIGURE 3 provides genomic sequences that span the gene encoding the phosphatase protein of the present invention. (SEQ ID NO:3) In addition structure and functional information, such as intron/exon structure, promoter location, etc., is provided where available, allowing one to readily determine specific uses of inventions based on this molecular sequence. As illustrated in Figure 3, known SNP variations include G3114A, T4514G, A7570G, C11672G, A11897C, T14523C, C16586T, T16644C, A17969G, C18117T, C18518A, G19882A, A21465G, C21625T, C26291T, T28012C, T28030G, A33671C, A37703G, C39269G, -20999T, -4004A, and G20988-.

25

DETAILED DESCRIPTION OF THE INVENTION

General Description

30 The present invention is based on the sequencing of the human genome. During the sequencing and assembly of the human genome, analysis of the sequence information revealed previously unidentified fragments of the human genome that encode peptides that share structural and/or sequence homology to protein/peptide/domains identified and characterized within the art as being a phosphatase protein or part of a phosphatase protein

and are related to the protein tyrosine phosphatase subfamily. Utilizing these sequences, additional genomic sequences were assembled and transcript and/or cDNA sequences were isolated and characterized. Based on this analysis, the present invention provides amino acid sequences of human phosphatase peptides and proteins that are related to the protein tyrosine 5 phosphatase subfamily, nucleic acid sequences in the form of transcript sequences, cDNA sequences and/or genomic sequences that encode these phosphatase peptides and proteins, nucleic acid variation (allelic information), tissue distribution of expression, and information about the closest art known protein/peptide/domain that has structural or sequence homology to the phosphatase of the present invention.

10 In addition to being previously unknown, the peptides that are provided in the present invention are selected based on their ability to be used for the development of commercially important products and services. Specifically, the present peptides are selected based on homology and/or structural relatedness to known phosphatase proteins of the protein tyrosine phosphatase subfamily and the expression pattern observed. Experimental data as provided in 15 Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. The art has clearly established the commercial importance of members of this family of proteins and proteins that have expression patterns similar to that of the present 20 gene. Some of the more specific features of the peptides of the present invention, and the uses thereof, are described herein, particularly in the Background of the Invention and in the annotation provided in the Figures, and/or are known within the art for each of the known phosphatase family or subfamily of phosphatase proteins.

25 Specific Embodiments

Peptide Molecules

The present invention provides nucleic acid sequences that encode protein molecules that have been identified as being members of the phosphatase family of proteins and are related to the protein tyrosine phosphatase subfamily (protein sequences are provided in 30 Figure 2, transcript/cDNA sequences are provided in Figure 1 and genomic sequences are provided in Figure 3). The peptide sequences provided in Figure 2, as well as the obvious variants described herein, particularly allelic variants as identified herein and using the

information in Figure 3, will be referred herein as the phosphatase peptides of the present invention, phosphatase peptides, or peptides/proteins of the present invention.

The present invention provides isolated peptide and protein molecules that consist of, consist essentially of, or comprise the amino acid sequences of the phosphatase peptides

5 disclosed in the Figure 2, (encoded by the nucleic acid molecule shown in Figure 1, transcript/cDNA or Figure 3, genomic sequence), as well as all obvious variants of these peptides that are within the art to make and use. Some of these variants are described in detail below.

As used herein, a peptide is said to be "isolated" or "purified" when it is substantially 10 free of cellular material or free of chemical precursors or other chemicals. The peptides of the present invention can be purified to homogeneity or other degrees of purity. The level of purification will be based on the intended use. The critical feature is that the preparation allows for the desired function of the peptide, even if in the presence of considerable amounts of other components (the features of an isolated nucleic acid molecule is discussed below).

15 In some uses, "substantially free of cellular material" includes preparations of the peptide having less than about 30% (by dry weight) other proteins (i.e., contaminating protein), less than about 20% other proteins, less than about 10% other proteins, or less than about 5% other proteins. When the peptide is recombinantly produced, it can also be substantially free of culture medium, i.e., culture medium represents less than about 20% of the volume of the protein 20 preparation.

The language "substantially free of chemical precursors or other chemicals" includes preparations of the peptide in which it is separated from chemical precursors or other chemicals that are involved in its synthesis. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of the phosphatase peptide having 25 less than about 30% (by dry weight) chemical precursors or other chemicals, less than about 20% chemical precursors or other chemicals, less than about 10% chemical precursors or other chemicals, or less than about 5% chemical precursors or other chemicals.

The isolated phosphatase peptide can be purified from cells that naturally express it, purified from cells that have been altered to express it (recombinant), or synthesized using 30 known protein synthesis methods. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. For example, a nucleic acid molecule encoding the phosphatase peptide is cloned into an expression vector, the

In some uses, the fusion protein does not affect the activity of the phosphatase peptide *per se*. For example, the fusion protein can include, but is not limited to, enzymatic fusion proteins, for example beta-galactosidase fusions, yeast two-hybrid GAL fusions, poly-His fusions, MYC-tagged, HI-tagged and Ig fusions. Such fusion proteins, particularly poly-His fusions, can facilitate the purification of recombinant phosphatase peptide. In certain host cells (e.g., mammalian host cells), expression and/or secretion of a protein can be increased by using a heterologous signal sequence.

A chimeric or fusion protein can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different protein sequences are ligated together in-frame in accordance with conventional techniques. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and re-amplified to generate a chimeric gene sequence (see 15 Ausubel *et al.*, *Current Protocols in Molecular Biology*, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST protein). A phosphatase peptide-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the phosphatase peptide.

As mentioned above, the present invention also provides and enables obvious variants of 20 the amino acid sequence of the proteins of the present invention, such as naturally occurring mature forms of the peptide, allelic/sequence variants of the peptides, non-naturally occurring recombinantly derived variants of the peptides, and orthologs and paralogs of the peptides. Such variants can readily be generated using art-known techniques in the fields of recombinant nucleic acid technology and protein biochemistry. It is understood, however, that variants 25 exclude any amino acid sequences disclosed prior to the invention.

Such variants can readily be identified/made using molecular techniques and the sequence information disclosed herein. Further, such variants can readily be distinguished from other peptides based on sequence and/or structural homology to the phosphatase peptides of the present invention. The degree of homology/identity present will be based primarily on whether 30 the peptide is a functional variant or non-functional variant, the amount of divergence present in the paralog family and the evolutionary distance between the orthologs.

To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for

optimal alignment and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, at least 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the length of a reference sequence is aligned for comparison purposes. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are 5 then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking 10 into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity and similarity between two sequences can be accomplished using a mathematical algorithm. (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; 15 *Computer Analysis of Sequence Data, Part 1*, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needleman and Wunsch (*J. Mol. Biol.* (48):444-453 20 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blossom 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferred embodiment, the percent identity between two nucleotide sequences 25 is determined using the GAP program in the GCG software package (Devereux, J., *et al.*, *Nucleic Acids Res.* 12(1):387 (1984)) (available at <http://www.gcg.com>), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences is determined using the algorithm of E. Myers and W. Miller (CABIOS, 30 4:11-17 (1989)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

The nucleic acid and protein sequences of the present invention can further be used as a "query sequence" to perform a search against sequence databases to, for example, identify other family members or related sequences. Such searches can be performed using the

NBLAST and XBLAST programs (version 2.0) of Altschul, *et al.* (*J. Mol. Biol.* 215:403-10 (1990)). BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to the nucleic acid molecules of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to the proteins of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.* (*Nucleic Acids Res.* 25(17):3389-3402 (1997)). When utilizing BLAST and gapped BLAST programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used.

10 Full-length pre-processed forms, as well as mature processed forms, of proteins that comprise one of the peptides of the present invention can readily be identified as having complete sequence identity to one of the phosphatase peptides of the present invention as well as being encoded by the same genetic locus as the phosphatase peptide provided herein. As indicated by the data presented in Figure 3, the map position was determined to be on 15 chromosome 14 by ePCR, and confirmed with radiation hybrid mapping. As indicated by the data presented in Figure 3, the gene provided by the present invention encoding a novel phosphatase maps to public BAC AC AL139317.2, which is known to be located on human chromosome 14.

Allelic variants of a phosphatase peptide can readily be identified as being a human 20 protein having a high degree (significant) of sequence homology/identity to at least a portion of the phosphatase peptide as well as being encoded by the same genetic locus as the phosphatase peptide provided herein. Genetic locus can readily be determined based on the genomic information provided in Figure 3, such as the genomic sequence mapped to the reference human. As indicated by the data presented in Figure 3, the map position was determined to be on 25 chromosome 14 by ePCR, and confirmed with radiation hybrid mapping. As indicated by the data presented in Figure 3, the gene provided by the present invention encoding a novel phosphatase maps to public BAC AC AL139317.2, which is known to be located on human chromosome 14. As used herein, two proteins (or a region of the proteins) have significant homology when the amino acid sequences are typically at least about 70-80%, 80-90%, and 30 more typically at least about 90-95% or more homologous. A significantly homologous amino acid sequence, according to the present invention, will be encoded by a nucleic acid sequence that will hybridize to a phosphatase peptide encoding nucleic acid molecule under stringent conditions as more fully described below.

Figure 3 provides SNP information that has been found in a gene encoding the phosphatase protein of the present invention. The following variations were seen: G3114A, T4514G, A7570G, C11672G, A11897C, T14523C, C16586T, T16644C, A17969G, C18117T, C18518A, G19882A, A21465G, C21625T, C26291T, T28012C, T28030G, 5 A33671C, A37703G and C39269G as substitutions, -20999T, -4004A as insertions and G20988- deletion. The changes in the amino acid sequence that these SNPs cause can readily be determined using the universal genetic code and the protein sequence provided in Figure 2 as a base.

Paralogs of a phosphatase peptide can readily be identified as having some degree of 10 significant sequence homology/identity to at least a portion of the phosphatase peptide, as being encoded by a gene from humans, and as having similar activity or function. Two proteins will typically be considered paralogs when the amino acid sequences are typically at least about 60% or greater, and more typically at least about 70% or greater homology through a given region or domain. Such paralogs will be encoded by a nucleic acid sequence that will 15 hybridize to a phosphatase peptide encoding nucleic acid molecule under moderate to stringent conditions as more fully described below.

Orthologs of a phosphatase peptide can readily be identified as having some degree of significant sequence homology/identity to at least a portion of the phosphatase peptide as well as being encoded by a gene from another organism. Preferred orthologs will be isolated from 20 mammals, preferably primates, for the development of human therapeutic targets and agents. Such orthologs will be encoded by a nucleic acid sequence that will hybridize to a phosphatase peptide encoding nucleic acid molecule under moderate to stringent conditions, as more fully described below, depending on the degree of relatedness of the two organisms yielding the proteins.

25 Non-naturally occurring variants of the phosphatase peptides of the present invention can readily be generated using recombinant techniques. Such variants include, but are not limited to deletions, additions and substitutions in the amino acid sequence of the phosphatase peptide. For example, one class of substitutions are conserved amino acid substitution. Such substitutions are those that substitute a given amino acid in a phosphatase peptide by another 30 amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu, and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues Asp and Glu; substitution between the amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among the aromatic residues Phe and Tyr. Guidance concerning which

amino acid changes are likely to be phenotypically silent are found in Bowie *et al.*, *Science* 247:1306-1310 (1990).

Variant phosphatase peptides can be fully functional or can lack function in one or more activities, e.g. ability to bind substrate, ability to dephosphorylate substrate, ability to mediate 5 signaling, etc. Fully functional variants typically contain only conservative variation or variation in non-critical residues or in non-critical regions. Figure 2 provides the result of protein analysis and can be used to identify critical domains/regions. Functional variants can also contain substitution of similar amino acids that result in no change or an insignificant change in function. Alternatively, such substitutions may positively or negatively affect 10 function to some degree.

Non-functional variants typically contain one or more non-conservative amino acid substitutions, deletions, insertions, inversions, or truncation or a substitution, insertion, inversion, or deletion in a critical residue or critical region.

Amino acids that are essential for function can be identified by methods known in the 15 art, such as site-directed mutagenesis or alanine-scanning mutagenesis (Cunningham *et al.*, *Science* 244:1081-1085 (1989)), particularly using the results provided in Figure 2. The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant molecules are then tested for biological activity such as phosphatase activity or in assays 20 such as an *in vitro* proliferative activity. Sites that are critical for binding partner/substrate binding can also be determined by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith *et al.*, *J. Mol. Biol.* 224:899-904 (1992); de Vos *et al.* *Science* 255:306-312 (1992)).

The present invention further provides fragments of the phosphatase peptides, in addition 25 to proteins and peptides that comprise and consist of such fragments, particularly those comprising the residues identified in Figure 2. The fragments to which the invention pertains, however, are not to be construed as encompassing fragments that may be disclosed publicly prior to the present invention.

As used herein, a fragment comprises at least 8, 10, 12, 14, 16, or more contiguous 30 amino acid residues from a phosphatase peptide. Such fragments can be chosen based on the ability to retain one or more of the biological activities of the phosphatase peptide or could be chosen for the ability to perform a function, e.g. bind a substrate or act as an immunogen. Particularly important fragments are biologically active fragments, peptides that are, for example, about 8 or more amino acids in length. Such fragments will typically comprise a domain or motif of the phosphatase peptide, e.g., active site, a transmembrane domain or a

substrate-binding domain. Further, possible fragments include, but are not limited to, domain or motif containing fragments, soluble peptide fragments, and fragments containing immunogenic structures. Predicted domains and functional sites are readily identifiable by computer programs well known and readily available to those of skill in the art (e.g., PROSITE analysis). The

5 results of one such analysis are provided in Figure 2.

Polypeptides often contain amino acids other than the 20 amino acids commonly referred to as the 20 naturally occurring amino acids. Further, many amino acids, including the terminal amino acids, may be modified by natural processes, such as processing and other post-translational modifications, or by chemical modification techniques well known in the art.

10 Common modifications that occur naturally in phosphatase peptides are described in basic texts, detailed monographs, and the research literature, and they are well known to those of skill in the art (some of these features are identified in Figure 2).

Known modifications include, but are not limited to, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, 15 covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent crosslinks, formation of cystine, formation of pyroglutamate, formylation, gamma carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic 20 processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination.

Such modifications are well known to those of skill in the art and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, 25 hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as *Proteins - Structure and Molecular Properties*, 2nd Ed., T.E. Creighton, W. H. Freeman and Company, New York (1993). Many detailed reviews are available on this subject, such as by Wold, F., *Posttranslational Covalent Modification of Proteins*, B.C. Johnson, Ed., Academic Press, New York 1-12 (1983); Seifter *et al.* (*Meth. Enzymol.* 182: 626-646 (1990)) and Rattan *et* 30 *al.* (*Ann. N.Y. Acad. Sci.* 663:48-62 (1992)).

Accordingly, the phosphatase peptides of the present invention also encompass derivatives or analogs in which a substituted amino acid residue is not one encoded by the genetic code, in which a substituent group is included, in which the mature phosphatase peptide is fused with another compound, such as a compound to increase the half-life of the phosphatase

peptide, or in which the additional amino acids are fused to the mature phosphatase peptide, such as a leader or secretory sequence or a sequence for purification of the mature phosphatase peptide or a pro-protein sequence.

5 Protein/Peptide Uses

The proteins of the present invention can be used in substantial and specific assays related to the functional information provided in the Figures; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its binding partner or ligand) in biological 10 fluids; and as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state). Where the protein binds or potentially binds to another protein or ligand (such as, for example, in a phosphatase-effector protein interaction or phosphatase-ligand interaction), the protein can be used to identify the binding partner/ligand 15 so as to develop a system to identify inhibitors of the binding interaction. Any or all of these uses are capable of being developed into reagent grade or kit format for commercialization as commercial products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include "Molecular Cloning: A Laboratory Manual", 20 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

The potential uses of the peptides of the present invention are based primarily on the source of the protein as well as the class/action of the protein. For example, phosphatases 25 isolated from humans and their human/mammalian orthologs serve as targets for identifying agents for use in mammalian therapeutic applications, e.g. a human drug, particularly in modulating a biological or pathological response in a cell or tissue that expresses the phosphatase. Experimental data as provided in Figure 1 indicates that phosphatase proteins of the present invention are expressed in the human brain, heart and liver etc. Specifically, a 30 virtual northern blot shows expression in human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node. In addition, PCR-based tissue screening panel indicates expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid. A large percentage of

pharmaceutical agents are being developed that modulate the activity of phosphatase proteins, particularly members of the protein tyrosine phosphatase subfamily (see Background of the Invention). The structural and functional information provided in the Background and Figures provide specific and substantial uses for the molecules of the present invention,

5 particularly in combination with the expression information provided in Figure 1.

Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. Such uses can readily be determined using the

10 information provided herein, that which is known in the art, and routine experimentation.

The proteins of the present invention (including variants and fragments that may have been disclosed prior to the present invention) are useful for biological assays related to phosphatases that are related to members of the protein tyrosine phosphatase subfamily. Such assays involve any of the known phosphatase functions or activities or properties useful for

15 diagnosis and treatment of phosphatase-related conditions that are specific for the subfamily of protein tyrosine phosphatases that the one of the present invention belongs to, particularly in cells and tissues that express the phosphatase. Experimental data as provided in Figure 1 indicates that phosphatase proteins of the present invention are expressed in the human brain, heart and liver etc. Specifically, a virtual northern blot shows expression in human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node. In addition, PCR-based tissue screening panel indicates expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid.

20 The proteins of the present invention are also useful in drug screening assays, in cell-based or cell-free systems. Cell-based systems can be native, i.e., cells that normally express the phosphatase, as a biopsy or expanded in cell culture. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. In an alternate embodiment, cell-based assays involve recombinant host cells expressing the

30 phosphatase protein.

The polypeptides can be used to identify compounds that modulate phosphatase activity of the protein in its natural state or an altered form that causes a specific disease or pathology associated with the phosphatase. Both the phosphatases of the present invention and appropriate variants and fragments can be used in high-throughput screens to assay candidate compounds

for the ability to bind to the phosphatase. These compounds can be further screened against a functional phosphatase to determine the effect of the compound on the phosphatase activity.

Further, these compounds can be tested in animal or invertebrate systems to determine activity/effectiveness. Compounds can be identified that activate (agonist) or inactivate

5 (antagonist) the phosphatase to a desired degree.

Further, the proteins of the present invention can be used to screen a compound for the ability to stimulate or inhibit interaction between the phosphatase protein and a molecule that normally interacts with the phosphatase protein, e.g. a substrate or a component of the signal pathway that the phosphatase protein normally interacts (for example, another phosphatase).

10 Such assays typically include the steps of combining the phosphatase protein with a candidate compound under conditions that allow the phosphatase protein, or fragment, to interact with the target molecule, and to detect the formation of a complex between the protein and the target or to detect the biochemical consequence of the interaction with the phosphatase protein and the target, such as any of the associated effects of signal transduction such as protein
15 phosphorylation, cAMP turnover, and adenylate cyclase activation, etc.

Candidate compounds include, for example, 1) peptides such as soluble peptides, including Ig-tailed fusion peptides and members of random peptide libraries (see, e.g., Lam *et al.*, *Nature* 354:82-84 (1991); Houghten *et al.*, *Nature* 354:84-86 (1991)) and combinatorial chemistry-derived molecular libraries made of D- and/or L- configuration amino acids; 2)

20 phosphopeptides (e.g., members of random and partially degenerate, directed phosphopeptide libraries, see, e.g., Songyang *et al.*, *Cell* 72:767-778 (1993)); 3) antibodies (e.g., polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, and single chain antibodies as well as Fab, F(ab')₂, Fab expression library fragments, and epitope-binding fragments of antibodies); and 4) small organic and inorganic molecules (e.g., molecules obtained from combinatorial and natural
25 product libraries).

One candidate compound is a soluble fragment of the receptor that competes for substrate binding. Other candidate compounds include mutant phosphatases or appropriate fragments containing mutations that affect phosphatase function and thus compete for substrate.

Accordingly, a fragment that competes for substrate, for example with a higher affinity, or a

30 fragment that binds substrate but does not allow release, is encompassed by the invention.

The invention further includes other end point assays to identify compounds that modulate (stimulate or inhibit) phosphatase activity. The assays typically involve an assay of events in the signal transduction pathway that indicate phosphatase activity. Thus, the dephosphorylation of a substrate, activation of a protein, a change in the expression of genes that

are up- or down-regulated in response to the phosphatase protein dependent signal cascade can be assayed.

Any of the biological or biochemical functions mediated by the phosphatase can be used as an endpoint assay. These include all of the biochemical or biochemical/biological events

5 described herein, in the references cited herein, incorporated by reference for these endpoint assay targets, and other functions known to those of ordinary skill in the art or that can be readily identified using the information provided in the Figures, particularly Figure 2. Specifically, a biological function of a cell or tissues that expresses the phosphatase can be assayed.

Experimental data as provided in Figure 1 indicates that phosphatase proteins of the present 10 invention are expressed in the human brain, heart and liver etc. Specifically, a virtual northern blot shows expression in human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node. In addition, PCR-based tissue screening panel indicates expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid.

15 Binding and/or activating compounds can also be screened by using chimeric phosphatase proteins in which the amino terminal extracellular domain, or parts thereof, the entire transmembrane domain or subregions, such as any of the seven transmembrane segments or any of the intracellular or extracellular loops and the carboxy terminal intracellular domain, or parts thereof, can be replaced by heterologous domains or subregions. For example, a substrate-binding region can be used that interacts with a different substrate than that which is recognized 20 by the native phosphatase. Accordingly, a different set of signal transduction components is available as an end-point assay for activation. This allows for assays to be performed in other than the specific host cell from which the phosphatase is derived.

The proteins of the present invention are also useful in competition binding assays in 25 methods designed to discover compounds that interact with the phosphatase (e.g. binding partners and/or ligands). Thus, a compound is exposed to a phosphatase polypeptide under conditions that allow the compound to bind or to otherwise interact with the polypeptide. Soluble phosphatase polypeptide is also added to the mixture. If the test compound interacts with the soluble phosphatase polypeptide, it decreases the amount of complex formed or activity 30 from the phosphatase target. This type of assay is particularly useful in cases in which compounds are sought that interact with specific regions of the phosphatase. Thus, the soluble polypeptide that competes with the target phosphatase region is designed to contain peptide sequences corresponding to the region of interest.

To perform cell free drug screening assays, it is sometimes desirable to immobilize either the phosphatase protein, or fragment, or its target molecule to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay.

5 Techniques for immobilizing proteins on matrices can be used in the drug screening assays. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the cell lysates (e.g., 35 S-labeled)

10 and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of phosphatase-

15 binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques. For example, either the polypeptide or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin using techniques well known in the art. Alternatively, antibodies reactive with the protein but which do not interfere with binding of the protein to its target molecule can be derivatized to the wells of the plate, and the protein

20 trapped in the wells by antibody conjugation. Preparations of a phosphatase-binding protein and a candidate compound are incubated in the phosphatase protein-presenting wells and the amount of complex trapped in the well can be quantitated. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include

25 immunodetection of complexes using antibodies reactive with the phosphatase protein target molecule, or which are reactive with phosphatase protein and compete with the target molecule, as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the target molecule.

Agents that modulate one of the phosphatases of the present invention can be identified using one or more of the above assays, alone or in combination. It is generally preferable to use

30 a cell-based or cell free system first and then confirm activity in an animal or other model system. Such model systems are well known in the art and can readily be employed in this context.

Modulators of phosphatase protein activity identified according to these drug screening assays can be used to treat a subject with a disorder mediated by the kinase pathway, by treating

cells or tissues that express the phosphatase. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. These methods of 5 treatment include the steps of administering a modulator of phosphatase activity in a pharmaceutical composition to a subject in need of such treatment, the modulator being identified as described herein.

In yet another aspect of the invention, the phosphatase proteins can be used as "bait proteins" in a two-hybrid assay or three-hybrid assay (see, e.g., U.S. Patent No. 5,283,317; 10 Zervos *et al.* (1993) *Cell* 72:223-232; Madura *et al.* (1993) *J. Biol. Chem.* 268:12046-12054; Bartel *et al.* (1993) *Biotechniques* 14:920-924; Iwabuchi *et al.* (1993) *Oncogene* 8:1693-1696; and Brent WO94/10300), to identify other proteins, which bind to or interact with the phosphatase and are involved in phosphatase activity. Such phosphatase-binding proteins are also likely to be involved in the propagation of signals by the phosphatase proteins or 15 phosphatase targets as, for example, downstream elements of a kinase-mediated signaling pathway. Alternatively, such phosphatase-binding proteins are likely to be phosphatase inhibitors.

The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes 20 two different DNA constructs. In one construct, the gene that codes for a phosphatase protein is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein ("prey" or "sample") is fused to a gene that codes for the activation domain of the known transcription factor. If the "bait" and the "prey" proteins are 25 able to interact, *in vivo*, forming a phosphatase-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) which is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor 30 can be isolated and used to obtain the cloned gene which encodes the protein which interacts with the phosphatase protein.

This invention further pertains to novel agents identified by the above-described screening assays. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model. For example, an agent

identified as described herein (e.g., a phosphatase-modulating agent, an antisense phosphatase nucleic acid molecule, a phosphatase-specific antibody, or a phosphatase-binding partner) can be used in an animal or other model to determine the efficacy, toxicity, or side effects of treatment with such an agent. Alternatively, an agent identified as described 5 herein can be used in an animal or other model to determine the mechanism of action of such an agent. Furthermore, this invention pertains to uses of novel agents identified by the above-described screening assays for treatments as described herein.

The phosphatase proteins of the present invention are also useful to provide a target for diagnosing a disease or predisposition to disease mediated by the peptide. Accordingly, the 10 invention provides methods for detecting the presence, or levels of, the protein (or encoding mRNA) in a cell, tissue, or organism. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. The method 15 involves contacting a biological sample with a compound capable of interacting with the phosphatase protein such that the interaction can be detected. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

One agent for detecting a protein in a sample is an antibody capable of selectively 20 binding to protein. A biological sample includes tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject.

The peptides of the present invention also provide targets for diagnosing active protein activity, disease, or predisposition to disease, in a patient having a variant peptide, particularly 25 activities and conditions that are known for other members of the family of proteins to which the present one belongs. Thus, the peptide can be isolated from a biological sample and assayed for the presence of a genetic mutation that results in aberrant peptide. This includes amino acid 30 substitution, deletion, insertion, rearrangement, (as the result of aberrant splicing events), and inappropriate post-translational modification. Analytic methods include altered electrophoretic mobility, altered tryptic peptide digest, altered phosphatase activity in cell-based or cell-free assay, alteration in substrate or antibody-binding pattern, altered isoelectric point, direct amino acid sequencing, and any other of the known assay techniques useful for detecting mutations in a protein. Such an assay can be provided in a single detection format or a multi-detection format such as an antibody chip array.

In vitro techniques for detection of peptide include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations and immunofluorescence using a

detection reagent, such as an antibody or protein binding agent. Alternatively, the peptide can be detected *in vivo* in a subject by introducing into the subject a labeled anti-peptide antibody or other types of detection agent. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging

5 techniques. Particularly useful are methods that detect the allelic variant of a peptide expressed in a subject and methods which detect fragments of a peptide in a sample.

The peptides are also useful in pharmacogenomic analysis. Pharmacogenomics deal with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See, e.g., Eichelbaum, M. (*Clin. Exp. Pharmacol. Physiol.* 23(10-11):983-985 (1996)), and Linder, M.W. (*Clin. Chem.* 43(2):254-266 (1997)). The clinical outcomes of these variations result in severe toxicity of therapeutic drugs in certain individuals or therapeutic failure of drugs in certain individuals as a result of individual variation in metabolism. Thus, the genotype of the individual can determine the way a therapeutic compound acts on the body or the way the body metabolizes the compound.

10 Further, the activity of drug metabolizing enzymes effects both the intensity and duration of drug action. Thus, the pharmacogenomics of the individual permit the selection of effective compounds and effective dosages of such compounds for prophylactic or therapeutic treatment based on the individual's genotype. The discovery of genetic polymorphisms in some drug metabolizing enzymes has explained why some patients do not obtain the expected drug effects,

15 show an exaggerated drug effect, or experience serious toxicity from standard drug dosages. Polymorphisms can be expressed in the phenotype of the extensive metabolizer and the phenotype of the poor metabolizer. Accordingly, genetic polymorphism may lead to allelic protein variants of the phosphatase protein in which one or more of the phosphatase functions in one population is different from those in another population. The peptides thus allow a target to

20 ascertain a genetic predisposition that can affect treatment modality. Thus, in a ligand-based treatment, polymorphism may give rise to amino terminal extracellular domains and/or other substrate-binding regions that are more or less active in substrate binding, and phosphatase activation. Accordingly, substrate dosage would necessarily be modified to maximize the therapeutic effect within a given population containing a polymorphism. As an alternative to

25 genotyping, specific polymorphic peptides could be identified.

The peptides are also useful for treating a disorder characterized by an absence of, inappropriate, or unwanted expression of the protein. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human

brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. Accordingly, methods for treatment include the use of the phosphatase protein or fragments.

Antibodies

5 The invention also provides antibodies that selectively bind to one of the peptides of the present invention, a protein comprising such a peptide, as well as variants and fragments thereof. As used herein, an antibody selectively binds a target peptide when it binds the target peptide and does not significantly bind to unrelated proteins. An antibody is still considered to selectively bind a peptide even if it also binds to other proteins that are not substantially 10 homologous with the target peptide so long as such proteins share homology with a fragment or domain of the peptide target of the antibody. In this case, it would be understood that antibody binding to the peptide is still selective despite some degree of cross-reactivity.

As used herein, an antibody is defined in terms consistent with that recognized within the art: they are multi-subunit proteins produced by a mammalian organism in response to an 15 antigen challenge. The antibodies of the present invention include polyclonal antibodies and monoclonal antibodies, as well as fragments of such antibodies, including, but not limited to, Fab or $F(ab')_2$, and Fv fragments.

Many methods are known for generating and/or identifying antibodies to a given target peptide. Several such methods are described by Harlow, *Antibodies*, Cold Spring Harbor Press, 20 (1989).

In general, to generate antibodies, an isolated peptide is used as an immunogen and is administered to a mammalian organism, such as a rat, rabbit or mouse. The full-length protein, an antigenic peptide fragment or a fusion protein can be used. Particularly important fragments are those covering functional domains, such as the domains identified in Figure 2, and domain of 25 sequence homology or divergence amongst the family, such as those that can readily be identified using protein alignment methods and as presented in the Figures.

Antibodies are preferably prepared from regions or discrete fragments of the phosphatase proteins. Antibodies can be prepared from any region of the peptide as described herein. However, preferred regions will include those involved in function/activity 30 and/or phosphatase/binding partner interaction. Figure 2 can be used to identify particularly important regions while sequence alignment can be used to identify conserved and unique sequence fragments.

An antigenic fragment will typically comprise at least 8 contiguous amino acid residues. The antigenic peptide can comprise, however, at least 10, 12, 14, 16 or more amino acid residues. Such fragments can be selected on a physical property, such as fragments correspond to regions that are located on the surface of the protein, e.g., hydrophilic regions or can be selected based on sequence uniqueness (see Figure 2).

5 Detection on an antibody of the present invention can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include 10 horseradish peroxidase, alkaline phosphatase, β -galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include 15 luciferase, luciferin, and aequorin, and examples of suitable radioactive material include ^{125}I , ^{131}I , ^{35}S or ^3H .

Antibody Uses

The antibodies can be used to isolate one of the proteins of the present invention by 20 standard techniques, such as affinity chromatography or immunoprecipitation. The antibodies can facilitate the purification of the natural protein from cells and recombinantly produced protein expressed in host cells. In addition, such antibodies are useful to detect the presence of one of the proteins of the present invention in cells or tissues to determine the pattern of expression of the protein among various tissues in an organism and over the course of normal 25 development. Experimental data as provided in Figure 1 indicates that phosphatase proteins of the present invention are expressed in the human brain, heart and liver etc. Specifically, a virtual northern blot shows expression in human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node. In addition, PCR-based tissue screening panel indicates expression in human fetal brain, human brain, human heart, human liver, human lung, 30 human placenta, and human thyroid. Further, such antibodies can be used to detect protein *in situ*, *in vitro*, or in a cell lysate or supernatant in order to evaluate the abundance and pattern of expression. Also, such antibodies can be used to assess abnormal tissue distribution or abnormal

expression during development or progression of a biological condition. Antibody detection of circulating fragments of the full length protein can be used to identify turnover.

Further, the antibodies can be used to assess expression in disease states such as in active stages of the disease or in an individual with a predisposition toward disease related to the 5 protein's function. When a disorder is caused by an inappropriate tissue distribution, developmental expression, level of expression of the protein, or expressed/processed form, the antibody can be prepared against the normal protein. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human 10 brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. If a disorder is characterized by a specific mutation in the protein, antibodies specific for this mutant protein can be used to assay for the presence of the specific mutant protein.

The antibodies can also be used to assess normal and aberrant subcellular localization of 15 cells in the various tissues in an organism. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. The diagnostic uses can be applied, not only in genetic testing, but also in monitoring a treatment modality. Accordingly, where treatment is ultimately aimed at correcting expression level or the presence 20 of aberrant sequence and aberrant tissue distribution or developmental expression, antibodies directed against the protein or relevant fragments can be used to monitor therapeutic efficacy.

Additionally, antibodies are useful in pharmacogenomic analysis. Thus, antibodies prepared against polymorphic proteins can be used to identify individuals that require modified treatment modalities. The antibodies are also useful as diagnostic tools as an immunological 25 marker for aberrant protein analyzed by electrophoretic mobility, isoelectric point, tryptic peptide digest, and other physical assays known to those in the art.

The antibodies are also useful for tissue typing. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human 30 brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. Thus, where a specific protein has been correlated with expression in a specific tissue, antibodies that are specific for this protein can be used to identify a tissue type.

The antibodies are also useful for inhibiting protein function, for example, blocking the binding of the phosphatase peptide to a binding partner such as a substrate. These uses can also

be applied in a therapeutic context in which treatment involves inhibiting the protein's function. An antibody can be used, for example, to block binding, thus modulating (agonizing or antagonizing) the peptides activity. Antibodies can be prepared against specific fragments containing sites required for function or against intact protein that is associated with a cell or cell membrane. See Figure 2 for structural information relating to the proteins of the present invention.

The invention also encompasses kits for using antibodies to detect the presence of a protein in a biological sample. The kit can comprise antibodies such as a labeled or labelable antibody and a compound or agent for detecting protein in a biological sample; means for determining the amount of protein in the sample; means for comparing the amount of protein in the sample with a standard; and instructions for use. Such a kit can be supplied to detect a single protein or epitope or can be configured to detect one of a multitude of epitopes, such as in an antibody detection array. Arrays are described in detail below for nucleic acid arrays and similar methods have been developed for antibody arrays.

15 Nucleic Acid Molecules

The present invention further provides isolated nucleic acid molecules that encode a phosphatase peptide or protein of the present invention (cDNA, transcript and genomic sequence). Such nucleic acid molecules will consist of, consist essentially of, or comprise a nucleotide sequence that encodes one of the phosphatase peptides of the present invention, an allelic variant thereof, or an ortholog or paralog thereof.

As used herein, an "isolated" nucleic acid molecule is one that is separated from other nucleic acid present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. However, there can be some flanking nucleotide sequences, for example up to about 5KB, 4KB, 3KB, 2KB, or 1KB or less, particularly contiguous peptide encoding sequences and peptide encoding sequences within the same gene but separated by introns in the genomic sequence. The important point is that the nucleic acid is isolated from remote and unimportant flanking sequences such that it can be subjected to the specific manipulations described herein such as recombinant expression, preparation of probes and primers, and other uses specific to the nucleic acid sequences.

Moreover, an "isolated" nucleic acid molecule, such as a transcript/cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by

recombinant techniques, or chemical precursors or other chemicals when chemically synthesized. However, the nucleic acid molecule can be fused to other coding or regulatory sequences and still be considered isolated.

For example, recombinant DNA molecules contained in a vector are considered isolated.

- 5 Further examples of isolated DNA molecules include recombinant DNA molecules maintained in heterologous host cells or purified (partially or substantially) DNA molecules in solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of the isolated DNA molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically.
- 10 Accordingly, the present invention provides nucleic acid molecules that consist of the nucleotide sequence shown in Figure 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NO:2. A nucleic acid molecule consists of a nucleotide sequence when the nucleotide sequence is the complete nucleotide sequence of the nucleic acid molecule.
- 15 The present invention further provides nucleic acid molecules that consist essentially of the nucleotide sequence shown in Figure 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NO:2. A nucleic acid molecule consists essentially of a nucleotide sequence when such a nucleotide sequence is present with only a few additional nucleic acid residues in the final nucleic acid molecule.
- 20 The present invention further provides nucleic acid molecules that comprise the nucleotide sequences shown in Figure 1 or 3 (SEQ ID NO:1, transcript sequence and SEQ ID NO:3, genomic sequence), or any nucleic acid molecule that encodes the protein provided in Figure 2, SEQ ID NO:2. A nucleic acid molecule comprises a nucleotide sequence when the nucleotide sequence is at least part of the final nucleotide sequence of the nucleic acid molecule.
- 25 In such a fashion, the nucleic acid molecule can be only the nucleotide sequence or have additional nucleic acid residues, such as nucleic acid residues that are naturally associated with it or heterologous nucleotide sequences. Such a nucleic acid molecule can have a few additional nucleotides or can comprises several hundred or more additional nucleotides. A brief
- 30 description of how various types of these nucleic acid molecules can be readily made/isolated is provided below.

In Figures 1 and 3, both coding and non-coding sequences are provided. Because of the source of the present invention, humans genomic sequence (Figure 3) and cDNA/transcript sequences (Figure 1), the nucleic acid molecules in the Figures will contain

genomic intronic sequences, 5' and 3' non-coding sequences, gene regulatory regions and non-coding intergenic sequences. In general such sequence features are either noted in Figures 1 and 3 or can readily be identified using computational tools known in the art. As discussed below, some of the non-coding regions, particularly gene regulatory elements such 5 as promoters, are useful for a variety of purposes, e.g. control of heterologous gene expression, target for identifying gene activity modulating compounds, and are particularly claimed as fragments of the genomic sequence provided herein.

The isolated nucleic acid molecules can encode the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature peptide (when the 10 mature form has more than one peptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, facilitate protein trafficking, prolong or shorten protein half-life or facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in situ*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

15 As mentioned above, the isolated nucleic acid molecules include, but are not limited to, the sequence encoding the phosphatase peptide alone, the sequence encoding the mature peptide and additional coding sequences, such as a leader or secretory sequence (e.g., a pre-pro or pro-protein sequence), the sequence encoding the mature peptide, with or without the additional coding sequences, plus additional non-coding sequences, for example introns and non-coding 5' 20 and 3' sequences such as transcribed but non-translated sequences that play a role in transcription, mRNA processing (including splicing and polyadenylation signals), ribosome binding and stability of mRNA. In addition, the nucleic acid molecule may be fused to a marker sequence encoding, for example, a peptide that facilitates purification.

Isolated nucleic acid molecules can be in the form of RNA, such as mRNA, or in the 25 form DNA, including cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The nucleic acid, especially DNA, can be double-stranded or single-stranded. Single-stranded nucleic acid can be the coding strand (sense strand) or the non-coding strand (anti-sense strand).

The invention further provides nucleic acid molecules that encode fragments of the 30 peptides of the present invention as well as nucleic acid molecules that encode obvious variants of the phosphatase proteins of the present invention that are described above. Such nucleic acid molecules may be naturally occurring, such as allelic variants (same locus), paralogs (different locus), and orthologs (different organism), or may be constructed by recombinant DNA methods or by chemical synthesis. Such non-naturally occurring variants may be made by mutagenesis

techniques, including those applied to nucleic acid molecules, cells, or organisms. Accordingly, as discussed above, the variants can contain nucleotide substitutions, deletions, inversions and insertions. Variation can occur in either or both the coding and non-coding regions. The variations can produce both conservative and non-conservative amino acid substitutions.

5 The present invention further provides non-coding fragments of the nucleic acid molecules provided in Figures 1 and 3. Preferred non-coding fragments include, but are not limited to, promoter sequences, enhancer sequences, gene modulating sequences and gene termination sequences. Such fragments are useful in controlling heterologous gene expression and in developing screens to identify gene-modulating agents. A promoter can readily be
10 identified as being 5' to the ATG start site in the genomic sequence provided in Figure 3.

A fragment comprises a contiguous nucleotide sequence greater than 12 or more nucleotides. Further, a fragment could at least 30, 40, 50, 100, 250 or 500 nucleotides in length. The length of the fragment will be based on its intended use. For example, the fragment can encode epitope bearing regions of the peptide, or can be useful as DNA probes and primers.

15 Such fragments can be isolated using the known nucleotide sequence to synthesize an oligonucleotide probe. A labeled probe can then be used to screen a cDNA library, genomic DNA library, or mRNA to isolate nucleic acid corresponding to the coding region. Further, primers can be used in PCR reactions to clone specific regions of gene.

A probe/primer typically comprises substantially a purified oligonucleotide or
20 oligonucleotide pair. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 20, 25, 40, 50 or more consecutive nucleotides.

Orthologs, homologs, and allelic variants can be identified using methods well known in the art. As described in the Peptide Section, these variants comprise a nucleotide sequence
25 encoding a peptide that is typically 60-70%, 70-80%, 80-90%, and more typically at least about 90-95% or more homologous to the nucleotide sequence shown in the Figure sheets or a fragment of this sequence. Such nucleic acid molecules can readily be identified as being able to hybridize under moderate to stringent conditions, to the nucleotide sequence shown in the Figure sheets or a fragment of the sequence. Allelic variants can readily be determined by
30 genetic locus of the encoding gene. As indicated by the data presented in Figure 3, the map position was determined to be on chromosome 14 by ePCR, and confirmed with radiation hybrid mapping. As indicated by the data presented in Figure 3, the gene provided by the present invention encoding a novel phosphatase maps to public BAC AC AL139317.2, which is known to be located on human chromosome 14.

Figure 3 provides SNP information that has been found in a gene encoding the phosphatase protein of the present invention. The following variations were seen: G3114A, T4514G, A7570G, C11672G, A11897C, T14523C, C16586T, T16644C, A17969G, C18117T, C18518A, G19882A, A21465G, C21625T, C26291T, T28012C, T28030G, A33671C;

5 A37703G and C39269G as substitutions, -20999T, -4004A as insertions and G20988- deletion. The changes in the amino acid sequence that these SNPs cause can readily be determined using the universal genetic code and the protein sequence provided in Figure 2 as a base.

As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences encoding a peptide 10 at least 60-70% homologous to each other typically remain hybridized to each other. The conditions can be such that sequences at least about 60%, at least about 70%, or at least about 80% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those skilled in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. One example of stringent 15 hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65C. Examples of moderate to low stringency hybridization conditions are well known in the art.

Nucleic Acid Molecule Uses

20 The nucleic acid molecules of the present invention are useful for probes, primers, chemical intermediates, and in biological assays. The nucleic acid molecules are useful as a hybridization probe for messenger RNA, transcript/cDNA and genomic DNA to isolate full-length cDNA and genomic clones encoding the peptide described in Figure 2 and to isolate cDNA and genomic clones that correspond to variants (alleles, orthologs, etc.) producing the 25 same or related peptides shown in Figure 2. As illustrated in Figure 3, known SNP variations include G3114A, T4514G, A7570G, C11672G, A11897C, T14523C, C16586T, T16644C, A17969G, C18117T, C18518A, G19882A, A21465G, C21625T, C26291T, T28012C, T28030G, A33671C, A37703G, C39269G, -20999T, -4004A, and G20988-.

30 The probe can correspond to any sequence along the entire length of the nucleic acid molecules provided in the Figures. Accordingly, it could be derived from 5' noncoding regions, the coding region, and 3' noncoding regions. However, as discussed, fragments are not to be construed as encompassing fragments disclosed prior to the present invention.

The nucleic acid molecules are also useful as primers for PCR to amplify any given region of a nucleic acid molecule and are useful to synthesize antisense molecules of desired length and sequence.

The nucleic acid molecules are also useful for constructing recombinant vectors. Such 5 vectors include expression vectors that express a portion of, or all of, the peptide sequences. Vectors also include insertion vectors, used to integrate into another nucleic acid molecule sequence, such as into the cellular genome, to alter *in situ* expression of a gene and/or gene product. For example, an endogenous coding sequence can be replaced via homologous recombination with all or part of the coding region containing one or more specifically 10 introduced mutations.

The nucleic acid molecules are also useful for expressing antigenic portions of the proteins.

The nucleic acid molecules are also useful as probes for determining the chromosomal positions of the nucleic acid molecules by means of *in situ* hybridization methods. As indicated 15 by the data presented in Figure 3, the map position was determined to be on chromosome 14 by ePCR, and confirmed with radiation hybrid mapping. As indicated by the data presented in Figure 3, the gene provided by the present invention encoding a novel phosphatase maps to public BAC AC AL139317.2, which is known to be located on human chromosome 14.

The nucleic acid molecules are also useful in making vectors containing the gene 20 regulatory regions of the nucleic acid molecules of the present invention.

The nucleic acid molecules are also useful for designing ribozymes corresponding to all, or a part, of the mRNA produced from the nucleic acid molecules described herein.

The nucleic acid molecules are also useful for making vectors that express part, or all, of the peptides.

25 The nucleic acid molecules are also useful for constructing host cells expressing a part, or all, of the nucleic acid molecules and peptides.

The nucleic acid molecules are also useful for constructing transgenic animals expressing all, or a part, of the nucleic acid molecules and peptides.

30 The nucleic acid molecules are also useful as hybridization probes for determining the presence, level, form and distribution of nucleic acid expression. Experimental data as provided in Figure 1 indicates that phosphatase proteins of the present invention are expressed in the human brain, heart and liver etc. Specifically, a virtual northern blot shows expression in human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node. In addition, PCR-based tissue screening panel indicates expression in human fetal brain,

human brain, human heart, human liver, human lung, human placenta, and human thyroid. Accordingly, the probes can be used to detect the presence of, or to determine levels of, a specific nucleic acid molecule in cells, tissues, and in organisms. The nucleic acid whose level is determined can be DNA or RNA. Accordingly, probes corresponding to the peptides 5 described herein can be used to assess expression and/or gene copy number in a given cell, tissue, or organism. These uses are relevant for diagnosis of disorders involving an increase or decrease in phosphatase protein expression relative to normal results.

10 *In vitro* techniques for detection of mRNA include Northern hybridizations and *in situ* hybridizations. *In vitro* techniques for detecting DNA includes Southern hybridizations and *in situ* hybridization.

15 Probes can be used as a part of a diagnostic test kit for identifying cells or tissues that express a phosphatase protein, such as by measuring a level of a phosphatase-encoding nucleic acid in a sample of cells from a subject e.g., mRNA or genomic DNA, or determining if a phosphatase gene has been mutated. Experimental data as provided in Figure 1 indicates that phosphatase proteins of the present invention are expressed in the human brain, heart and liver etc. Specifically, a virtual northern blot shows expression in human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node. In addition, PCR-based tissue screening panel indicates expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid.

20 Nucleic acid expression assays are useful for drug screening to identify compounds that modulate phosphatase nucleic acid expression.

25 The invention thus provides a method for identifying a compound that can be used to treat a disorder associated with nucleic acid expression of the phosphatase gene, particularly biological and pathological processes that are mediated by the phosphatase in cells and tissues that express it. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues. The method typically includes assaying the ability of the compound to modulate the expression of the phosphatase nucleic acid and thus 30 identifying a compound that can be used to treat a disorder characterized by undesired phosphatase nucleic acid expression. The assays can be performed in cell-based and cell-free systems. Cell-based assays include cells naturally expressing the phosphatase nucleic acid or recombinant cells genetically engineered to express specific nucleic acid sequences.

The assay for phosphatase nucleic acid expression can involve direct assay of nucleic acid levels, such as mRNA levels, or on collateral compounds involved in the signal pathway. Further, the expression of genes that are up- or down-regulated in response to the phosphatase protein signal pathway can also be assayed. In this embodiment the regulatory regions of these 5 genes can be operably linked to a reporter gene such as luciferase.

Thus, modulators of phosphatase gene expression can be identified in a method wherein a cell is contacted with a candidate compound and the expression of mRNA determined. The level of expression of phosphatase mRNA in the presence of the candidate compound is compared to the level of expression of phosphatase mRNA in the absence of the candidate 10 compound. The candidate compound can then be identified as a modulator of nucleic acid expression based on this comparison and be used, for example to treat a disorder characterized by aberrant nucleic acid expression. When expression of mRNA is statistically significantly greater in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of nucleic acid expression. When nucleic acid expression is 15 statistically significantly less in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of nucleic acid expression.

The invention further provides methods of treatment, with the nucleic acid as a target, using a compound identified through drug screening as a gene modulator to modulate phosphatase nucleic acid expression in cells and tissues that express the phosphatase. 20 Experimental data as provided in Figure 1 indicates that phosphatase proteins of the present invention are expressed in the human brain, heart and liver etc. Specifically, a virtual northern blot shows expression in human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node. In addition, PCR-based tissue screening panel indicates expression in human fetal brain, human brain, human heart, human liver, human lung, 25 human placenta, and human thyroid. Modulation includes both up-regulation (i.e. activation or agonization) or down-regulation (suppression or antagonization) or nucleic acid expression.

Alternatively, a modulator for phosphatase nucleic acid expression can be a small molecule or drug identified using the screening assays described herein as long as the drug or small molecule inhibits the phosphatase nucleic acid expression in the cells and tissues that 30 express the protein. Experimental data as provided in Figure 1 indicates expression in the human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node, as well as expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid tissues.

The nucleic acid molecules are also useful for monitoring the effectiveness of modulating compounds on the expression or activity of the phosphatase gene in clinical trials or in a treatment regimen. Thus, the gene expression pattern can serve as a barometer for the continuing effectiveness of treatment with the compound, particularly with compounds to which 5 a patient can develop resistance. The gene expression pattern can also serve as a marker indicative of a physiological response of the affected cells to the compound. Accordingly, such monitoring would allow either increased administration of the compound or the administration of alternative compounds to which the patient has not become resistant. Similarly, if the level of nucleic acid expression falls below a desirable level, administration of the compound could be 10 commensurately decreased.

The nucleic acid molecules are also useful in diagnostic assays for qualitative changes in phosphatase nucleic acid expression, and particularly in qualitative changes that lead to pathology. The nucleic acid molecules can be used to detect mutations in phosphatase genes and gene expression products such as mRNA. The nucleic acid molecules can be used as 15 hybridization probes to detect naturally occurring genetic mutations in the phosphatase gene and thereby to determine whether a subject with the mutation is at risk for a disorder caused by the mutation. Mutations include deletion, addition, or substitution of one or more nucleotides in the gene, chromosomal rearrangement, such as inversion or transposition, modification of genomic DNA, such as aberrant methylation patterns or changes in gene copy number, such as 20 amplification. Detection of a mutated form of the phosphatase gene associated with a dysfunction provides a diagnostic tool for an active disease or susceptibility to disease when the disease results from overexpression, underexpression, or altered expression of a phosphatase protein.

Individuals carrying mutations in the phosphatase gene can be detected at the nucleic 25 acid level by a variety of techniques. Figure 3 provides SNP information that has been found in a gene encoding the phosphatase protein of the present invention. The following variations were seen: G3114A, T4514G, A7570G, C11672G, A11897C, T14523C, C16586T, T16644C, A17969G, C18117T, C18518A, G19882A, A21465G, C21625T, C26291T, T28012C, T28030G, A33671C, A37703G and C39269G as substitutions, -20999T, -4004A as insertions 30 and G20988- deletion. The changes in the amino acid sequence that these SNPs cause can readily be determined using the universal genetic code and the protein sequence provided in Figure 2 as a base. As indicated by the data presented in Figure 3, the map position was determined to be on chromosome 14 by ePCR, and confirmed with radiation hybrid mapping. As indicated by the data presented in Figure 3, the gene provided by the present invention

encoding a novel phosphatase maps to public BAC AC AL139317.2, which is known to be located on human chromosome 14. Genomic DNA can be analyzed directly or can be amplified by using PCR prior to analysis. RNA or cDNA can be used in the same way. In some uses, detection of the mutation involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g. U.S. Patent Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran *et al.*, *Science* 241:1077-1080 (1988); and Nakazawa *et al.*, *PNAS* 91:360-364 (1994)), the latter of which can be particularly useful for detecting point mutations in the gene (see Abravaya *et al.*, *Nucleic Acids Res.* 23:675-682 (1995)). This method can include the steps of collecting a sample of cells 5 from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers which specifically hybridize to a gene under conditions such that hybridization and amplification of the gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. Deletions 10 and insertions can be detected by a change in size of the amplified product compared to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to normal RNA or antisense DNA sequences.

Alternatively, mutations in a phosphatase gene can be directly identified, for example, by alterations in restriction enzyme digestion patterns determined by gel electrophoresis. 15 Further, sequence-specific ribozymes (U.S. Patent No. 5,498,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site. Perfectly matched sequences can be distinguished from mismatched sequences by nuclease cleavage digestion assays or by differences in melting temperature.

Sequence changes at specific locations can also be assessed by nuclease protection 20 assays such as RNase and S1 protection or the chemical cleavage method. Furthermore, sequence differences between a mutant phosphatase gene and a wild-type gene can be determined by direct DNA sequencing. A variety of automated sequencing procedures can be utilized when performing the diagnostic assays (Naeve, C.W., (1995) *Biotechniques* 19:448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 30 94/16101; Cohen *et al.*, *Adv. Chromatogr.* 36:127-162 (1996); and Griffin *et al.*, *Appl. Biochem. Biotechnol.* 38:147-159 (1993)).

Other methods for detecting mutations in the gene include methods in which protection 25 from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA duplexes (Myers *et al.*, *Science* 230:1242 (1985)); Cotton *et al.*, *PNAS* 85:4397 (1988); Saleeba *et al.*,

Meth. Enzymol. 217:286-295 (1992)), electrophoretic mobility of mutant and wild type nucleic acid is compared (Orita *et al.*, *PNAS* 86:2766 (1989); Cotton *et al.*, *Mutat. Res.* 285:125-144 (1993); and Hayashi *et al.*, *Genet. Anal. Tech. Appl.* 9:73-79 (1992)), and movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed 5 using denaturing gradient gel electrophoresis (Myers *et al.*, *Nature* 313:495 (1985)). Examples of other techniques for detecting point mutations include selective oligonucleotide hybridization, selective amplification, and selective primer extension.

The nucleic acid molecules are also useful for testing an individual for a genotype that while not necessarily causing the disease, nevertheless affects the treatment modality. Thus, the 10 nucleic acid molecules can be used to study the relationship between an individual's genotype and the individual's response to a compound used for treatment (pharmacogenomic relationship). Accordingly, the nucleic acid molecules described herein can be used to assess the mutation content of the phosphatase gene in an individual in order to select an appropriate compound or dosage regimen for treatment. Figure 3 provides SNP information that has been found in a gene 15 encoding the phosphatase protein of the present invention. The following variations were seen: G3114A, T4514G, A7570G, C11672G, A11897C, T14523C, C16586T, T16644C, A17969G, C18117T, C18518A, G19882A, A21465G, C21625T, C26291T, T28012C, T28030G, A33671C, A37703G and C39269G as substitutions, -20999T, -4004A as insertions and 20 G20988- deletion. The changes in the amino acid sequence that these SNPs cause can readily be determined using the universal genetic code and the protein sequence provided in Figure 2 as a base.

Thus nucleic acid molecules displaying genetic variations that affect treatment provide a diagnostic target that can be used to tailor treatment in an individual. Accordingly, the 25 production of recombinant cells and animals containing these polymorphisms allow effective clinical design of treatment compounds and dosage regimens.

The nucleic acid molecules are thus useful as antisense constructs to control phosphatase gene expression in cells, tissues, and organisms. A DNA antisense nucleic acid molecule is designed to be complementary to a region of the gene involved in transcription, preventing transcription and hence production of phosphatase protein. An antisense RNA or DNA nucleic 30 acid molecule would hybridize to the mRNA and thus block translation of mRNA into phosphatase protein.

Alternatively, a class of antisense molecules can be used to inactivate mRNA in order to decrease expression of phosphatase nucleic acid. Accordingly, these molecules can treat a disorder characterized by abnormal or undesired phosphatase nucleic acid expression. This

technique involves cleavage by means of ribozymes containing nucleotide sequences complementary to one or more regions in the mRNA that attenuate the ability of the mRNA to be translated. Possible regions include coding regions and particularly coding regions corresponding to the catalytic and other functional activities of the phosphatase protein, such as 5 substrate binding.

The nucleic acid molecules also provide vectors for gene therapy in patients containing cells that are aberrant in phosphatase gene expression. Thus, recombinant cells, which include the patient's cells that have been engineered *ex vivo* and returned to the patient, are introduced into an individual where the cells produce the desired phosphatase protein to treat the individual.

10 The invention also encompasses kits for detecting the presence of a phosphatase nucleic acid in a biological sample. Experimental data as provided in Figure 1 indicates that phosphatase proteins of the present invention are expressed in the human brain, heart and liver etc. Specifically, a virtual northern blot shows expression in human total fetus, human germinal B cell, human fetal liver, human fetal liver spleen and human lymph node. In addition, PCR-based tissue screening panel indicates expression in human fetal brain, human brain, human heart, human liver, human lung, human placenta, and human thyroid. For example, the kit can 15 comprise reagents such as a labeled or labelable nucleic acid or agent capable of detecting phosphatase nucleic acid in a biological sample; means for determining the amount of phosphatase nucleic acid in the sample; and means for comparing the amount of phosphatase 20 nucleic acid in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect phosphatase protein mRNA or DNA.

Nucleic Acid Arrays

25 The present invention further provides nucleic acid detection kits, such as arrays or microarrays of nucleic acid molecules that are based on the sequence information provided in Figures 1 and 3 (SEQ ID NOS:1 and 3).

As used herein "Arrays" or "Microarrays" refers to an array of distinct 30 polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support. In one embodiment, the microarray is prepared and used according to the methods described in US Patent 5,837,832, Chee *et al.*, PCT application W095/11995 (Chee *et al.*), Lockhart, D. J. *et al.* (1996; *Nat. Biotech.* 14: 1675-1680) and Schena, M. *et al.* (1996; *Proc. Natl. Acad. Sci.*

93: 10614-10619), all of which are incorporated herein in their entirety by reference. In other embodiments, such arrays are produced by the methods described by Brown *et al.*, US Patent No. 5,807,522.

The microarray or detection kit is preferably composed of a large number of unique, 5 single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25 nucleotides in length. For a certain type of microarray or detection kit, it may be preferable to use oligonucleotides that are only 7-20 nucleotides in length. The microarray or 10 detection kit may contain oligonucleotides that cover the known 5', or 3', sequence, sequential oligonucleotides which cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray or detection kit may be oligonucleotides that are specific to a gene or genes of interest.

In order to produce oligonucleotides to a known sequence for a microarray or 15 detection kit, the gene(s) of interest (or an ORF identified from the contigs of the present invention) is typically examined using a computer algorithm which starts at the 5' or at the 3' end of the nucleotide sequence. Typical algorithms will then identify oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. 20 In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray or detection kit. The "pairs" will be identical, except for one nucleotide that preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, 25 filter, chip, glass slide or any other suitable solid support.

In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application W095/251116 (Baldeschweiler *et al.*) which is incorporated 30 herein in its entirety by reference. In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and

machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536, 6144 or more oligonucleotides, or any other number between two and one million which lends itself to the efficient use of commercially available instrumentation.

In order to conduct sample analysis using a microarray or detection kit, the RNA or 5 DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray or detection kit so that the probe sequences hybridize to complementary oligonucleotides of the microarray or detection kit. Incubation conditions are adjusted so that 10 hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray or detection kit. The biological samples may be obtained from any bodily fluids 15 (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large-scale correlation studies on the sequences, expression patterns, mutations, variants, or polymorphisms among samples.

Using such arrays, the present invention provides methods to identify the expression 20 of the phosphatase proteins/peptides of the present invention. In detail, such methods comprise incubating a test sample with one or more nucleic acid molecules and assaying for binding of the nucleic acid molecule with components within the test sample. Such assays will typically involve arrays comprising many genes, at least one of which is a gene of the 25 present invention and or alleles of the phosphatase gene of the present invention. Figure 3 provides SNP information that has been found in a gene encoding the phosphatase protein of the present invention. The following variations were seen: G3114A, T4514G, A7570G, C11672G, A11897C, T14523C, C16586T, T16644C, A17969G, C18117T, C18518A, G19882A, A21465G, C21625T, C26291T, T28012C, T28030G, A33671C, A37703G and 30 C39269G as substitutions, -20999T, -4004A as insertions and G20988- deletion. The changes in the amino acid sequence that these SNPs cause can readily be determined using the universal genetic code and the protein sequence provided in Figure 2 as a base.

Conditions for incubating a nucleic acid molecule with a test sample vary. Incubation conditions depend on the format employed in the assay, the detection methods employed, and

the type and nature of the nucleic acid molecule used in the assay. One skilled in the art will recognize that any one of the commonly available hybridization, amplification or array assay formats can readily be adapted to employ the novel fragments of the Human genome disclosed herein. Examples of such assays can be found in Chard, T, *An Introduction to*

5 *Radioimmunoassay and Related Techniques*, Elsevier Science Publishers, Amsterdam, The Netherlands (1986); Bullock, G. R. *et al.*, *Techniques in Immunocytochemistry*, Academic Press, Orlando, FL Vol. 1 (1982), Vol. 2 (1983), Vol. 3 (1985); Tijssen, P., *Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology*, Elsevier Science Publishers, Amsterdam, The Netherlands (1985).

10 The test samples of the present invention include cells, protein or membrane extracts of cells. The test sample used in the above-described method will vary based on the assay format, nature of the detection method and the tissues, cells or extracts used as the sample to be assayed. Methods for preparing nucleic acid extracts or of cells are well known in the art and can be readily be adapted in order to obtain a sample that is compatible with the system utilized.

15 In another embodiment of the present invention, kits are provided which contain the necessary reagents to carry out the assays of the present invention.

20 Specifically, the invention provides a compartmentalized kit to receive, in close confinement, one or more containers which comprises: (a) a first container comprising one of the nucleic acid molecules that can bind to a fragment of the Human genome disclosed herein; and (b) one or more other containers comprising one or more of the following: wash reagents, reagents capable of detecting presence of a bound nucleic acid.

25 In detail, a compartmentalized kit includes any kit in which reagents are contained in separate containers. Such containers include small glass containers, plastic containers, strips of plastic, glass or paper, or arraying material such as silica. Such containers allows one to efficiently transfer reagents from one compartment to another compartment such that the samples and reagents are not cross-contaminated, and the agents or solutions of each container can be added in a quantitative fashion from one compartment to another. Such containers will include a container which will accept the test sample, a container which

30 contains the nucleic acid probe, containers which contain wash reagents (such as phosphate buffered saline, Tris-buffers, etc.), and containers which contain the reagents used to detect the bound probe. One skilled in the art will readily recognize that the previously unidentified phosphatase gene of the present invention can be routinely identified using the sequence

information disclosed herein can be readily incorporated into one of the established kit formats which are well known in the art, particularly expression arrays.

Vectors/host cells

5 The invention also provides vectors containing the nucleic acid molecules described herein. The term "vector" refers to a vehicle, preferably a nucleic acid molecule, which can transport the nucleic acid molecules. When the vector is a nucleic acid molecule, the nucleic acid molecules are covalently linked to the vector nucleic acid. With this aspect of the invention, the vector includes a plasmid, single or double stranded phage, a single or double 10 stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, YAC, OR MAC.

A vector can be maintained in the host cell as an extrachromosomal element where it replicates and produces additional copies of the nucleic acid molecules. Alternatively, the vector may integrate into the host cell genome and produce additional copies of the nucleic acid 15 molecules when the host cell replicates.

The invention provides vectors for the maintenance (cloning vectors) or vectors for expression (expression vectors) of the nucleic acid molecules. The vectors can function in prokaryotic or eukaryotic cells or in both (shuttle vectors).

20 Expression vectors contain cis-acting regulatory regions that are operably linked in the vector to the nucleic acid molecules such that transcription of the nucleic acid molecules is allowed in a host cell. The nucleic acid molecules can be introduced into the host cell with a separate nucleic acid molecule capable of affecting transcription. Thus, the second nucleic acid molecule may provide a trans-acting factor interacting with the cis-regulatory control region to allow transcription of the nucleic acid molecules from the vector. Alternatively, a trans-acting 25 factor may be supplied by the host cell. Finally, a trans-acting factor can be produced from the vector itself. It is understood, however, that in some embodiments, transcription and/or translation of the nucleic acid molecules can occur in a cell-free system.

The regulatory sequence to which the nucleic acid molecules described herein can be 30 operably linked include promoters for directing mRNA transcription. These include, but are not limited to, the left promoter from bacteriophage λ , the lac, TRP, and TAC promoters from *E. coli*, the early and late promoters from SV40, the CMV immediate early promoter, the adenovirus early and late promoters, and retrovirus long-terminal repeats.

In addition to control regions that promote transcription, expression vectors may also include regions that modulate transcription, such as repressor binding sites and enhancers. Examples include the SV40 enhancer, the cytomegalovirus immediate early enhancer, polyoma enhancer, adenovirus enhancers, and retrovirus LTR enhancers.

5 In addition to containing sites for transcription initiation and control, expression vectors can also contain sequences necessary for transcription termination and, in the transcribed region a ribosome binding site for translation. Other regulatory control elements for expression include initiation and termination codons as well as polyadenylation signals. The person of ordinary skill in the art would be aware of the numerous regulatory sequences that are useful in
10 expression vectors. Such regulatory sequences are described, for example, in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual. 2nd. ed.*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989).

A variety of expression vectors can be used to express a nucleic acid molecule. Such vectors include chromosomal, episomal, and virus-derived vectors, for example vectors derived
15 from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, Vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, and retroviruses. Vectors may also be derived from combinations of these sources such as those derived from plasmid and bacteriophage genetic elements, e.g. cosmids and phagemids.
20 Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual. 2nd. ed.*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989).

The regulatory sequence may provide constitutive expression in one or more host cells (i.e. tissue specific) or may provide for inducible expression in one or more cell types such as by
25 temperature, nutrient additive, or exogenous factor such as a hormone or other ligand. A variety of vectors providing for constitutive and inducible expression in prokaryotic and eukaryotic hosts are well known to those of ordinary skill in the art.

The nucleic acid molecules can be inserted into the vector nucleic acid by well-known methodology. Generally, the DNA sequence that will ultimately be expressed is joined to an
30 expression vector by cleaving the DNA sequence and the expression vector with one or more restriction enzymes and then ligating the fragments together. Procedures for restriction enzyme digestion and ligation are well known to those of ordinary skill in the art.

The vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using well-known techniques. Bacterial cells

include, but are not limited to, *E. coli*, *Streptomyces*, and *Salmonella typhimurium*. Eukaryotic cells include, but are not limited to, yeast, insect cells such as *Drosophila*, animal cells such as COS and CHO cells, and plant cells.

As described herein, it may be desirable to express the peptide as a fusion protein.

5 Accordingly, the invention provides fusion vectors that allow for the production of the peptides. Fusion vectors can increase the expression of a recombinant protein, increase the solubility of the recombinant protein, and aid in the purification of the protein by acting for example as a ligand for affinity purification. A proteolytic cleavage site may be introduced at the junction of the fusion moiety so that the desired peptide can ultimately be separated from the fusion moiety.

10 Proteolytic enzymes include, but are not limited to, factor Xa, thrombin, and enterokinase. Typical fusion expression vectors include pGEX (Smith *et al.*, *Gene* 67:31-40 (1988)), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. Examples of suitable inducible non-fusion *E. coli* expression vectors

15 include pTrc (Amann *et al.*, *Gene* 69:301-315 (1988)) and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185:60-89 (1990)).

Recombinant protein expression can be maximized in host bacteria by providing a genetic background wherein the host cell has an impaired capacity to proteolytically cleave the recombinant protein. (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 20 185, Academic Press, San Diego, California (1990) 119-128). Alternatively, the sequence of the nucleic acid molecule of interest can be altered to provide preferential codon usage for a specific host cell, for example *E. coli*. (Wada *et al.*, *Nucleic Acids Res.* 20:2111-2118 (1992)).

The nucleic acid molecules can also be expressed by expression vectors that are operative in yeast. Examples of vectors for expression in yeast e.g., *S. cerevisiae* include pYEpSec1 (Baldari, *et al.*, *EMBO J.* 6:229-234 (1987)), pMFa (Kurjan *et al.*, *Cell* 30:933-943(1982)), pJRY88 (Schultz *et al.*, *Gene* 54:113-123 (1987)), and pYES2 (Invitrogen Corporation, San Diego, CA).

The nucleic acid molecules can also be expressed in insect cells using, for example, baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., Sf 9 cells) include the pAc series (Smith *et al.*, *Mol. Cell Biol.* 3:2156-2165 (1983)) and the pVL series (Lucklow *et al.*, *Virology* 170:31-39 (1989)).

In certain embodiments of the invention, the nucleic acid molecules described herein are expressed in mammalian cells using mammalian expression vectors. Examples of mammalian

expression vectors include pCDM8 (Seed, B. *Nature* 329:840(1987)) and pMT2PC (Kaufman *et al.*, *EMBO J.* 6:187-195 (1987)).

The expression vectors listed herein are provided by way of example only of the well-known vectors available to those of ordinary skill in the art that would be useful to express the 5 nucleic acid molecules. The person of ordinary skill in the art would be aware of other vectors suitable for maintenance propagation or expression of the nucleic acid molecules described herein. These are found for example in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual. 2nd, ed.*, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

10 The invention also encompasses vectors in which the nucleic acid sequences described herein are cloned into the vector in reverse orientation, but operably linked to a regulatory sequence that permits transcription of antisense RNA. Thus, an antisense transcript can be produced to all, or to a portion, of the nucleic acid molecule sequences described herein, including both coding and non-coding regions. Expression of this antisense RNA is subject to 15 each of the parameters described above in relation to expression of the sense RNA (regulatory sequences, constitutive or inducible expression, tissue-specific expression).

The invention also relates to recombinant host cells containing the vectors described herein. Host cells therefore include prokaryotic cells, lower eukaryotic cells such as yeast, other eukaryotic cells such as insect cells, and higher eukaryotic cells such as mammalian cells.

20 The recombinant host cells are prepared by introducing the vector constructs described herein into the cells by techniques readily available to the person of ordinary skill in the art. These include, but are not limited to, calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transduction, infection, lipofection, and other techniques such as those found in Sambrook, *et al.* (*Molecular Cloning: A Laboratory Manual. 2nd, ed.*, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

Host cells can contain more than one vector. Thus, different nucleotide sequences can 30 be introduced on different vectors of the same cell. Similarly, the nucleic acid molecules can be introduced either alone or with other nucleic acid molecules that are not related to the nucleic acid molecules such as those providing trans-acting factors for expression vectors. When more than one vector is introduced into a cell, the vectors can be introduced independently, co-introduced or joined to the nucleic acid molecule vector.

In the case of bacteriophage and viral vectors, these can be introduced into cells as packaged or encapsulated virus by standard procedures for infection and transduction. Viral

vectors can be replication-competent or replication-defective. In the case in which viral replication is defective, replication will occur in host cells providing functions that complement the defects.

Vectors generally include selectable markers that enable the selection of the 5 subpopulation of cells that contain the recombinant vector constructs. The marker can be contained in the same vector that contains the nucleic acid molecules described herein or may be on a separate vector. Markers include tetracycline or ampicillin-resistance genes for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for eukaryotic host cells. However, any marker that provides selection for a phenotypic trait will be effective.

10 While the mature proteins can be produced in bacteria, yeast, mammalian cells, and other cells under the control of the appropriate regulatory sequences, cell- free transcription and translation systems can also be used to produce these proteins using RNA derived from the DNA constructs described herein.

15 Where secretion of the peptide is desired, which is difficult to achieve with multi-transmembrane domain containing proteins such as phosphatases, appropriate secretion signals are incorporated into the vector. The signal sequence can be endogenous to the peptides or heterologous to these peptides.

20 Where the peptide is not secreted into the medium, which is typically the case with phosphatases, the protein can be isolated from the host cell by standard disruption procedures, including freeze thaw, sonication, mechanical disruption, use of lysing agents and the like. The peptide can then be recovered and purified by well-known purification methods including ammonium sulfate precipitation, acid extraction, anion or cationic exchange chromatography, phosphocellulose chromatography, hydrophobic-interaction chromatography, affinity chromatography, hydroxylapatite chromatography, lectin chromatography, or high performance 25 liquid chromatography.

It is also understood that depending upon the host cell in recombinant production of the peptides described herein, the peptides can have various glycosylation patterns, depending upon the cell, or maybe non-glycosylated as when produced in bacteria. In addition, the peptides may include an initial modified methionine in some cases as a result of a host-mediated process.

30

Uses of vectors and host cells

The recombinant host cells expressing the peptides described herein have a variety of uses. First, the cells are useful for producing a phosphatase protein or peptide that can be further

purified to produce desired amounts of phosphatase protein or fragments. Thus, host cells containing expression vectors are useful for peptide production.

Host cells are also useful for conducting cell-based assays involving the phosphatase protein or phosphatase protein fragments, such as those described above as well as other formats known in the art. Thus, a recombinant host cell expressing a native phosphatase protein is useful for assaying compounds that stimulate or inhibit phosphatase protein function.

Host cells are also useful for identifying phosphatase protein mutants in which these functions are affected. If the mutants naturally occur and give rise to a pathology, host cells containing the mutations are useful to assay compounds that have a desired effect on the mutant phosphatase protein (for example, stimulating or inhibiting function) which may not be indicated by their effect on the native phosphatase protein.

Genetically engineered host cells can be further used to produce non-human transgenic animals. A transgenic animal is preferably a mammal, for example a rodent, such as a rat or mouse, in which one or more of the cells of the animal include a transgene. A transgene is exogenous DNA which is integrated into the genome of a cell from which a transgenic animal develops and which remains in the genome of the mature animal in one or more cell types or tissues of the transgenic animal. These animals are useful for studying the function of a phosphatase protein and identifying and evaluating modulators of phosphatase protein activity. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, and amphibians.

A transgenic animal can be produced by introducing nucleic acid into the male pronuclei of a fertilized oocyte, e.g., by microinjection, retroviral infection, and allowing the oocyte to develop in a pseudopregnant female foster animal. Any of the phosphatase protein nucleotide sequences can be introduced as a transgene into the genome of a non-human animal, such as a mouse.

Any of the regulatory or other sequences useful in expression vectors can form part of the transgenic sequence. This includes intronic sequences and polyadenylation signals, if not already included. A tissue-specific regulatory sequence(s) can be operably linked to the transgene to direct expression of the phosphatase protein to particular cells.

Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, both by Leder *et al.*, U.S. Patent No. 4,873,191 by Wagner *et al.* and in Hogan, B., *Manipulating the Mouse Embryo*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986). Similar methods are used for

production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the transgene in its genome and/or expression of transgenic mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene can further 5 be bred to other transgenic animals carrying other transgenes. A transgenic animal also includes animals in which the entire animal or tissues in the animal have been produced using the homologously recombinant host cells described herein.

In another embodiment, transgenic non-human animals can be produced which contain selected systems that allow for regulated expression of the transgene. One example of such a 10 system is the *cre/loxP* recombinase system of bacteriophage P1. For a description of the *cre/loxP* recombinase system, see, e.g., Lakso *et al.* *PNAS* 89:6232-6236 (1992). Another example of a recombinase system is the FLP recombinase system of *S. cerevisiae* (O'Gorman *et al.* *Science* 251:1351-1355 (1991). If a *cre/loxP* recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the *Cre* recombinase 15 and a selected protein is required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, I. *et al.* *Nature* 385:810-813 (1997) and PCT 20 International Publication Nos. WO 97/07668 and WO 97/07669. In brief, a cell, e.g., a somatic cell, from the transgenic animal can be isolated and induced to exit the growth cycle and enter G₀ phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyst and then 25 transferred to pseudopregnant female foster animal. The offspring born of this female foster animal will be a clone of the animal from which the cell, e.g., the somatic cell, is isolated.

Transgenic animals containing recombinant cells that express the peptides described herein are useful to conduct the assays described herein in an *in vivo* context. Accordingly, the various physiological factors that are present *in vivo* and that could effect substrate binding, 30 kinase protein activation, and signal transduction, may not be evident from *in vitro* cell-free or cell-based assays. Accordingly, it is useful to provide non-human transgenic animals to assay *in vivo* phosphatase protein function, including substrate interaction, the effect of specific mutant phosphatase proteins on phosphatase protein function and substrate interaction, and the effect of

chimeric phosphatase proteins. It is also possible to assess the effect of null mutations, that is mutations that substantially or completely eliminate one or more phosphatase protein functions.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the above-described modes for carrying out the invention which are obvious to those skilled in the field of molecular biology or related fields are intended to be within the scope of the following claims.

Claims

That which is claimed is:

1. An isolated peptide consisting of an amino acid sequence selected from the group consisting of:
 - (a) an amino acid sequence shown in SEQ ID NO:2;
 - (b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
 - (c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; and
 - (d) a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.
2. An isolated peptide comprising an amino acid sequence selected from the group consisting of:
 - (a) an amino acid sequence shown in SEQ ID NO:2;
 - (b) an amino acid sequence of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said allelic variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
 - (c) an amino acid sequence of an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said ortholog is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3; and
 - (d) a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids.
3. An isolated antibody that selectively binds to a peptide of claim 2.

4. An isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2;
- (b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (d) a nucleotide sequence that encodes a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids; and
- (e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).

5. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence that encodes an amino acid sequence shown in SEQ ID NO:2;
- (b) a nucleotide sequence that encodes of an allelic variant of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (c) a nucleotide sequence that encodes an ortholog of an amino acid sequence shown in SEQ ID NO:2, wherein said nucleotide sequence hybridizes under stringent conditions to the opposite strand of a nucleic acid molecule shown in SEQ ID NOS:1 or 3;
- (d) a nucleotide sequence that encodes a fragment of an amino acid sequence shown in SEQ ID NO:2, wherein said fragment comprises at least 10 contiguous amino acids; and
- (e) a nucleotide sequence that is the complement of a nucleotide sequence of (a)-(d).

6. A gene chip comprising a nucleic acid molecule of claim 5.

7. A transgenic non-human animal comprising a nucleic acid molecule of claim 5.
8. A nucleic acid vector comprising a nucleic acid molecule of claim 5.
9. A host cell containing the vector of claim 8.
10. A method for producing any of the peptides of claim 1 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
11. A method for producing any of the peptides of claim 2 comprising introducing a nucleotide sequence encoding any of the amino acid sequences in (a)-(d) into a host cell, and culturing the host cell under conditions in which the peptides are expressed from the nucleotide sequence.
12. A method for detecting the presence of any of the peptides of claim 2 in a sample, said method comprising contacting said sample with a detection agent that specifically allows detection of the presence of the peptide in the sample and then detecting the presence of the peptide.
13. A method for detecting the presence of a nucleic acid molecule of claim 5 in a sample, said method comprising contacting the sample with an oligonucleotide that hybridizes to said nucleic acid molecule under stringent conditions and determining whether the oligonucleotide binds to said nucleic acid molecule in the sample.
14. A method for identifying a modulator of a peptide of claim 2, said method comprising contacting said peptide with an agent and determining if said agent has modulated the function or activity of said peptide.
15. The method of claim 14, wherein said agent is administered to a host cell comprising an expression vector that expresses said peptide.

16. A method for identifying an agent that binds to any of the peptides of claim 2, said method comprising contacting the peptide with an agent and assaying the contacted mixture to determine whether a complex is formed with the agent bound to the peptide.

17. A pharmaceutical composition comprising an agent identified by the method of claim 16 and a pharmaceutically acceptable carrier therefor.

18. A method for treating a disease or condition mediated by a human phosphatase protein, said method comprising administering to a patient a pharmaceutically effective amount of an agent identified by the method of claim 16.

19. A method for identifying a modulator of the expression of a peptide of claim 2, said method comprising contacting a cell expressing said peptide with an agent, and determining if said agent has modulated the expression of said peptide.

20. An isolated human phosphatase peptide having an amino acid sequence that shares at least 70% homology with an amino acid sequence shown in SEQ ID NO:2.

21. A peptide according to claim 20 that shares at least 90 percent homology with an amino acid sequence shown in SEQ ID NO:2.

22. An isolated nucleic acid molecule encoding a human phosphatase peptide, said nucleic acid molecule sharing at least 80 percent homology with a nucleic acid molecule shown in SEQ ID NOS:1 or 3.

23. A nucleic acid molecule according to claim 22 that shares at least 90 percent homology with a nucleic acid molecule shown in SEQ ID NOS:1 or 3.

1/32

```

1  ATGGAGGACG TGAAGCTGGA GTTCCCTTCC CTTCCACAGT GCAAGGAAGA
51  CGCCGAGGAG TGGACCTACC CTATGAGACG AGAGATGCAG GAAATTTCAC
101 CTGGATGTGTT CTTAGGCCA TATTTCATCTG CTATGAAAAG CAAGCTACCT
151 GTACTACAGA AACATGGAAT AACCCATATA ATATGCATAC GACAAAATAT
201 TGAAGCAAC TTTTATTAAC CAAACTTCA GCAGTTATTT AGATATTTAG
251 TCCTGGATAT TGCGAGATAAT CCAGTTGAAA ATATAATACG TTTTTCCCT
301 ATGACTAAGG AATTATTGTA TGGGAGCTTA CAAATGGGAG GAAAAGTTCT
351 TGTGCATGGA AATGCAGGGA TCTCCAGAAG TGCAGCCTT GTTATTGCAT
401 ACATTATGGA AACATTTGGA ATGAAGTACA GAGATGCTT TGCTTATGTT
451 CAAGAAAGAA GATTTGTAT TAATCCTAAT GCTGGATTG TCCATCAACT
501 TCAGGAATAT GAACCCATCT ACCTAGCAAA ATTAACAATA CAGATGATGT
551 CACCACTCCA GATAGAAAGG TCATTATCTG TTCATTCTGG TACCACAGGC
601 AGTTTGAAGA GAACACATGA AGAAGAGGAT GATTTGGAA CCATGCAAGT
651 GGCAGTGCA CAGAATGGCT GA

```

FEATURES:

Start codon: 1

Stop codon: 670

cDNA Sequence:

```

1  AACACCACGC GTCCGGCAGC GGCATGGCGG CCGGGTGTAA GACGCCGAC
51  CCTCCCTTTC CCTGTCTTCG CCGCCGCCGC TGCTGGAGTC ACTGGGACCC
101 TGTAGTCTGC GTGTGTTAGT TGTAAATCCCG CCGCCCTCCT GTCAGCCCTC
151 CGCTCCGCCG GCCCTCCCTC CTTCCGCCGC CGCAGCCAGC CCGAGGGTCG
201 GCCGGCTGTG TAACACTCTC CCACCCACC CACCAGCCCG CGGGCCAGCA
251 CCATGGAGGA CGTGAAGCTG GAGTCCCTT CCCTCCACA GTGCAAGGAA
301 GACGCCGAGG AGTGGACATC CCCTATGAGA CGAGAGATGC AGGAAATTTC
351 ACCTGGATTG TTCTTAGGCC CATATTCTAC TGCTATGAAA AGCAAGCTAC
401 CTGTACTACA GAAACATGGA ATAACCCATA TAATATGCAT ACGACAAAAT
451 ATTGAAGCAA ACTTTTAAAC ACCAAACTTT CAGCAGTTAT TTAGATATTT
501 AGTCCTGGAT ATTGCAGATA ATCCAGTTGA AAATATAATA CGTTTTTCC
551 CTATGACTAA GGAATTATTAT GATGGGAGCT TACAAATGGG AGGAAAAGTT
601 CTTGTGCATG GAAATGCAGG GATCTCCAGA AGTGCAGCCT TTGTTATTGC
651 ATACATTATG GAAACATTTG GAATGAAGTA CAGAGATGCT TTTGCTTATG
701 TTCAAGAAAG AAGATTTGT ATTAATCCTA ATGCTGGATT TGTCCATCAA
751 CTTCAGGAAT ATGAAGCCAT CTACCTAGCA AAATTAACAA TACAGATGAT
801 GTCACCACTC CAGATAGAAA GGTCAATTAC TGTTCAATTCT GGTACCCACAG
851 GCAGTTGAA GAGAACACAT GAAGAAGAGG ATGATTTGG AACCATGCAA
901 GTGGCCACTG CACAGAATGG CTGACTTGAA GACCAACATC ATAGAGTGTG
951 AATTTCTATT TGGGAAGGAG AAAATACAAG AGAAAATTAT AATGTAAAAT
1001 GGTAACACAA TAAGTAGTTT TTTTTCAAT TACATGTTGC TTCCAGACAT
1051 ACTTCTCTGC AACTTGTGA GCAACATTTT AAGATGTTGG ACTTCTGCAA
1101 TAGATGACAC TGATGGTTT ACTCCTTTT TTTAAAAACAA CATGCGCGCG
1151 CACACACACA TGCTTACAA GTTTTATTAT AAACCAAGAA TTTGGACTT
1201 GCAAAAAAAA AAAAAAAA

```

FEATURES:

Start codon: 253

Stop codon: 922

2/32

Homologous proteins:**Top 10 BLAST Hits**

| | | | | |
|----------------------------|---|--------|-----|-------|
| gi 2137698 pir I49365 | protein tyrosine phosphatase - mouse | >gi... | 462 | e-129 |
| gi 2137697 pir I49364 | protein tyrosine phosphatase - mouse | >gi... | 356 | 1e-97 |
| gi 1842088 | (U87169) tyrosine phosphatase-like protein homolog h... | >gi... | 141 | 5e-33 |
| gi 4758206 ref NP_004409.1 | dual specificity phosphatase 2 | >gi... | 94 | 9e-19 |
| gi 4758212 ref NP_004411.1 | dual specificity phosphatase 8 | >gi... | 93 | 2e-18 |
| gi 6679156 ref NP_032774.1 | neuronal tyrosine/threonine phosph... | >gi... | 93 | 2e-18 |
| gi 4758204 ref NP_004408.1 | dual specificity phosphatase 1 | >gi... | 92 | 5e-18 |
| gi 1050849 emb CAA58710 | (X83742) MAP kinase phosphatase [Xenop... | >gi... | 91 | 8e-18 |
| gi 4150963 emb CAA77232 | (Y18620) DsPTP1 protein [Arabidopsis t... | >gi... | 90 | 1e-17 |
| gi 6714641 dbj BAA89534.1 | (AB036834) MAP kinase phosphatase [D... | >gi... | 90 | 1e-17 |

EST

| | | | | |
|-----------------------------------|------------|----------------------------|-----|-------|
| gi 2059098 gb AA404320.1 AA404320 | zw36g07.s1 | Soares_total_fetus... | 761 | 0.0 |
| gi 2810244 gb AA761314.1 AA761314 | nz21c05.s1 | NCI_CGAP_GCB1_Homo... | 630 | e-178 |
| gi 1472397 gb AA011350.1 AA011350 | zi01b04.s1 | Soares_fetal_liver... | 607 | e-171 |
| gi 1230791 gb N73506.1 N73506 | za49c05.s1 | Soares fetal liver sple... | 597 | e-168 |
| gi 4389706 gb AI497724.1 AI497724 | ti50c07.x1 | NCI_CGAP_Lym12_Hom... | 379 | e-103 |

EXPRESSION INFORMATION FOR MODULATORY USE:

| | |
|--------------------------|--------------------------|
| gi 2059098 gb AA404320.1 | Human total fetus |
| gi 2810244 gb AA761314.1 | Human Germinal B cell |
| gi 1472397 gb AA011350.1 | Human fetal liver |
| gi 1230791 gb N73506.1 | Human fetal liver spleen |
| gi 4389706 gb AI497724.1 | Human Lymph node |

PCR-BASED TISSUE SCREENING PANEL:

Human fetal brain, human Brain, human heart, human liver, human lung, human placenta, human thyroid.

3/32

1 MEDVKLEPPS LPQCKEDAEE WTYPMRREMQ EILPGLFLGP YSSAMKSCLP
51 VLQKHGITHI ICIQRNIEAN FIKPNFQQLF RYLVLDIADN PVENIIRFFP
101 MTKEFIDGSL QMGGKVLVHG NAGISRSAAF VIAYIMETFG MKYRDAFAYV
151 QERRFCINPN AGFVHQLQEY EAIYLAKLTI QMMSPLQIER SLSVHSGTTG
201 SLKRTHHEEED DFGTMQVATA QNG

FEATURES:**Functional domains and key regions:**

[1] PDOC00005 PS00005 PKC_PHOSPHO_SITEProtein kinase C phosphorylation site
201-203 SLK

[2] PDOC00006 PS00006 CK2_PHOSPHO_SITECasein kinase II phosphorylation site
205-208 THEE

[3] PDOC00007 PS00007 TYR_PHOSPHO_SITE

Tyrosine kinase phosphorylation site

Number of matches: 2 1 15-23 KEDAEWTY 2 142-149 KYRDAFAY

[4] PDOC00008 PS00008 MYRISTYL

N-myristylation site

Number of matches: 2 1 123-128 GISRSA 2 197-202 GTTGSL

Membrane spanning structure and domains:

| Helix | Begin | End | Score | Certainty |
|-------|-------|-----|-------|-----------|
| 1 | 123 | 143 | 0.626 | Putative |

FIGURE 2

4/32

BLAST Alignment to Top Hit:

```
>gi|2137698|pir||I49365 protein tyrosine phosphatase - mouse
>gi|1063626|gb|AAA87037.1| (U34973) protein tyrosine
phosphatase-like [Mus musculus]
Length = 223
```

Score = 444 bits (1131), Expect = e-124
 Identities = 214/223 (95%), Positives = 221/223 (98%)

Query: 1 MEDVKLEFPSLPQCKEDAAEEWTPMRREMQEILPGLFLGPYSSAMSKLPLQKHGITHI 60
 MEDVKLEFPS+PQCK+DAEEWTPMRREMQE+LPGLFLGPYSSAMSKLPL+LQKHGITHI
 Sbjct: 1 MEDVKLEFPSVPQCKDDAAEEWTPMRREMQEVLPGFLGPYSSAMSKLPLQKHGITHI 60

Query: 61 ICIRQNIEANFIKPNFQQLFRYLVLVDIADNPVENIIRFFPMTKEFIDGSLQMGGKVLVHG 120
 ICIRQNIEANFIKPNFQQLFRYLVLVDIADNPVENIIRFFPMTKEFIDGSLQ GGKVLVHG
 Sbjct: 61 ICIRQNIEANFIKPNFQQLFRYLVLVDIADNPVENIIRFFPMTKEFIDGSLQNGGKVLVHG 120

Query: 121 NAGISRSAAFVIAYIMETFGMKYRDAFAYVQERRFCINPNAGFVHQLQYEAIYLAKLTI 180
 NAGISRSAAFVIAYIMETFGMKYRDAFAYVQERRFCINPNAGFVHQLQYEAIYLAKLTI
 Sbjct: 121 NAGISRSAAFVIAYIMETFGMKYRDAFAYVQERRFCINPNAGFVHQLQYEAIYLAKLTI 180

Query: 181 QMMSPLQIERSLSVHSGTTGSLKRTTHEEDDFGTMQVATAQNG 223
 QMMSPLQIERSL+VHSGTTGS+KRTHEE+DDFG MQVATAQNG
 Sbjct: 181 QMMSPLQIERSLAVHSGTTGSVKRTHEEDDFGNMQVATAQNG 223

Hmmer search results (Pfam):

Scores for sequence family classification (score includes all domains):

| Model | Description | Score | E-value | N |
|---------|--|-------|---------|---|
| PF00782 | Dual specificity phosphatase, catalytic doma | 221.5 | 1.2e-62 | 1 |

FIGURE 2

1 TTGAAATCCA AAAATATCTG AAGCTACATT TGGACCCCTG TAAATAATGT
 51 AATGTATAAG GATTTTCCA AAATAAGTCT TAATTTCACT TTTCATATAT
 101 CAACAAAAG GTACTATTAG GAGTACATAG TTGCCACACT TGAGACATAT
 151 TCCAAATGCA TACACCTAAC GGTACTACTA TTACAGAACCA GCACATTCTA
 201 ATCCACATAT ACACGGAGTTT TAATTAAATT TAGCACTATG TCTATAATCA
 251 GAATGAATAC CTGGAATACA TGTTTCTAGC AGGAATATT GTTAGCAGCT
 301 TTAAGGTTACT TGAAATCACC ATAATCATT CTATTTAAA TTTAAATTTC
 351 ACTACTGGGG TAAATTCCAT GAGGGAAAGGT TGTGGCTATG AATTTTTATT
 401 TATTCTTTT CTTTTGTGGT AAATATGGAG AACTTACCAA ATCTCTTATA
 451 TAGCCTGGCT GTAGATGGCA ATGGCAGGAA AGAAAAAGGA AGCAGAAAGA
 501 AAAAAAAAGG CAATCAGAAA AAATGGCAAC GAAGCAAAGA AAAAGTTGCG
 551 GTCACCTGCA ACCAAAATT CCAGCCAAA GTCATGCAA AAAACTACTTT
 601 AGGTAGAAAC CAAGCAAAGT AAATGCAAGA ATGAAAAATG AAAATGAGGA
 651 AGCAGCAATT ACTTTCATT TAGAACACTG AGAAAACACTC CACATTATTT
 701 TAGAATGTTA AATTTGCTA AAGAACCTAA GGGTAGAAAT TTGTTAGGGAG
 751 AAGATAAAAA GAGCAAATAT TTCTTTCCCC CTACATCGTG TACCCAGTTA
 801 CATCGTGTAC CCAGTTCTCA CCGGTTAAGG TAAAGCCAT TATTTAGTA
 851 GCAAAATAAA AGTATCCAAA AGCCTTTAAA GTCTTCTCAG ATTTACTCAG
 901 ATAATATGAT CCATGCACTG CTTTCAGAA ATAAGAATTG GAAGGCATAA
 951 AATAAGTGCA GTGCCCATCT GTTTCTTTT TTACACAAGA AAAGCAAACC
 1001 CCTCAGTTAC CATGTGTTT TTGCATCCTT TTTCCTGGAA GGGAAAACAA
 1051 AGAGATGCCG TATACTACAT GAGGAATTTC GGCTTTATGG CATTAGTCAT
 1101 TTCCATTAG ATTAACATAA ATCAACATAT AGAATAATTTC TTCAAAATTT
 1151 AAAAATCCAG TTTGAGAGTC ATATTATTT AAAAATACCC ACAGCATGTT
 1201 TAGTTAATAT ATATATAATT GAAGGGAAATT AAAGTAGGTT AAATAACAACA
 1251 GGTTATTTG ATAGACCCAA AGAAAAACTA CGAGTCTATG CCCAGGTAGG
 1301 GAAGAATGTC CTTGTGGCCT GCACATCTTC CTACAGCCTC CAGAACGCAA
 1351 CTGGATACAG CTTAATAATT ACTGAGCACT ATGTCCAGTG TGACTAGTGT
 1401 GGATCTGAC ACACAGTAGC AACTAAACCTT CTGAATGTCA CTACTTACTA
 1451 GGCACCAAGGG CAATAACATC ATGGTCGCTA TTCTCTGGAA ACAATTTTT
 1501 TTCTGACAC GGAGTTTAC TCTTGTGCG CAGGCTGGAG TGCAATGGCG
 1551 CCATCTTGGC TCACTGCAAC CTCCACCTCC CAGGTACAGG TGATTCTCCT
 1601 GCCTCAGCCT CCCAAGTAGC TGGCATTATA GGCGTGCACC ACCATGCCG
 1651 GCTAATTTTT GTAGTTTTAG TAGAGATGGG GTTTCACCAT GTTGGCCAGG
 1701 CTGGCTCGA ACTCCTGACC TCAGGTGTT CACTCACCTC GGCCCTCCCTA
 1751 AGTGCTGGGA TTACAGGTGT GAGCCACCGC ACCTAGCCCA ACACAACATAT
 1801 TCAATAGAAA TTCTCTCTC GGTCAAGGCAT GGTGGCTCAC GCCTGTAATC
 1851 CCAGCACTC GGGAGGGCTGA GGTGGGTGGA TCATCTGAGG TCAGGAGTTC
 1901 AAGACCAAGCC TGCAAATACA GTGAAACCC ATCTCTCTA AAAGTACAAA
 1951 AATTAGCCAG GTGTGGGGT GGGCCTGTG GTCCCAGCTA CTCAGGAGGC
 2001 TGAGACAGGA GAATCTCTTG TACCCGGGAG GCAGAGTTG CAATGACCA
 2051 AGATCATGCC ATTGCACTCC AGCCTGGGCA ACAGACTCTG TCTCAAAAAAA
 2101 AAAGAAAATT CTCTCTTAAG TTACTGGTAC TATAAGTAAT TTAAATTGGA
 2151 CTTTCAGATC TTCAATTCT CTAGTCTCTA CTTTTCTTCC TTGAATCAGT
 2201 CTTGAGAGCA GAACATACTG TTCTTTAAA GCTGCCGTGG CAAAATGCCA
 2251 ACAGATAAAA ATTGTATATA CTTTTCTCT TGGTATGTTG TCAAATCCAT
 2301 CCCCCCTTT AGAATTATTT TGTGTGTTAT TTTCAATGCA AAACATGTT
 2351 AGATCTTTG AGTTGTGTT TTGTTTTATA TGTTCATTTG ACTTAACTGA
 2401 TTTTTTGTG GTATAATTTC TCAATTGAGGT ATAATTACAT TAAAAAAATG
 2451 TAGATTCTTA AGTGTACATT TCAAATATGT TTGGACAAGT TATATATCTG
 2501 TGTAACCATC ACCCAATCA AGTGTGTGGT TTATTTAAA AACATTATTT
 2551 GAAATTTTT AGATTTAAGA GATCTTAAAT CTACCTGGAG CAAAACCTCT
 2601 TAATATAAAAT GGTTTACCT ACCATGGAAG TCTAGGTCTA TTAAGAATTA
 2651 TGATGTGTAC ACCTAAACTAA GTGTGATATT GACTTAGAGT ATTTGAAAGT
 2701 ACATTAAGGG TCTTGTACTAA CTTTTTAAGA AAGATTTAAC TTCTTTCTA
 2751 GGTGATGAA TTACCTCTTA CAAACCCAGA GTTATTTCAAG CGTGTAGGAA
 2801 TAATACCTCC AAAAGGCTGT TTGTTATATG GACCACCAAGG TTGGTATTGA
 2851 ATTATTCTA CTCCACCAAT AGATAAATG AATTAAGGAA TTAAAAAA
 2901 AAAGACAATT TTTTTATTTT TATTTTTTG AGACACGGTC TCACTCTGTT
 2951 GCCCAGGCTG TAGTGCAGTG GCACAATCTG GGCTAACTGCA AACCTCTGCC
 3001 TTCCGGGCTC AAGTGTATTCT CCCACCTCAG TCTCCCACGT AGCTGGGACT
 3051 GCAGGCGTGC ATCACCATGT CTGGTTAATT TTGTTATGTT TTGTTAGGAA
 3101 GCAATTGTC CATGTGCTC AGGCTATCTC AAACCTCTGG ACTCAAGCGA
 3151 TCTGCCACC TTAGCCTCCC AAAATGTTGG GATTACAAGC ATAACCAACT

6/32

3201 GCGCCTGGCC ATAAGGTGGA AATTTGATGT GGGCAGTTCC AACTTCTCCT
 3251 CTCTTCAGAG TGAGAATGAG ATAGGATATT TATGTCCTACT GTTCTTTGAG
 3301 GCATGCTTAG TGCATTTGTG CCTCACAGTA CATTATCTT AACAGGCCAT
 3351 GTGATTCTAG TGCAACAGTC CTCAAATTGT GGTTCACAGA CCCAGAGGTG
 3401 CTTTCATGGA CTCTGTAAGG TCAAAACTAC TTTATAATAC TGAAATCTTA
 3451 AGCCAGGCAGC AGTGGCTCAC ACCTGTAATC CCAGCACTTC GGGAGGCCGA
 3501 GGCAGGAGA TCACCCAGGG TCAGGAGTTT GAGAGCAGCC TGGCCAACCA
 3551 ACATGATGAA ACCCTGTCTC TACTAAAAT ACAAAATGAA GCCAGGGTG
 3601 GTGGCGTGCA CCTGTAATCC CAGCTACTCG GGAAGCTGAG GCAGGAGAAT
 3651 TGCTTGAAACC TGGGAGGCAG AGGTTGCACT GAGCCGAGAT TGCCCCACTG
 3701 CACTCCAGCC TGGCTGACAG AGTGAGACTC CTTCTCAAAA AAAAAAAA
 3751 AAAAAAAA ATTTTTATA TAAAGCAAAT GTACCTATAG CATACTGCTT
 3801 GACATATGTA GCCCCACAAT GACACAAAAC AAAAAACTAA AATGTTGTTT
 3851 GGCTCTTCCA CTGTTGTTGAC ATTGTTGCTG ATGGTGCAG AGCACCATGG
 3901 GTAAAAATTAA ATTACTTGCA CTGTTAGTGTG AATCAGCATT AGTGGCATGA
 3951 AACGGTGTCA GTTAGTAGCC ATTGCGTTCT TGACTGCCAC ATACTTGAG
 4001 TGTAaaaaaaa AAAAAAGTC AGTTCACTA TAAAGTCTT GGTGAAACAG
 4051 TAAAAATTAT TAATTTGTT AAATCTTCAT CTTGGGTAA TATTTGTGT
 4101 TCTTCATGAT AAAAGGGAAA ATAAATATAA AGTACTGCTG CATATTGAAT
 4151 AAGATAGTTG TCTTTAGGAA AAGCACTTGT GCAGTTATT AAGTTGCCAG
 4201 CTGAATTCTAT TGCTTTTTAT GGAACTACTAT TTTTGCTTGA ATGGACCAATT
 4251 TACAGATATG CTGTTGATTAT CAGACTGGTT ATTGGTTATT AGTTATTGAT
 4301 TACTCAAGAC TGGTTTTGTT TTATTGGCC CACATTTTT CCAAAGCGAA
 4351 CAAATTAAAGC CTGTCATGTT AAACAACCTGA CACCATCTAT TGCCATTGAT
 4401 AAAATATGAA ATGTCAGTG AAAATTAGAA TTTTTAGAAA CATATATCTG
 4451 GCACTATGTG GTGAAAGCTT TTTCTTTTT TCTTTCTTT TCTTTTTTT
 4501 TTTTTGATA AGGTGTTACT CTGTTACCCA GGCTGGAGTG CAGTGGCGT
 4551 ATCATCCTGG CTCGCTGCAA CTTCGCTC TTGGGCTCAG GTGATTCTTC
 4601 CACCTCAGCC TCCCTGAGTAG CTGTTACTAC AGGTGTTGTC CACCATGCCA
 4651 GGCTAATTCTT TGTTGTTTTA GTAGAGGCAG GGTTTGCCCA TGTTGCCAG
 4701 GCTGGCTTG AATTCTGGG CTCAAGCAAC CCGCCCCACCT CAGCCTCCCA
 4751 AAGTGTGGG ATTACAGGCA TGAGCCACAA TGCCAGCCA CGGCAGCTT
 4801 CTAATATTATT AATACTTTAA GACTTTCTG ATGAGATAAG TGGTGAGAAT
 4851 AACAAAAATT TTTTATAATG TGTTGGGAA AATGTCAACA TTTGGAAAGAT
 4901 TTGCATAACT CAACCAAGTAG TTTCCAATAA ATCAATGCTT GATATTAAAA
 4951 TATTCTATAAG TAAAAGATCC AGTCAGTGCA CAGGATAGAC CAATGTATTT
 5001 TAATGTAACA GAAGTTCTG TCATAGTCCA TGTGTAAGT AGATAGCTAT
 5051 TATAAAAAG ACAAAAGTGT TTGCAAGATG TAGAGAAAAG AGAAAAGAAC
 5101 CTTGTCACACT ACTGGTGGGA ATGTTAAATT GAACAGCCAT TTTGAAAAC
 5151 ATGGAGGTTTCTCCTTAAAC TAAAATAGA ATTACCATAT GATTCAAGCAA
 5201 TCCCACCTCTT GGGTTTATAT CTAAGGAAT TGAAATCAGT GTGTCAGAGA
 5251 TAGCTGCACT CCCATGATTA TTTCACAATA GCCAAGATAT AGAAACAGCC
 5301 TAAAATTGCA CCATCAATGG ATGAATGGAT AAAGAAAATG TGGTAGCCGG
 5351 GTGCAGTGGC TCATACCTGT AGTGCACAA CTTGGGAGG CCGAGGCCGG
 5401 CGGATCACCT GAGGTGGGA GTTCCAGAAC AGCCTGACCA ACATGGAGAA
 5451 ACCCCCTCTC TGTGAAATT ACAAAATTAG CTGGGTGTAG TAGTTCATGC
 5501 CTGTAATCCC AGCTACTCGG GAGGCAGAGG CAGGAGAAC ACTTGAACCT
 5551 GGGAGGCAGA GGTTGCAGTG AGCTGAGATC ATGCCATTGTC ACTCCAGCCT
 5601 GGGCAACAAG AGTGAACACTC CATCTCAAAA AAAAAAGAAA AAGAAATGTG
 5651 GTAAATACAC ACATTGGAAT ACTATTCTGC CTAAAAAAG GAAACTCTGT
 5701 CATTGTCACACT AGTGTGGG ATAGGGGAGA TGTTGGTCAA AGGATATAAA
 5751 AGCCAGACAC AGAAAGACAG TTACACATA ATCTCATTTC CATGTGGAAT
 5801 CTTAAAAAAT TGAACCTGTA GAAACCAAGA GTAGAATGGT GGTTACCCAGA
 5851 AGTTGTGGT GTGTATGGGG ATAGGGGAGA TGTTGGTCAA AGGATATAAA
 5901 GTTCACTTAG ACAGGAGGAA TAAGTTCTAG GTGACATATT GCATAGCATG
 5951 GTGACTATAA TTAATAATGT ATTAGTCTT TCAAAATTGC TAAAAGTAGA
 6001 TTTTAAATGTT TCTAACCCACA AAGTAATGCT AACCATGTA GCGGATGGAT
 6051 ATGTTGATTT GCCTGATTTA ATCATTCTTC AATATATACA TGTATCATAA
 6101 TTTAACCCAT AAATATACAA TTTTATTGTC AATTAAAAAT AGATTTAAA
 6151 AATTATAACA TTTTGATTAA AATTTTAATG TTGACAGCAG AAGTACTTTG
 6201 GAATTTTTTT TTTTTTTTT TTTTTTGAGA CAGAGTCTTG CTCTGTCACC
 6251 CAGGCTGGAG TGCAGTGGCG AGATTATAAG CTCAC TGCAA CCCCCACCTC
 6301 CGGGAATTCAA GCGATTCTCC TGCCCTCAGCC TCCCCAGTAG GTGGGACTAC
 6351 AGGCATGTGC CACCAAGCCTC AGCTAATTGTT TTGTTTTT AGTAGAGACG
 6401 GGGTTCACT GTGTTTCGAT CTCCCTGACCC TGTCATCTGC CGGCCTCAGC

FIGURE 3

7/32

6451 CTCCTAAAGT GCTGGGATTA CAGGTGTAG CCACCACACC TGGCCAAGTA
 6501 CTTTGAATT TAAATGAAA ATTCTATTAA GGATTTAGCT TTCATTG
 6551 AAAATTACT TGCCAAACGA TTATATTCTT AAAAGGATT TAAAATTG
 6601 TTTCACATAG GCCGGTGC GGGTTCTG CCTGTAATCC CAGCACTTG
 6651 GGAGGCTGAA GTGGCAGGAT CACCTGAGCC CAAGAGTTCA AGACCAGCAT
 6701 GCGCCAACAC AGAGAGACCC CGTCTCTGAA AAACAAACAG ACAACAAAA
 6751 AACTTAGCTG TGGGTGATGG CACATGCCG TCATCCCAGC TACTTGGGAG
 6801 GCTGAGGTGG GAAATCGCT TAGGTCCTGG AGGTCAAGGT TGCAGTGAGC
 6851 TGTGATCTCG CCACACTCCC AGCCTAGGTG ACAGAGTGT TGCCTGTC
 6901 AAAACAAATT TTTTCTACC TTACCATCTA ATTAAGACTT CTTTTGTCAT
 6951 TCTTAGGTAC GGGAAAAACA CTCTTGGCAC GACCGTTGC TAGCCAGCTG
 7001 GACTGCAATT TCTTAAAGGT AAAGGGAAAGA TTATTTGTA CTTATTGAAA
 7051 TTTAATTAACTT CTTGAAATTAT CTTATATTAA CCTTACTGTT TTTCTTTAA
 7101 TCAGGTGTA TCTAGTTCTA TTGTAGACAA GTACATTGGT GAAAGTGCTC
 7151 GTTTGATCAG AGAAATGTTT AATTATGCTA GAGATCATCA ACCATGCATC
 7201 ATTTTATGG ATGAAATAGA TGCTATTGGT AAGAATAACA CCCTTGTG
 7251 AAGTTTCTAGG ACTTTTTTTTAAATGTTAAAGA GAACTTTTT CCCTCTCTTA
 7301 ATCTGTAATT GTGACTGCTA TGAAGTAGAT ACCACAATGA ATCAGATGTT
 7351 AGTTAACCA ATTTAAATAA ATAACCTTTC ATGCCGGGT GTGGTGGCTC
 7401 ATGCCTGAA TCCCAGCACT TTGAGAGGCC AAGGTGGGCA GATCACCAGG
 7451 TCAGGAGATC GAGACCACATG GGCAACATG GTGAAACCC GTCTCTACTA
 7501 AAAATACAAA AATTAGCTGG ATGTTGGTGGC ACATGCCCTG AATCCCAGCT
 7551 ACTGAGGAGG CTGAGGCACG AGAACGCTT GAACCCAGGA GACGTAGGTT
 7601 GCAGTGAGCC GAGATCACAC CACTGCACTC CAGCCTGGCG ACAGAGCGAG
 7651 ACTCCGCTC AATAAAATAAC CTTTCACTT AACAAAATGA GAAATGTTAC
 7701 ACCAAATCA AGTCTAATT TGTCAGCATA ATTCTGCTC TTTAATTTC
 7751 ATCTTAATGT TTTAACCCAC AGACTGTTAT GTTCTGTTT CTTAAATGAT
 7801 GGTTGTAGAG GAAAAGAGTA ATGCATATAA ATTTCAAAT CTACTATCTT
 7851 AGGTGGTCGT CGGTTTCTG AGGGTACTTC AGCTGACAGA GAGATTAGA
 7901 GAACGTTAAT GGAGGTAATA TTTGGTAAAG GGGGTTATA AAGAAACCAA
 7951 TGTTTATTAATGAAAGACT GAACATTGCA TTTTGATAG TCAAAATATA
 8001 TAGAACATT TAAATGAAAT ATGAAATTG AAAATATTG CAGGAACAAA
 8051 CATGTTCTC TATCACAAAC TCTAACGCAA ATGACTACTG GAAAATAAGG
 8101 CTATCTGCCA AATTCAATTG GTGATACACC TGACTATTG TGTGTTTTT
 8151 TGAGTAGATC AGTCATTCTAT ATATTTAAAT TCTTATGAAT GTGATCTTGC
 8201 GGTAGTTTA TGAAGACATT TTTGTAATG GTCATATTAA GACTGTTGGC
 8251 AATAATGAG CTATAATTAT GTATGAAGCT GCTCTAAAAA TTATTTTTT
 8301 CTCTCACTTT ATTGCTGAGA CTGAGGCAAC TAAAATAGTT TTGATAATTG
 8351 AAGGAGATAG ATGACAGAAT GAAAAGATGC ACATAAAGCC TTCCCTCCAGT
 8401 TTACCTTTTC CCCACTCCAA ATTCTGTGAA AGTGTATCA AGAGTCAAA
 8451 TACATTCTTC ACTTCAAAATAA GAAACTAGGT AGCATGGGT ATGCAGTGT
 8501 AAATCTTTC TCCTTCTGAG TATTGAAAAA ATCTTTTTTC ATAAATTATA
 8551 CAGATCCGCT CAGAAGATAA CATAGCATTG GAAATTATA AAATCTCTTA
 8601 GAAACCTAA ATTGAGATAT TTTAAATAA CACAAATACT CATTTTATT
 8651 CAAGTAACTA ATATATCATC AACTAACACA TTGTCAGGAC TAGCTATATT
 8701 TTTAGAGGAGG TTTGTTAAAT GCACTAAAGG TTTTCATT ATTCAAGAAA
 8751 ACTTTAGAAA TTGAGGACAA TATTGTTTAT GTCTTTAGT ATTTCTGTG
 8801 ACAGTAGAAT TATTGAAAAA ATAGGGCCAG GCATGGTGGC TTCTGCTGT
 8851 AATCCCAGCA CTTGGGAGG CCCAGCTGGG CAGATCATGA GGTCTGAGCA
 8901 TTGAGGAGG CCGTACCAAC GTAGGAAAC ACCATCTCA GCTAAAGATAC
 8951 AAAAATTAGC TGGGCTGGT GGCCTGTGCC TGTAAATCCA GTTACTCTAG
 9001 AGGCTGAGGC AGGAGAATTG CTTGAACCCA GGAGGTGAGG TTGCAGTGGG
 9051 CTGAGATCGC CCCATTGCAC TCCAGCCTGG GTGACAGAGC GAGAGTCTGT
 9101 CTCCAAAAAA AAAAAAAA AAAAGCAGTC CCAGCTACTC AGGAGGTTGA
 9151 GGTGGGAGGA CTGGTCGAGC CCAGGAGGTG AAGGTTGCAG TGAGCGATGA
 9201 TCAGGGCACA GTACTCCAGC CTGGGTGACA GAGTGAACCT CTGCTCAA
 9251 AAAAAAAAGA CTATCAAATA TGCATGTTTC ATTATCAGTT TATTATCAA
 9301 TTTGTTAAAT TAACTTTGTA TCCATTATTC CTAATATAA TGTTATGCT
 9351 GACATATCAT AAGCACTTAA TATATTGGAT TTATTATTA GCTTTCC
 9401 TAAAAAATAA TTGATGAAAT TTTGGACATT CGAAATTAGA TCCACATAGT
 9451 TTAATTCTCAT ATTCTTGAC ATGATGGAAG CCTTCAGATT TATTAAGA
 9501 ACCTGGTAGC TATAGAAAGA TACATAGCTA TTAAAGGTA CATAATCTAG
 9551 CTTAGAACTT TGAGGCTAGA AACTATATCC CTTTATATAA GAGAGGAGAAA
 9601 AAGAATTCTA TCAAATGACC ATTCTGAAGA TAGAACATAT CTATCTGTAG
 9651 ACAACATATT TCATGGCATT AGACATATAA AAGGTGTGTG CTATTTTTT

FIGURE 3

8/32

9701 TAATGGTTAG AATTTTGTA AAATCTGATT CTTAATATTG TTAGTTACTG
 9751 AATCAAATGG ATGGATTGTA TACTCTGCAT AGAGTTAAA TGATCATGGC
 9801 TACAAACAGA CCAGATAACAC TGGATCCTGC TTTGCTGCGT CCAGGAAGAT
 9851 TAGATAGAAA AATACGTGAG TTAAGATTCT TTACCTACTG TCCATTTC
 9901 TTTGTGCCA TTTCTTTTC CATACTTCAC TTACCTTCC ACTGTATT
 9951 AAAAAAGATA AACTGGACT ATAAAATAAT TTTTATTTT CAGATATTGA
 10001 TTTGCCAAT GAACAAAGCAA GATTAGACAT ACTGAAAATC CATGCAGGTC
 10051 CCATTACAAA GCATGGTGAA ATAGGTAAGG AAGTCATCTA TTTTATATGT
 10101 ATTACATTG GTTAAATGAA GAAAAATACT TTAGAAATT ACTGATACTT
 10151 TCCTAAATCT GGTTTAAAT TCAGCAAATG TGGTGGTTT AAATTCA
 10201 AATACTTATT GAGCATCTAC TATAAGCTAG GAACCAATTG AAGTGT
 10251 TAAGGGCTGA CAATATAGCA AGGAACAAAA CAGACAAATT TCTGCCATT
 10301 GAGAACTTAT ATTCTTGTTA GGAAAAAAACA GATAAAGTTA GTAAAACAAA
 10351 GTATAATAGA TGATGATAAG TGCTATGGAG AAAATAAG CAAGAAAGTG
 10401 GGGGGGGGCG ATGGTGGCTC ACTCTGTAA TCCTAATGGT TTTGGAGGCC
 10451 GAGGCAGAAG GACCCGCTGA GCCCAGGAGT TTGAGGTTGC AGGGAGCTAT
 10501 GATCATGTGA CTGCACTCCA GTTGGCAAG ACGCTGTTTC AGGGGAAAAA
 10551 AAAAGAAAAG GGGGATAGGA AATTAGGGAA GTGCCAGGAC CAGGCATGAG
 10601 GATATGTTT TAATGACAG GGAGGATTAG CACAGGGAA GCCTTACCAA
 10651 GAAGGTAAATT TATTTTTAG AGACAGGGTC TCACTCTGTC CCAGGCTGGA
 10701 GTGCAATGGT GTGATCCCAG CTCACTGCCTA CTTCTGCCCT CCAAGTCAA
 10751 ATGATCCTCA CACCTCAGCC TCCTGATTAG CTGGGACTAC AGGCACACAC
 10801 CACCAACCCCT GGCTGTGTTT TTGTTAGGGG TGGGGTTCA CCATGTTGCC
 10851 CAGGCTGATC TTGAACTACT GGGCTCAAGC AATCTGCCCA CCTCGGCCAC
 10901 CCAAAGTCTC GGGATAACAG CGCTGTGCCA CTGCAACCGG CCTGGTTGTT
 10951 TGTTGTTTG TTTTAAAT TGATTCCGT TAAATGCTGA CAATAGGTCA
 11001 GATAAAGAGT TCTCAGAGTA GACCTTTGGA TTAACTATA TGGAGGTCA
 11051 TGGTAATCTT GTCAAAGTA GCTTCTTGGG AGTGGTGGAG GTGAAACCT
 11101 ATTTCAAGATG GGTTTCAGAG AGATTGGGAG GAGAGGCATT GAGTTAGAC
 11151 ATTTCTTTA AGAGTTCTAC AGAGGGGGCA GAAGAACTAG AAGGGGAATG
 11201 CCGATGAGGA GTTGGCAGAG TTTTCTATAA GATGGAAGAG TTTATGACCC
 11251 CCTGCCCCCT TTTTTTTT TTAAATAAT GCTACTGGGA ATGACCTAGG
 11301 AGAAAGAGAA ATTGCAATG TTCTTCCCTT GAAGAGGGAT TGGCCCTATA
 11351 TATATGTGTA CTTTTATGAG ACTGGAGGAA AGGCAGAGTA CATAGATGCT
 11401 TATGATGACA GTTCTTAGA TAGTGCAGGA ACTTGTGAA GTGTTTTTT
 11451 CTGAATGCTT CTGTTTCTC AGTGAAGTAG AATGCACGTT CAGAATGAG
 11501 ATAGGGAAAGT GTTCTTAGAG ATTGAGGAC AAAGGAGAAAG GTATAAGTC
 11551 ATTATCTATG GAAGTGAGGG ATTGGACTAG GGTGCAAGGCC AGTAAACAT
 11601 GGCTTGAA CCAAATTCTG CCTGCCCTGT GTTTTTGAA ACACACAAAG
 11651 TTTGTTGTA ACCAAAGCAT GCTCATTTAT CTGTTGTCTA TGGCTGCTT
 11701 CCTACTGGAA TAGCTGAGTT GAATAGTTAC AACAGAAAC ATATGGCTTG
 11751 CAAAGCATAC ATGTTTACT CTCTGGCCCT TTACATAAAA AGTTGCTGA
 11801 CCTCCAGACT AGGGAAATCT AGTATAATT CCAGGCAAGC TTAAAAACTC
 11851 TTTAGAAGTT AATGGTCCAG AATAATGACA AATAGCTGAT TGTTGAATT
 11901 CACTATCTTC ATTGCCCTG TTAGAGAGTT TTGAGCTGGA AAGACCGAAC
 11951 TGACAAAGG ATGTCATATG ATAGGTTCTC TCCACAAATA CTGAGCTTT
 12001 GCTAGATGCC AGATACTGTG CTAGCCTTGG GAATTCTTGC TCTCAGGAAG
 12051 CCTACAAATG ACTTAAACCT GATTAAGAC AATTGATGAA TATATGTGT
 12101 ATTCAAAATA GAGAACGACA TGCCCTATAT TGCCGTACCA AACGGTGCAT
 12151 CATCAAAGTT ATTCAAAACTG TAGTAGCTG TGCTGTCTTA CTTCCTCTCC
 12201 TATTCTGTAT CAGATCCATT GTTGCTACCC CAATCTTATA GCTCTTGAT
 12251 TCATGCTGT TATGTGGGTG GATGGAGAAC TCACTTTATT ACTGCTACCA
 12301 TAGATCTGAT ACTTCACCAC TTGAATCTTG CACAGAAACC AGAGAAAGCTA
 12351 GCTAATGCAT GCTGTAGCAT TTAAGAAATTG CATGTGATAC AATTATGTAT
 12401 GATTACATTT CAGTTTGCT ATACTTTATA TTTGGCTTGT ATGATTAAG
 12451 TAAACAAAGT AAATTCATT GTTATAATTG GTTTTGAGTG TTATAGGTTT
 12501 ATTCAATCC AAGATTGAT TACAGTTTG ATAAGAGTC CAGCTTAACA
 12551 GGTATCTGGA GTTCACATGT GCATAGCTAT TTCACTGTAT AAAAATAGAT
 12601 TAAGATATTG TGAGATTG TGATATTTC CTGTTTTAA AGTTTCAGGG
 12651 GTGTGTCTAA TTCTCTTGG TGCTGGTTA TTAAACAGAA GTCTTAGTTT
 12701 TTGGATATTA ATATTGTGGA AAGTTAACAG AGCTGATGTC TAGCTGATCA
 12751 AACTCAAAGT AAGCTCTTCA GTTAAATTG TCGATGTGGG CATAAAATCAA
 12801 GTAAAGGTCT AATTTTAAA ACTAATTCC AGTATTTTT CTAAACAGAT
 12851 TATGAAAGCAA TTGTGAAGCT TTGGATGGC TTAAATGGAG CAGATCTGAG
 12901 AAATGTTGT ACTGAAGCGAG GTAAAGGGTT AAAGTACAGT TTTACTATTG

FIGURE 3

9/32

12951 ATTTTGATTT TTAAAATTTG CTGAAACTGT TTTGAGTTA TCTGAAAGCG
 13001 GAGCATAGAC TTTGCAAGGA TTTGGGTTCA TGCTGTTCTT TAGGAATCG
 13051 ATTCCAGGAA ATAGGAGAAG CAGGGCAAGT GAGATGGAAA GAGGGAAAGC
 13101 TAATATGAGG GTGCACCAATT GAGGTAGGTG CTGTAGGAAA GGGAGGTAG
 13151 ATCTCAGAGA ACCATACAGA ATGCCCTTCCA GGATCACCCA GCTGAAACTT
 13201 GGGAGACTAG AACATTGATT TACCACTACT CATCCCCCAT TGGATGAGAT
 13251 TTGTCCTTGG TAGTTGAC TCCTTGCAC TTCTACCTGC CTTAGGGCAG
 13301 AATGTGGAAG GAGAGGCATG TAATAGAAC A CTGGCCCCCT AAAGTAAGTC
 13351 TGAGGTGCTA CAGAATTGCC TACCAACACCT GTGGCTGGAA TTAGAATGGG
 13401 CCAGCACCAG AGGTATCTGC TGCAAAATGA ATTGTGTATG TTGTCTAATA
 13451 CTAGTCTGTG AGCAGTGTG TGAAAGATTG ATTTATGAAT TATGTGATCA
 13501 TGCCATTGTTG GTAAAATGTA GTATTTAAAT ATAATTCTCT GTGGATTGTG
 13551 TGATACTATT TTTTCACCT CTACATGGTA TGTAaaaATT GTGTGATGCT
 13601 ATTTTATTTT CCAGTACCAA GTAGCTTTAA TACCCCTACCT AGAACATTT
 13651 AGTTTTGTC TTCCATACAG AATCTTTAAA TAGAAAAAAT AAACCTTCTAC
 13701 AGTATAGTTA CTGACTTTAT AGCTTATAGA TTTTCTTAAG TATTAGAATA
 13751 TGTGATTTCC TCTTGCTTTT CATATCATGT TTAGCCTTAG TAAATTCAAC
 13801 ACAGTGTGTTA AAGTGGCTGC TCAGGGAGGG CTTCTCAGTA CAGGTATCTT
 13851 CATGGGTATT GGGTATGCTG TGAGTCAGTA TCTGCATCAG ATATGCAGGT
 13901 CAGATACTTC TGTTCACGTC TAGAAATGCT GTCAATGCAA ATTAGGGTAA
 13951 ATCATGCTCA CAGAGCGTTA TCAATAAAACT AAACATTATTG GAGGTAAACT
 14001 GTCATATAGC TTGAAACAAAGT TAGAGTAATT TATGACATTG TCTTTCCAAA
 14051 ATGTAACCA GACCAAAATTA TTATCAGAAG ATTGCTTTGG TTAGATTGTA
 14101 ATCCAAATGCA AAGCTGTGCA GTGAACCTAA AGGCTGTTGC TATCAAATA
 14151 TACGCTTTT TTCCCTTACAT ATTCTTACAA ATTTACCTT AGTTATTGCA
 14201 AATGAGCTAT AACTCTGTG TGGATTAAAA TTGTAGTTCT TTTTTAACTA
 14251 GGTGGGACAT TCACATCTGG AAACATACTG AAATTTTTAT CTTCTTTTA
 14301 GACTTGAGG CTTTTTGTT AACATTTTTC GTAAGTTAAA ATACACTTGA
 14351 TTCAACTACA GTTGCCTTC CTGTTCAAGGT CCTGACATT TCTCTTTGG
 14401 ATTATAATAC ATCTCTATT TATTTTTCT TTTGAGACGG AGTCTCACTC
 14451 TGGCCCAAGGC TGGAGTGCAG TGGCATGATC ACTGCTCCCT GTAGCCCAGA
 14501 CCTGATCATT TCTCCTTTAT CTCCCCAGTAG CTGGGACTAT AGGCGTGGC
 14551 CACCACACCC AGCTAATTTC TGATTTTTTG GTAGAGACGG GTTTCACCAT
 14601 GTTGTCCAGG CTGGTCTCAA ATTCCCTGGC CCGAGTAATC CACCCACCTG
 14651 GGCCTCCCAA AATGCTGGGA TTACAGGCAC AAGCTACCAAG GCCTGGCCAG
 14701 GCATCTCTTG TGCAAGTTA CTTATTCACT AAAGTGATTG GGAAAATAGC
 14751 CATGTGTGCA AGCTTACAA AAATAACTTA CCTAGTTTCA CTGTAGCTT
 14801 CTAACAAAGT TTTGAAACTT TGTTATTTT TAAAAATCAG TCATTTCCAT
 14851 TCACCCGGTT TCTAGACAA CATAGATTGT TTCCCTATGT AGAAATCTAG
 14901 AAAGGAAGTA ATCCCTGAAA TCTTCTATAT TAACTCCCTC ATTTTATGTA
 14951 AGTAAAAATT CAATACAGGC AGATCCTCAG TGGAAATTGG AGAATTCTATT
 15001 TAATTAGTAG ATAGCAATAA ACTTACCTGC TTTAGTTTAT CATGAGTTAG
 15051 GATTATCTCA AAATCTGGGA CCCATATCCA TAACACAATC AATGTTAAA
 15101 AAACTGCATA CAAGGAAACT TTACCCCTT TGTCAAATAC TGTTTGAGAA
 15151 GGTACTGTGCA AAAAGTGA AGGAAAAAAT TGAGTTGTG TACTCAAATA
 15201 TGAATCAAAT AAAATACCA ATTGTACAT AAATTAGTTA AATTTTAAACA
 15251 CATGATAAT GACTTCGAGT TTGCTAAAA CCCGCTGTTG GCTTTCTATA
 15301 TGATTCCCTA TTCTCAACGT TTTGATTAT TAACAAAGAA TGGCTATCAA
 15351 ACTTACTCAA GATTTTTTTT CCCCCATAAA TGTGTGCCTT CCAGCAAATT
 15401 GCTTCTGTGCA AAGTTAAGTT ACGCTTAAAA TGTGTATGTG TTGGTAGTT
 15451 TGATTGCTTC GGTTTTTTAT GCTGTTTTT ATTAAAGAGCT ACAATCAGAT
 15501 ACAGGGACCA TTTAAGCCTG ATTTTTATT TTTTATTATT TTTGAGACAG
 15551 AGCCTCACTC TGTCAACCCAG ACTGGAGTGC AGTGGTGCAG TCTTGGCTCA
 15601 CTGCAACCTC TGCCTCCCGG GTTCAAGCGA TTCTCCTGCCTA CTAGCCTCCC
 15651 AAGTAGCTGG GTTCAAGAT GCCCACTACT ACGCCCAAGCT AATTTTTCTG
 15701 TTTTTAGTAG AAACGGGGTT TTACCATGTT GGCTAGGCTG GTCTCGAACT
 15751 CCCGACCCCA GTTAATCCGT CCACCTTGGC CTCCCCAAAGT GTTGGGATTA
 15801 CAGGTGTGAG CCACCGTGCC CAGCCTTGAA CCGGATGTTA AATATTCTATA
 15851 TAATGGTCAT ACCTGTTTTT GTTTAGAAC ATAATCACAA CACCGCTATG
 15901 GATTTTTTTT TTTTTTTTTT TTTTGAGATG GGGTCTCGCT CTGTTGCCAG
 15951 GCTGGAGTGC AGTGCCACTA TCTCAGCTCA CTGCAACCTC CGCCTCTGG
 16001 GTTCAAGCCA TTCTCCTGCC TTAGCCTCCC GAGTAGCTGG GACTACAGGC
 16051 GCGGCCACC ATGCCCAAGCT AATTTTTTTT TTTTTTGTA TTTTTAGTAG
 16101 AGATGGGGTT TCACCGTGTG GCCCAGGATG GTCTTAATCT CTTGACATTG
 16151 CAATCTGCC ATCTTGGCCT CCTAAAGTGT TGGGATTACA GGCGTGAGCC

FIGURE 3

10/32

16201 ACCGCACCCG GCCTGTGGAT TTTAATTGAA AAAAGATAAGT GGTTTTAGC
 16251 AAATTACAAC TACTGGCTCA GAAGTAATAA ATCTAAGCTT CACATTATT
 16301 CCATAGAATT ATATTGTTT TCTTATAATG AACATATAAT TCATATGTGA
 16351 TATATAGCAG TCATGTTGTT TTATTCTCTA CAGGTATGTT CGCAATTCT
 16401 GCTGATCATG ATTTGTAGT ACAGGAAGAC TTCATGAAAG CAGTCAGAAA
 16451 AGTGGCTGAT TCTAAGAAGC TGGAGTCTAA ATTGGACTAC AAACCTGTGT
 16501 AATTACTGT AAGATTTTG ATGGCTGCAT GACAGATGTT GGCTTATTGT
 16551 AAAAATAAAG TAAAGAAAAA TAATGTATGT ATTGGCAATG ATGTCACTAA
 16601 AAGTATATGA ATAAAAATAT GAGTAACATC ATAAAAATTA GTAATTCAAC
 16651 TTTTAAGATA CAGAAGAAAAT TTGTATGTTT GTTAAAGITG CATTATTC
 16701 AGCAAGTTAC AAAGGGAAAG TGTTGAAGCT TTTCATATTG GCTGCGTGAG
 16751 CATTGTTAA AATATTGAAA GTGTTTGAG ATAGTGGTAT AAGAAAGCAT
 16801 TTCTTATGAC TTATTTGTA TCATTTGTTT TCCTCATCTA AAAAGTTGAA
 16851 TAAAACTGTG TTGATTCACT TCTCCTACAT ATATATTCTT GTCTTTCTG
 16901 AGTATTTA CTGTTGCTCCT TAGGTTCTT TAGCAAGTAA ACTATTGAT
 16951 AACCCAGATG GATTGTTGAT TTTGAAATAT TATTTTAAAG TAGTACACAT
 17001 ACTTAATGTT CATAAGATCA TCTTCTTAAA TAAAACATGG ATGTGTGGG
 17051 ATGTCGTAC TCCTCCTTC AGAAAGTGT TACATATTCT TCATCTACTG
 17101 TGATTAAGCT CATTGTTGGT TAATTGAAA TATACATGCA CATCCATAAC
 17151 TTTTTAAAGA GTATGATTCA ACGTAATATT TGCTAATATG TGACTGGTT
 17201 TTCTTGGTTT ATGTAAGACG ATAGGTCCCT GTTGAGGATG TGAAGGTCTG
 17251 GACCCCTTC CAGGAAAAAT TCTAACATAC AATTGGCGT ATACTATAAT
 17301 TTCAGGAAAT TTATGTTTC CCAAGCTCAT CCAAGGATTC TTAGGTATG
 17351 TATGGATACC TGCTAAGAG TGATGATGT AGGGGATGTA GGAGTGTCA
 17401 AAATGTTCAA AACATGATTT CTGTTACCTA TACATGATT TTATATCATC
 17451 TGGCAATAAA AGCTATAACA AAGTACACAA AGGAATCATC ATTGGGCATC
 17501 AATAATTATT AAAGATGCTG GTGAAAAGAA AAGACAACCT CAGTTCATA
 17551 AACACTAAAG AACCAAAAT ACATGACCTA GCTAATTATA CAATAATTCT
 17601 TCAAATAAA AACTCCCTAG CAGGATATAA TGTGCCCTTT TATAATTTT
 17651 AGAAAGATGA ACAGTTAAA TAGAAAATGG AGTGGTCAAG TTAGCCATCT
 17701 CATACTAAA ATTATTGTAC AGTTCTATT CTATGTGTTG GCAGTGCATT
 17751 TTATGTCACA AAAAGTAGAA TGAGGGGGG GTTTTAAGTC AAATATCTAT
 17801 GTGATCTTT CACTTATAAT TTGCAATTAG TTAAGGAGTG ACTATCTGC
 17851 CTTTACCTT TGTGCTGGCG GTGGTTTTT AAAGAATCAA TTTGGTGTAC
 17901 AAATCCTTTC TTCTTTTTT TATTTTGAT TTTTTTGAG ATGGAGTTTC
 17951 GCTCTTGTG CCCAGGCTAT AGTGCCATTG CACTATCTCA GCTCATTGCA
 18001 ACCTCCGCCT CCCGGATTTA AGCGGTTCTC CTGCTCAAGC CTTCTAAGTA
 18051 GCTGCGATTA CTGGCATGCG CCACCCACCC CAGCTAATT TTGTTTTT
 18101 AGTAGAGACG GGGTTTTCC ATGTTGGTCA GGCTGGTCTC AAACCTCCGA
 18151 CCTCAGGTGA TCCACACGCC TCAGCCGCCAA AGATGCTGG GATTACAGGC
 18201 GTGAGCCTCC GCGCCCGGCC CAAATCTTTT CACCATGGG TTACAGGCAT
 18251 AACGCCACCA CACCCAGGGA ATTTAAAAT TGTTTTTAG AGAGGGGGT
 18301 CTTACTATTT TGCTCAGGCT GGCCTAACTCC TTTTAAAAGA TATTGAAAGC
 18351 CATCTGGTTT ATTATTTTTA TTTCAAAATA TAATAATGGA AGAAATTAA
 18401 CAGTATTATA TACAATTTC TGAGTCAGCT ATCAGTTCTT TTTCTGATT
 18451 TTTCCTAGT TGCCATTCTT GATATTCTT AGGTAATCTA AACTGAGTTG
 18501 TATTTTCAAG TACTCTCAA ATACTTTAA AAATTTAAA TTGAGCCGTT
 18551 TAATTCTTTG CTAAAGGTG ATGGGTATT TATTTCTGT ATGGCACCAC
 18601 GTGATTTAA ATTGAACCTC TCATTTATTA GTCATTTGGT TATAAACTCA
 18651 GCATAGATTG CGCAGAATTG TGAGAGGGG GAAACTATAG CTTTCCTTTC
 18701 GGATGCCACT GGTGGTAGC CTGTTTTGCC TGTTTGTCT TATGTTAAAG
 18751 AAGGGCTCTA CGTCTCTGTCT GAAAGGGCG GAGCTGGCTC GGACGCC
 18801 ACTGCCCTTC CCAGGACCTT CACTCGTCT GTCCCCACCGC AGCCCCGCCT
 18851 CCTCCACGCC GGGTGAGCTG TGCCCTAGCA GCATCCGAGG CTCCGCC
 18901 CCCACCCCCC AGCTCTGCG CTCTAGCGA GGGCGGAGG AGGGCGGTGG
 18951 CGCGCTGACA CCTGGCGGCG CGGGAGGGG GGCAGAACGC GAGCGTGGC
 19001 TGGGATTGGC TGAGGCGACG CGGGTGGAGG GGGCGGGAAAG GAGGCGGG
 19051 GACGGGTGT CGGGCTGGTT CCTGTCGCTGG ATCCTGGCG GCCTGAGGG
 19101 TACGGAGACT CTGGGGGAGG GAGACGGCAG CGGCATGGCG GCCGGGTGTA
 19151 AGACGCCGA CCCTCCTCTT CCCTGTCTC GCGCCGCCG CTGCTGGAGT
 19201 CACTGGGACC CTCTAGCTG CGTGTGTTAG TTGTAATCCC GCCGCCCTCC
 19251 TGTCAAGGCTCT CGCCTCCGCC GGGCCCTCTT CCTTCCGCCG CGCAGCCAG
 19301 CCCGAGGGTC GGCGGGCTGT GTAACACTCT CCCACCCCCC CCACCA
 19351 GCGGGCCAGC ACCATGGAGG ACGTGAAGCT GGAGTTCCCT TCCCTCCAC
 19401 AGTGCAAGGA AGACGCCGAG GTGAGTCGCT CCCGTGGCTG CCACGCCAG

FIGURE 3

11/32

19451 GCCTCTCCCT GTGGCTCCGG CCGAGGGGCG ACCCCAGTCC CCAACCGTCT
 19501 TAGCGCCAC CTGTACGGGC GCCCCTGCCTC CTAAGGGCGT CCCGGGACCT
 19551 CTGAACCGA GCGGTCGGCT CCAATCCCCA CTGAGTTGCT CGTCCTCTCC
 19601 AGACCCCGCG GAGGGGCAGC GTCTGGTGT A CTTACATTTG AGAAGAGGAA
 19651 AAGCAATCCC TTACTCCCTA GGCTTGGCAT CCAGGACTGA CCTGGAGTAA
 19701 GGTTCCCTT TTATTGTCAA AGTAACAAAGA GAGCGAAGTT GGTTTAGTCT
 19751 CCTTTTGAGG AATATCTGTG GTGTAACAGA TTCACTTGTG GGACACATGG
 19801 CCCCCACATGT GAAAATGACT CGGGCCCTGA AGTTTGGAG CGCGCCTTCG
 19851 AAAAGTTTCC CAAAGTTTT TGTTTGTGTT TGGACAAAGC TATGACCCCG
 19901 ACAACAAAGT GTCTCAAAGC TAGCTCATCT TAATCTGAGA ACTCTTAATC
 19951 AGAAATCTTG ACCTTGGAG GAAAATTAAT ATTGAAAGTA AAATACTATA
 20001 TACCTTTCTC CCTGGTTCTA AATTTGTGGC TATTTTTACT CCACCTTGA
 20051 TCCCTGCCTG CTGTTCTAC TCGGATTTT TTTCATCTGT TGCTAGTTA
 20101 ACATTTACG GCATTGCAGA CTACTAAATT AGAATTTCT GGAGGCTAAA
 20151 TTAACAGAC GAAGATACTC AGCTATACTT TAGTAGGATT AAGAAAGAAA
 20201 ATCTAACATC GCTAGTTAAA AATACCTTTA AAGTAGTTG GAAAATAAA
 20251 GCCCTATTAA TAGGAGACCA TTCAATTAT TCCGAATATT TATTCTATTG
 20301 AATATCTTCA TTGGAGGTTC ACTTTTTTTT TTTTTTTTT TTTGAGACGG
 20351 AGTCCTGCTC TGTCGCCAGG CTGGAGTGCA ATGTGGCGCG ATCTCGGCTC
 20401 ACTGCAACCT CGCCCTTCCG GGTTCAAGCG ATTCTCTGCG CTCAGCCTCC
 20451 TGAGTAGCTG GAACTACAGG CGCGCACAC CACGCCAGC TAATTTTGT
 20501 GTTTTAGGG GAGACGGGTT TCACCATTTT GGCCAGGGTG GTCTCGATCT
 20551 CCTGACCTTG TGATCCGCC GACTCGGCCCT CCCAAAGTGC TGAAATTGCA
 20601 GGATGAGCC ACCCGGCCCG GCCTAGGTT ACATTTTGT TTGGAGGGCT
 20651 CTCTTGTGGT ATTGATGCTT GACAATTACA TTTGTTTAA GAGTAGAGAC
 20701 TTTGTTGTG ACTATCACTG TTGCAAAATG TAGTGCAGTG GTGTGATCTC
 20751 GGTTCACTGC AGTCTCGAAC TCCCCATGCTC AAGCCATCCT TTCACCTCAG
 20801 CCTCTGGAGT AGCTGGGACCT ATGCCGGGCT AATTTTTCTT TTTTTTTTT
 20851 TTGTAGCGAT GGGTTTTTC TCCAGGGCTGG TCTCGAACTC TTGGCCTCAA
 20901 GATCCTCCCG CCTTGTCTC CGAAAGTGTG GGGATTACAG GTGTGAGCCA
 20951 CTGACCTGG CCCAAGATA TACTCATGGT TTTTTGTGTT TTTTTTTTT
 21001 TTTGACACAG AGTTCACTC TTGTTGCCCG AGGCTGGAGT GCAGTGGCC
 21051 TGTCTCAGCC CACCGCAGCC TCTGCCCTCGG GTCCCGGTTT AAACAGTTCT
 21101 CCTGCCTAAG CCTCCTGAGT AGCTGGGGAT TACAGGCCCG CACCGCCAGG
 21151 CCCACCTTTT TTTTTTTTTT TTTTTTGAGA CAGAGTCTCA CTCTGTCGCC
 21201 CAGGCTGGAA TGATCTTGCA GTGGTGCGAT CTGGGCTCAC TGCAAGCTCT
 21251 GCCTCCCGT TTCAACGCCAT TCTCCCGCC CAGGCCCTCCG AGTAGCTGGG
 21301 ACTGCAGGCA CCCGCTACCA CACCGGGCTA ATTTTTTGT ATTTTTAGTA
 21351 GAGACGGGGT TTCAACCATAT TGCCCAGGAT GGTCTCAAC ACCTGACCTT
 21401 GTGATCCGCC TGGCTTGGCC TCCCCAAAGTG CAGGGATTAC AGGCGTAGGC
 21451 TACCGCGCCC GGCAATATA CTCTTAGAAA ACAGGAGGTC ATATTTAGGC
 21501 TAGTTATAAA AATGAATTAA TACTTAACAT ACAATAATGT GAATGAAGAG
 21551 TATGCTTTA TTTATTTATT TATTTTTTTG AGACGGAGTT TCACTCTGT
 21601 TGCCCAAGGTG GGAATGCGAGT GGCGCGATCT CCGCTCACTG CAACCTCCGC
 21651 CTCCCACGTT CAAAAGATTG TCCTGCCCTCA GCCGCCCTGAG TAGCTGGGAT
 21701 TACAGGCCCG CCGCACCACT CCGCTCTAAT TTTGCTACTT TTAGTAGAGA
 21751 CGGGTTTCA CCATGTTGGC CCTGCTGGTC TGGAACGCCA GACCTCAAGT
 21801 GATCCGCCCTG CCTCGGCCCTC CCAAAAGTGTG GGGATTACAG GCTTGAGCCA
 21851 CGCGAAGGA GTATGCTTTC ATATCCTCAA AATGATTCAAG TAATTTAGC
 21901 ACTTAACACTGC AAGCAACCTT ACAAATAATG TAGAGGAGTC CCACATTCCA
 21951 GGTGAAGAAA TTGTAACCTTA CTGAAAATAA GTGATGTGCC AAATTAACAA
 22001 CACAGTAGCA CAAGACACAG AAGGACCTCC GCCTCCCTAAAT TCATTGTTCT
 22051 TTTTAATACA CTTCAATTCT TCCCTGCCCT AATCTTAAAA ATTCTAGTTT
 22101 AAAATTCTTCC CGGACTTTGC ATTTAATCTG TTACTGTGTA TATCATTATG
 22151 TATGCCTTAT TCCIGCAAAA CTGATAAAATT CTTGCTGGGA ATATATAACT
 22201 GTCTTTCTG TGTGGGACTT GAAAACACAC TCTTTTTTTT ATGCTACCG
 22251 ATGTGTGGGG GTTTTCCAT ACCAAGCAGT TTTCCAGCAG GCATGAACATG
 22301 AATGTCCCCT AATTCATTC TGACACATAT GTACCTGAAG TTAGTCAGAT
 22351 CCCACAGGTT AATGGGCTCA GTCCCGCAAG GCTGCCCTCA ACCTCAGATG
 22401 GTATCACAA GTAGTAGGTT GTCACCTATA CACTCCCTGAC TGACTGTAAA
 22451 TCAGGGTTC CGTTACTCCC TCCTGGTTC AGTTAACTTG CTAGAGTGAC
 22501 TTACAGGACT CAGGGAGTA CATTACGGG TTTTATTAAAGGATACTAC
 22551 AAAAGATCAG TGAACAGCCA GTAGGAAGAG ATGAATAGGG CAAGGTATGG
 22601 GGGAAAGGGGC ACACCAACCAT CCCAGTGTCA CCAGTAGAGT CATGATTGCA
 22651 AGCTGTCCAG GTTCTGGCG TTTGAACAA AGAATTGGAC AAAACTCCAA

FIGURE 3

12/32

22701 GCAAAGAAC AATGAAGCAA CAAAAGAAC AAAGCAGGGAA TTTATTGAAA
 22751 ACAAAGTAC ACTCCACAGT GTGGGAGCTG CCCTAGCAGC ACTCCCCCCC
 22801 GACCCCCGCT GCTTACCGA ATCTTCTTGG GTCCAATAC CCCCTAGAAG
 22851 TTTCCCAATTG GCCATTCCAT GCTCACCTCA TGTAATGAA GAGGTGGCTT
 22901 GCAATTGGTC TGATTTGGTTC CCAGACCCAC CCCACATCA GTCCGCTTGG
 22951 TTGTGGACAG CGACCATTCA GTGGCTAGAG TGAAGTTACA AAGTTGCAAA
 23001 CGAAGATTCC ACCGGCAGTC AGTCTGATT GTTGAGGACA GCCAATTCC
 23051 CGCTACTGT GCAGAAAAGG TAGGTGGTT GCAACGGGAG TAGCCTCTGG
 23101 TCCCTTGTT ACTTAGGCCTT GAAAAGTTAG GGTTTCCCT TCAAGTTAGT
 23151 TCTGGGAAGT CGGGGTGAAA CAGCCTTACA TTCCCTGCCT CCAGACCCCA
 23201 TTCACCTGCC TCACTAGCAC CTCCAGTGTGTT TTCATCCAGA AGCTAACAA
 23251 ATCTTATTCA ACGGTTTTA TAGAACTTCA TCTCCATCCC CTCCCATAGA
 23301 GTGTGTGTT GTGTGAGGC TGAGAGTTCA ACCCTTGTGTT CACATGGTCT
 23351 TTCTGGTGCAC TGGCCCCCCTT CAAATCACT TCAATTAGCAT AATCAGGTTT
 23401 GATAAAAAAAT AGTGGCTCAT AAATAACCAA AGACACTCCT ATTAGAAAAT
 23451 TCCAAGAGTT TTAGGAGGAC TGAGACAGGA ACTGGAGAGA AAGACCATGT
 23501 ATTTCATATT ATATCACAGG GACAGAGGTA ATGGTTAAAG CTAGTGGATA
 23551 ATGATGCAAG TATTGTCTGC TGAAAGCCAA TTCGTTCCGTT ATTCTTAAT
 23601 ATTGCATGTT TGGTATCTT TGGTTGCAAG CAACAAAAAC GAATTTAAGA
 23651 AAAAGAAGAA GTAAATTAAAT CCGGCGGGGC GCGGTGGCTC ACGCTGTAA
 23701 TCCCAGCACT GTGGGAGGCC GAGGCGGGACG GATCACGGAGG TCAGGAGATC
 23751 AAGACCATCC TGGCTAACAC GGTAACACCG CGTCTACT TAAAAAAA
 23801 TTAGCTAGGT ATGGTGGCGG CGCCCTGTAG TCCCAGCTAC TTGGGAGGCT
 23851 GAGCAGGGAG AATGGCATGA ACCCGGGGAGG CGGAGCTTGC AGTGAGCCGA
 23901 GATCTAGCCA CTGCACTCCA GCCTGGGAGA CAGAGCGAGA CTCCATCTCA
 23951 AAAAAAAAAG AAGTAATTAA ATCCAGAAGG GTAGTGGTGC AGCTAGTTTC
 24001 AAGGATTGAA CCAAACCCAG GTATTATAAA GCATCAGAAC TGCCCTTGTC
 24051 TCTCATGAGT TCTTATCTCT ACTTTCTCTC AGAGTCTCTG CTTTCTCTCT
 24101 GGCCTCTCCA AGATGTGAAG CTGGCCATC TGGGTCACA CCTTTATGAG
 24151 CTTGGTATT GAGGAATAAA ACTGAACACT TCCAGCTTCT GTGTTTGA
 24201 TCTAGAGGAA TTGCCAATT TAATTCTATGT TCCCACACTT TGGATCAGTC
 24251 ACTGTAGCCA GGAAGGGCA GATAAACATGA GGGGCCCCAT CTAGTCATA
 24301 TCCCTAATTCTT CTTGGCTAGA GGAGTGAAGT TTATTGTTG TAGCCCTCCC
 24351 ACCAAAAACCA TAGGAACATT TCCACAGGTA GAGGGTACTT TCTGGGCTGA
 24401 TAAAACATATA CATAGGGGCC ACATAAATAA ACTATTAAAT AGGAGCATAT
 24451 AGTTATTCTAT AATAAAACTGA CTAATAAAGCA CTGTTAAATT TCTAACTCTC
 24501 ACTGAGATAA TCTAAAGTGT CAAATGGTCT TAAGTACTTA GAGTGATCAG
 24551 CCAGCATTTGTT TTCTTGACAA CAGGGAGCAC TACCTGGAAA TCCAAATTAC
 24601 AGACCAAAATT TAATAAAACG GGAATTCAAG CAGAGATTC AGGGAATGCT
 24651 TTAAATGTTA ATGTGATCAA GCTATGATAG GTTGATGATT CTGTCACCTC
 24701 TACAAGAATA TTACTTTCAC GTTTCTGAA ATATTGGTAT TCTTTGTATA
 24751 GGACAGTGCT AACAAAAATT TAGATCAGTC AGTTTGTGAA AAGATTGTTA
 24801 CTTTTTTGTT TAAACACATT TTCACTGAATT TCCATTGTTT TGAAGATGAA
 24851 ATTTAAACCC TTGACATTAT TTCCAGGGTC CTGATGTC TGACATCTGC
 24901 ATACCTCTC AACCTCACTA TGAGCTACTC TTCTGCTCC TTTCTCTGTA
 24951 AGCCCTAGCC ATATTATCTCT TCTCTCAGTT CCTGGAACTGC TTTAATTCTC
 25001 ACCCCCCGCC TTCAAGGCCT TTATGTTTGC TATTTCCTCC TGCCCTGGCT
 25051 GCCAGCACCT TCCTTACCCCT CACCTAATTAA ACTGCTTACCC CTTGGGTTAG
 25101 ATCCCACCTT AGGCAACATT TCTTCAGAGA AGCTTTCCCT GTTGTCCAGT
 25151 TTCTCTAACT CCTTCCTCA TCCCTAGAC TGTTCAATT CCCCAGCTAC
 25201 TATGGCACTT GGTACTTTAA TACTTACCTT TGTAACATT AACAAATT
 25251 GGTCTTGTCT TATTTCCTAT TTAGACTGAA CCTTTCTATAA GAGAGCTTAG
 25301 ATATTAGGAA GAAGGAGTAG CTGATAGTAC CAATTTTAA GCAAATTGGT
 25351 TGAGCTGGG GCTATTGGTT TTATAATTAA AAAGTTAATG TTTTATCTTC
 25401 TCTCTGACA GAAAGTGAAT TATTATTTC CATTGCACTT TAGCACTTT
 25451 CCATCTTCC CTTTCCATT TTCTTGTGAA TCCCGTAGTA CAGGATC
 25501 GATAGGAATT ATTTAACATA CATGGCTGAG GATTCTTTT CTAGCTCCTT
 25551 TATTAGAAT GGTGCTTTT AACCCCTACT CTAGAGTAAG GAATTTTTA
 25601 AAAATACTGA TGCCCTGGACC CTACCAAGCAC CTATTGTAAG TTAATTATC
 25651 TGAATGAAGC TAGATGATTC TAATGTTCAAG TCAGGTTAA AAATTGCTGG
 25701 TTAGAAAT ATCTTGAGTA CTCTTCTGCCC CCTCCAGTCC CTGCCACCT
 25751 TCTCTTTTA TTGAGTGAACATTTCTT TTCTCCTTTG ATTTAAGC
 25801 AGCTCAAGCT TGTTGGGAA ATGAAAGGAA AAGGACTTTG GAGGGATTTA
 25851 CCTATTCTT CTAGGAGAGA AAGTGCATA CTAACCTTTC TGTTTGTGG
 25901 AATGTCCCAG TGCAAGTCTA GTATTCTGAT GTTTTTTTC TTCCCCAAC

FIGURE 3

13/32

25951 TGTTGCCCCC CACCTCCAGC CTATGTACAA TTTGTGTTT ATTTTAGTAT
 26001 TGTGTATATA GGATTCAAGCA CTATCCTCAA ATGTATGAAC ATATCCCCTG
 26051 TGGATAAAGGG GGGACTACTG TATTGTAAA AGTCATATT TCATATTCA
 26101 ATGCATATAA GAATTATTTT ATCTAATGGT TACAGTCTAT ATCCCTCAATT
 26151 GATGTGTTA TTTGAGGGTC TTTGAACATT TTTGTAACTT TTCTCTATCC
 26201 AAATGCAGTT TTATAGATCA TTTTATGGA AAGGAAGGAG ATAATTCCGA
 26251 AGGATGTTT AACATGTGGT ACTTCTACC TCATGTTGAT CGAAAGATTT
 26301 TCACTGTGA ATTAATTGTT CTCAGAATCA TGTTGTTCA CAATAGAGGG
 26351 TTATTTGGT TTATCTGGCT TGCCCTGGTT TGGTTAATGT GGTTGAAC TG
 26401 CTTGGCTACT CATAAAAGTTT GGGAAATTGA TTTCTACTAA TTAATTACAA
 26451 TAGTAACCTA AAATAGATCA TTGCTGGTGA TATGGAGATG CCTCCATTAA
 26501 TACCAACGTT TCTAAATGTA TAGATTCAG GAGTAGTGAG AGCAGGCTGA
 26551 GATTAAGAAT TAAGTGTGAT AGTGGCAAGA CTTGGTTATT AGACGTGTG
 26601 TCAAGCAGGAT GTGTGGTAGA AGAAGACTAT GAGCATTCAAG ACTTAAATC
 26651 TTGGTTAGTA AGATCCATAG ACAGGCAGGG TTTTTTGTG TGTTGTTTG
 26701 TTTAACAGG TTGGAGTGCAG TGCGCAGGAT CTCAACTCAC TGCAAGCTCC
 26751 GCCTCCCGGG TTCACGCCAT TCTCCTGCCT CAGCCTCCCG AGTAGCTGGG
 26801 ACTACAGGGCG CCCGCCACCA TGCCCGGCTA ATTTTTGTA TTTTGGTAG
 26851 AGACGGGGTG TCAACCATGT TAGCCAGGAT GGTCTCGATC TCCTGACCC
 26901 GTGATCCACC CTCCCTGGCC TCCCAAAGTG CTGGGATTAC AGGCGTGAGC
 26951 CACTGTGCCG GGCCAAACAGG CAGGTTTAAG GTTTGTCTG TAGGTGGTAA
 27001 TCTGGTTAG GGCAGCAAAG AAGGTGGATT CTGAGATCAG CATCTGATGA
 27051 TAACACCAAG AATACTTCA AATGAACTTT TCTGTGAGAG AAAGCTTTCT
 27101 AGGTTCAAA GGATCCATAC CTATTGCAAGT AATTACTAAAT GTTCTCTGAA
 27151 GAAGGCTCT TATCTGTCT GTGACTAGGA ATAATTTCAT ATTCCCTCCT
 27201 ACTATACAAAC TTGCTTTCC CTCTTATAAT ATCTTCCATA TATATATATA
 27251 TCTCAAGAGA GTCTTTCATG TTGTATTACA TATAACCTTA TGGAAAGCTC
 27301 AAAAGTTCTT TGAAGCCTCT GTTTTGCTA AAAGGTTCAAG GTAAATTG
 27351 CATTCTATTA CATATGTGCC GTTTGTTT AATATAAAA TTGTTTAAAT
 27401 TAGTAACCAAG TGAAAATACT GTTCTCCCT AAAGAATTTT TTTGATAAAA
 27451 TTGATACTTC AGTGGCTTTG AGITGTTTT GGCATATTGC CAAATGAAGG
 27501 TGTTGAGGAA ATGCCACTCC AAAATATGAC ACCTTGATAT ATTGATTACT
 27551 TTAAGTTGGA AACACTTGCA AAGTAGCAAA TGCAAAGAAA CACTTCTCT
 27601 GAACCTCTGT TACCTACCTA AGGACAGATC CTCCAAAAGA AGCTCAATT
 27651 GCTCTTAGGG AGTTTGATCA ACCAGGGAAAG ATTGTCTCTT ATCACTGGAG
 27701 AGGAGAGTAA AAGTCAGCAC CACACCCAGA CAAACTGACA CAAAGTATCA
 27751 TCTATTATA TTCTAAGGGC CCATTATCT GTCTCCAGAA TTGTTCTCT
 27801 AAATTGCTCTG TATACTCTA CCCCATGCT ATATAAAGG TATATAAATC
 27851 CCTAAATATC ACTTTTTTTT TTTTGTTATA CACGTTTCTT TCCTGTGATA
 27901 CCCCATGCA CATAATGAAT CTGTATACCT TTTCTCCGTT TAGTTTATT
 27951 CATAGACTGG TTTGAAATAT CACGGATTTT GTTTGTGTTT GGTATAACT
 28001 TTTTAAAAT ATCACTTTT TTTTTTGGT ATACACTTTT CTTTCTGTG
 28051 ATACTCCCAT ACACATAATA AATTGTATA CATTTCCTCC ATTTAGTTA
 28101 TTTCATAGAC TGTTATCGAA TCTGTGATGGT AGAGGGAAAG TCTTCTTGC
 28151 CTTACACAAAG TATTCTCCAG AATATATTTA CACCATTCCT TGATATGTG
 28201 TGCCCTGTTT TTTTTCTTT AATTACACAA AATTAGTGAA TTTCACTTA
 28251 GATAAATTCGA AAAACTACGCA TTCTTTAAAT TGATTTCTT CTTTATCACA
 28301 GCTCTGACAA GTTGCTTCAG GAAGATAAGG CTGGCTGTTA GACTACTG
 28351 GAATCTTTA AAAAGAAAAA AGTCAATAAC ATTTAGTGCA GTAGATCTCT
 28401 GAAATGCATC TATTGTGTC TTATTCTGTG TCAGGCACTG TGCTTATCAT
 28451 TAGGGTACCG ATGACTAAAA AGAGTATTG GCCTAAAGTC TTTAAAATC
 28501 GTTTCTTTT TCCTTCTTTT CTTTTTTTTT TTTTTTTTT TTTCGTTGAG
 28551 ATAGGGCTTG TCTCTGTTGC CCAGGCTGGA GTGCAATGGC ACCATGATGA
 28601 CTCACTGCAG CCTCGACCTC CCAAGCCCGA GTGATCTTCC TGCCCTCAGCC
 28651 TCCAAGTAG CTAGGACCTC AGTCATGCAC CACCAACCGCA CCTGGCTAAT
 28701 TTTTAAATT TTGTAGAGAT GAGGTCTCCC TATATTGCC AGGCTGGCT
 28751 TGAACCTGGG CTCAAGCTAT CCTCCTGCC CAGCCTCCA AAGGGCTGGG
 28801 ATTGCAGGTG TGAGCTACCA TACCTGGCTA AAAACTCAT ATATAAAAAG
 28851 ATTACCAAA CACATGGTA AGTAAAGAA TCTAGGCTGG GCGCGGTGGC
 28901 TCACTGCCTG AATCCCAAGCA CTTTGAGAGG CCGAGGCAGG TGGATCATGA
 28951 GGTCAAGGAGT TCAAGACCAA CCTGGCCAAG ATGGTAAAC CCCATCTCA
 29001 CTAAAATAC AAAATTAGC CAGGTTGGT GGTGGCGCT GTAAATCCA
 29051 GCTACTCAGG AGGCTGAGGC AGATAATTGC TTGAACCTGG GAAGCGGAGG
 29101 TTGCACTGAG CTGAGATCGT GCCACTGCAT TGCACCTCCAG CCTAGGCCAC
 29151 AGAGCGAGAC TCCGCTCAA AAAGAAAAAA AAAGTATCTA GTAAACAAATT

FIGURE 3

14/32

29201 ACATTTCCCT CATTGCTGGC TTAGAAATTA CATGCTTTAT TTCTATTCTG
 29251 TTAATATCCA TAAATTAGTC ATTATTTTAT GCAGCCAATA TTTGTTTAAT
 29301 TGTAACGTGTA TGTTTGCCGT AAAGTTCAATT CTTACATTGA AAGACTGTAT
 29351 AGTATATTGA TTCAGAGAAT GAACTCTGGG TTCAGACTAT CTGGATCCAA
 29401 AATCAAGTTA CTTAGGTCT CTATGACTAA AATAGACAGT GATAGTATCC
 29451 CTTCTTCAAA GAACATTAA ACTTTTTTC TTAAAGATA TTTTCCGAG
 29501 CATATATTCT TAATAACAG TTGTTTTGT CCTGCCACTA TGAATGAATT
 29551 ATTTGTGTCC TCTGGCTTCT GTTCATGCAA TTGAGAAGTC AGTGTCCATC
 29601 TGATTGCTCT TCCTTTGTGT GTAATCTGTC TTTGTCTAG TTGATCTTTT
 29651 TTAATAAAGG TAAAATTAT ATAGTGTAAAT GTACAAATAG TAAGTGTGCA
 29701 GTTCATTGAG TTTTGATGAA CATAACACTAA TCCACCCCAT CAAGATAACAA
 29751 GAACATTCTA TTAGCATAGA AGGTTACATC TATTTCCAGG CATTTCCTCT
 29801 CCCATTCCAC AATAGGAAAC CAGATTCTA TCAACATAGA TTAGTTTCC
 29851 TTGCTCTTGA ACTTGATACA AATGGAATCA TGCAATGGA CTCTTTGTG
 29901 TGTGGCTTTC TTCACTGAGC ATATGTCAA TGAAATTCAAT CCATGTTGTT
 29951 GTGTTATGA GTACTTCGTA GACTTTTATC CCTGAGTACT ACTATTCCT
 30001 TGTATGAAGA GACCAGAGAC ATTTGAGTTC TTTGAGACTA CAATAAATAA
 30051 AGCTGCTATA AATATTCAATG TATAAGTCTT TGTGTGGATA TATGTTTTA
 30101 TATATATATA TATATTTTTT TTGTTTTTG TAAAGCCAG GAGTGGAAATG
 30151 GCTAGATATT ATAATAGGGT AGGTGTATGT TTACCAATTTC ATTTCACATT
 30201 CCCACCAAGCA ATGTGTGAGA GTCCCAGTTG CTCCACATCA TCACCCAGCAT
 30251 TTGGTGTGTG CAATTTTTTT AACTTTAACC ATTCTAATGG TAGGTAATGA
 30301 TATCTTTGA TTTTACTTTT GAGTTTCGTG TGTGTGTGTA TGAGAGATGG
 30351 AGTCTCACTC TGTCACCCAG GCTGGAGTGC AGTGGTGC AA TCTCGGCTCA
 30401 CTGCAGCTTC CACCTCCCAG ATTCAAGCAA CTCTCCTGCC TCAGCCTCCC
 30451 GGGTAGCTGG GACTACAGGC GTGCCACCTC CATGCCCTGCC TAATTTTAT
 30501 ATTTTAGTA GAGACAGGGT TTCAACCATGT TGCCCAAGCT GGTAAACCTC
 30551 TGAGCTCAAG TGATCCGCT ACCTCAGTC CCCAAAGTAC TTGGTAATT
 30601 ACAGGTGAA GCCACCGCAG CTGGCCTATT CACTGATT TTAACTCAAT
 30651 TATACTCTT ATTCTACAT ATTCTGTGTT TTAAAAAATC AATTTCCTAG
 30701 TCTGGTCATA TTTTGATACT CTAATTCTT TAAATTTTTT ATATTTTCG
 30751 TTATTGCTTA TAATATCTGC AGTTTGTAAG GTGTAACTC GTTGTCTG
 30801 CTTCTGTGG TGGCTCATT CCGTTTTA AATTAGTTT TGATTGTGAG
 30851 CTTGTTGGGA CTTTATCTGT GTGAATTATT TCTGATCTAG GTTTAAGGTG
 30901 TGTTTTCTA GAGAATATGC ATTGCTTCT TCCAGGAATC CAGGGATGCA
 30951 ATCTACCCAG GACCACTTAC ATAAATTCTC CACTTGGCCT CACAAAAGTA
 31001 ACTGAATTCT AACCCAAAAC TTGAGTGGAT GCCAGATTGT GGTTAGGAAG
 31051 ACCCCACTCC ACCACTACCA ATACCTACCC AGAGCCAAAG CTAGGAAGGA
 31101 CAAGAGTACT CACTCTGTG GGATGAGTTG AGTTTTGTTT TTCTCTCTT
 31151 TCCCTAGTTT ATCTTCACT GAGGATGTTG CCTTTGGGAG TTCTAGCTT
 31201 TTGGTCTTGA TCTGAGTTCG ACTTGAGCA GATCATAGAC TTTGTCTTAT
 31251 GTTTACAAGT ACCTTCCAC TTAAATAAG GCCGTAGTGA AGATGTGAA
 31301 CAACTAGAAG TCCCATACAT TGCTGGTGGG AGTGTACAGT GGTTTACAA
 31351 AACTTTGGC AGTATCTAGT AAAGCCAAAC ATAGGCTAC CCTGTCTCAA
 31401 AAGACAAAAT TACAACAAAT TTAGCTTAA AATCTAACTC ACTTTTATTA
 31451 GTGGTTCATG AATCAGGCAG TGTCATCA AAAGATTAG AAAAGCATT
 31501 TCACTGTGCT GAGCAGAGGA AGTTGAATT ATAGGCAAAA TCTAGCTAA
 31551 TAAAGCAGAA ATGAAACAAA AAGTGGATTG GTCAATTCAA AGTTAGTTT
 31601 TTTATAGTAT TAAAACACAG GGGACTTCCT TATGCTGGCT CAGGATAACT
 31651 GGCCCTCTTC TGATTGATTG CTATGAAATCT TTGATTTTT TTTTTTTT
 31701 TGAGATGGAG TTTCACTGAT GTGCTCTAGG CCTGGACTGC AATGCCACGA
 31751 TCTCATCTCA CTGCAACCTC CGCTTCCAGG CATCAAGGGAA TCCTCCTGCC
 31801 TCAACCTCCC AGCAGCTGG GATTACAGGC TCCCTCCACC ATGCTGGCT
 31851 AGTTTTGTA TCTTTAATCT AGAAGGGACCC CCACCCCTGCA GCCCAGGGAA
 31901 CAGACTGATA CCCACCTAA AGAGATCCAC CGCGCTCATC CTCCCAATT
 31951 GCCAGGGGGC AGACTGCATT CCACCGGTCC CTGATTGGG TGCTTAAAC
 32001 TCAGAATTCTT CTTGGGGATT TTGGTCTCCG ACGTTATCGG GGAAAACGT
 32051 TTTTAACCTT TTATTTGAA ACAATTCTAG GATCTTTGAA AAGTTGCAAA
 32101 AATCCTCCAT GGAATTCCAT TTACCCCTTC CCCCAAGTTT TTCTTAGNN
 32151 NNN
 32201 TCCCGCCCCA TGCTGGCTA ATTGTTGTAT TTTTAGTAGA GATGGAGTTT
 32251 CACCATGTTG GCCAGGCTGG TCTCAAATTG CTAACCTCAG GTGATCCACC
 32301 CGCCTCAGCC TCCCCAAAGTG CTGGGATTAC AGGTGTGAGC CACCGGCC
 32351 GGCTTTTGA TTTTTTAAA CTGTCATTAC TCGGGGTTA TAGTCTACTA
 32401 CTATATTGCT GAGAACAGTT TCAAGATTA AAAATAAAA TGTTTCTGT

FIGURE 3

15/32

32451 TTCTCTTAGT TAAAAAAA AACCCTGTCTC TCATTGTAGG ATTATTATTC
 32501 TCTCTTTCA TTATAGATGT ATACTATTT TACCTTCTGT GTTAAAAATA
 32551 CTTTTCTGGG CCGGGGGCAG TAGCTCACTC CCGAAATCCC AGCACTTTGG
 32601 GAGGCCGAGG CGGGCAGATC ACGGAGGTCAAG GAGATCAAGA CCATCTTGGC
 32651 TAACACGGTG AAACCCCGTC TCTACTAAAAA GCACACAAAAA AAATTATGGC
 32701 GTGGTGTGG GTGCCGTAG TCCAGCTAC TCAGGAGGCT GAGGCAGGAG
 32751 AATGGTGTGA ACCCGGGAGA CGGAGCTTGC ATTGAGCCG AATCGCGCCA
 32801 CTGCACTCCA ACCTGGATGA CAGTGTAAAGA CTCGGTCTCA AAAAATAAAA
 32851 AAATAAAAAA AATACTTTTC TGACTTAGAG AATCTGGGTG AAGGGTAAAT
 32901 GGAATTCTT GTACTATTT TGCAACTTTT CTATAATCCT AAAATTGTTT
 32951 CAAAATAAAA GGTTAAAAAA ATATTTTCCA GACTACTTCA GAAACCTAAT
 33001 TACTAATAAT AATTCTGAGT TTTAAGGCAAC CAACTTAGAA ACTTTTGGAA
 33051 TGCAGTCAAC CCACTGACAA ATGAGGACTA TCTGTACTAT AGTATTTTTT
 33101 TAGACGGGT CTAGCTGTG CACCTCTAGCT GGAGTGGTGG GGTGATCTCA
 33151 GCTCATGCA ACCTCTGCCT CCGAGGCTCA ACGGATCTC CCACCTCAGC
 33201 CTCCCTGTGA GATGGGATTA CAGGGCAGGCT CCACCATGCC CAACGAATT
 33251 TTTTGTATTT TTAGTAGAGA AGGGGTTCA CCCTGTTCC CAGGCTGGTC
 33301 TCAAACCTCT GAGCTCAAGC AATCTGCTG CCTCGGCATC CCAAAGTGCT
 33351 GGGATTACAG ACATGACCA CAGACCTGG CCTTTTAGTC TATTCGATT
 33401 CTTCATTTCA ATTCACTATA CTTTTTTCTT AAGTTTTAAA ATATTTTTTA
 33451 TCTTTTACCA TTGACATTT GTGTTGTTT ACAGCTCTT TATATTGGTC
 33501 TGCACTTCAA AGACAAAATG AAGTCTCTTA TGTTTGTGA TATGTGTTAA
 33551 AATAATTGAA CTAGACAAGA ATGTTAGGCC CAAGTGAGAT GAAGGAAAGG
 33601 CTCTTGATA AGCATTTGGC ATTTTAGATC AGAGATGGCA AGTACGTATG
 33651 ACATAGCATT CTTCTTTAT ACATTTCAGA TATTATTTGT TGATCAGACA
 33701 CTCTTCTTCC TGCTTGGAC CACACAGTGT TTTAGGTATC TGCTGTCAGT
 33751 TGATCAGAGT TGGCATGAGA AACAAAAAAA ATCTATTGGC ATCTCTGACT
 33801 TAGAACATCA GTTTGGGAG AATCTCTGG AATATCTATT CTATTCTTAA
 33851 GTTTAATGAG TAATTCATC CATTTTATGA AGTAACATAA CAATTCTGGA
 33901 AGCCTAGTT TTAAAAGAAT GCTTTAAGCT TTGTTCTTG TCACTTCAAT
 33951 TTTCAGATGT TTGTGAAACC AAGTCTGCTA TTAAATAAA ATGTTCTTAA
 34001 AGTATAATGT AACTTTAAA AATCTACATA CTTGTGTGTC ACATCTTTAG
 34051 CCTTTAATTG GGTGACTTTT TAAATGTTAT CTACTTTTAT TCTTATGTTT
 34101 TCCTTCCCAG GAGTGGACCT ACCCTATGAG ACGAGAGATG CAGGTATGGC
 34151 AACCTTTCT TTGTTCAAAC CAACCCATGT TATTATCATA ATAAGAACCT
 34201 TAGTTTATAG GATTGAGAC CTGCTGATT CATGATCTGT AGGTTCATCA
 34251 TTATGTATT TAAATAATT TTTAAATAT TTAAGGTTAA TCTTGGATCT
 34301 TAAACAGATG GGAAATTAGA AAGAGGAACG TAGTAATAGG TGTATGTGCT
 34351 TAATGACTCA CTTTCTTTG GTTTTTTTT TGTTTTTTT TTTTGAAAC
 34401 AGAGTTTCGC TCTTGTGCC CAGGCTAGAG TGCAATGGCA CGATCTCGGC
 34451 TCACCGCAAC GTCCACCTCC CGGGTTCAAG TGATTCTCCT GCCTCAGCCT
 34501 CCCGAGTAGC TGGGATTACA GGCATGCGCC ACCACACCCA GCTAATTGG
 34551 TATTTTTAGT AGAGACAGGG TTCTCTCTTG TTCAGGCTGG TCTCACACTC
 34601 CTGACCTCAG GTGATCCAGT GACCTCAGGT GATCCACCCA CCTTGGCCCTC
 34651 CCAAAGTGCT GGGATTACAG GCATGAGGCC CCGTGCCTGG CCAATGAGTC
 34701 ACTTTCTTT TCCCTACGTG AAAAATTGGA TACTTCTTT GTATTCTTT
 34751 TGAAAGCACTG TTGCTTTCTC TGTTTGTCTA GATAAGTTAG GGAGAGTTGT
 34801 CTGTACAACA AATAAGCATT GTTCATTTTG TGTCGGATT TTAATCAACT
 34851 TCCACAATTAGTCTCTAG AAGATCAAAT TGAATACTTT CAGTTGGAA
 34901 TGAATTAAAC GATAGCTAAC CCTCATAGCA GTTCATTTT TTTGCATT
 34951 CATAACATT ACCGTCAGT CTGTTGCC CAGGATTAAG CAGTATCTG
 35001 TTCTGGGAA TCCCATGACT TCTAAAAATC TGTTACTTTT CTCTCTTAAAT
 35051 GAAAGTCAC TTGAAAAAA TAGGTGAGTA CCTATGAGGC ATTTTACTTG
 35101 GTGTTAGGAG GAATGCAAAG ATGACTAAAT TGAATTTCTG CCCACAAAG
 35151 CCTGGTGGAA GAAATCAGTT TTATATACAA AATATTATGA CTTATAGAAC
 35201 TGAACATATAA AGTTACTGTT AGTATCTAGG GTATGATATA TCCAGACTGA
 35251 AAGCTTCTG TATTGAATT ACATAAAATA AATTGAAATT CAACATCTGG
 35301 AAGGTACATA CTTGTTGAAA TTTTGTCAAC TGGCAAATAT TTGAATTGG
 35351 AATTTTTATG TTACACTAAT AATTGCTTC TATTAACATAT AGATAATAGT
 35401 TTAGGTCAAG GCACAGGAGT TCATGCTGT AATTCCAGCC GTTTGGGAGG
 35451 CTGAGGCAGA AGGATCACTA GAGCCAGGA GTTCCCTTATC AGCCTGGC
 35501 ACATAGTGAAG ACTTCGTCTC TATTTTTAA AGAAAAAAA AAAGATTA
 35551 AAAATAGATA ATAGTTCCAA TCTTGTGTGA TCTTGTGCTG CTTTTGATT
 35601 GGCCAAATAA GGTTGTCTT ATTTATATAG CCTTATAGAT TTAAATTGCT
 35651 GATGGTAAAT ACCTCAAATT TTTTTTTTC TAGGAAATT TACCTGGATT

FIGURE 3

16/32

35701 GTTCTTAGGC CCATATTCACT CTGCTATGAA AAGCAAGGTA TGAACCTTGT
 35751 TAGATTCACTC AAGAGAGACT TTTATTAAACC AACTTTCTT GGGTAAGTTT
 35801 TTTAGTAATA AAGAGTTTA TTTAGGGAG CATCCACAAA TACTGTCTGT
 35851 TAACAGTAAT TGTCACTCTG GAGTACCTTC CTCTTCCCT ATTTTACTAG
 35901 ACCAGTAGTT CTCAGTGTTC TCACCACAAA TCAGAGTTTT TGTTTTTCC
 35951 TCATGAAATT TGTATGTTTG AAAGATTTCAC CAAATAACTG ACCTTTAATA
 36001 ACTTATTAC TCTCTAAAAC ACTAGACATC TGTAATTGCT AATCATAGCT
 36051 TCAGAACAAAT ATGAGATGTA GTTAAAGCCC AAAATAAGGA ATTCATAGT
 36101 TTAGTTAAC CTTCTTATC AAGGTAAGA CTGTGTGTGT TAATTGAAAG
 36151 TCATTCACT TAGTTCTGTT TTGCCAGCCA GACTTTAGAG AGCTAGTTGG
 36201 TATCCCCGCT CTGAAATTG AAACTTTTG AGCACCAGTA TGTCACTCGA
 36251 AGGAAATCCT CACTGGAGTA TTTCGGATT CGGATTTTG GATTAGGGAT
 36301 GCTCAATTAT AAGTATAATG CAAATAGGCA AAACAAACAA ATCCAAACTC
 36351 TGAAATATT CTGGTCCCTG GCATTTAAA TAAGGGATAT TCAATCCGTA
 36401 TAGATATTCT ACATAGTCAA ACTTTAATGG ACTTACTCAG TTGCACTTAA
 36451 AATAGGTAGA TCTCTTTTA ATAATATAG CAATGTTCTT GCCACTTCTA
 36501 AAAGATCAA TGCTACTAAT TCTCTTGAG TTACAACGTG GAACATATCA
 36551 CAGATGCTT TCCCCAATAC TTGCTTATT CAGAAGTCAG TATACTTAA
 36601 TTGTGTTGA TATATCCATA ATTTAATTG ATGTTCTTAG GAATTAAACC
 36651 GGTTTAAAAA GGTCAATTGAT TTTGAAACTG GAAGATTTTT TTGACAGTTG
 36701 AGACATGGCT AAGAGTAAAC CTGGTCATCT TGATGATTT TGCTTAGTTG
 36751 GAAAGATAGG GAGTTAGTAA AAAAAGTAC TAGGGAAAGG ATAGGGCAGG
 36801 TAACTATAGA CATAGCGTA ATTTATTTG TAAAGGACAG ATGTAACAA
 36851 GGTTATTGTC CATATAATTG GCTATTCA CAGTACTAGT CTTCCAGATG
 36901 GTTTAGATA ATTTACATTG TTGAAATTCC CACTGTAATT TATAAATATA
 36951 CATAACAGTAT TTATCACATT AAATTAAAGT ATTTGTTAA AGGTCTATCT
 37001 CCTCAATGGG AGGCTGAGGC AGGCGGATTA CATGAGGCCA GGAGTTCGAG
 37051 ACCAGCTGG CCAACATGGC AAAACCCCGT CTCTACTAA AATACAAAAA
 37101 TTAGCTGGT ATGGTGGTAC ACACCTGTAAC TCCCTAGCTAC TCACGAGGCT
 37151 GAGGCGCCAG AATTGCTTGA ATCTGGGAGG TAGAAGTTGC AGTGAGGCCA
 37201 CATGGCACCA CTGTACTCCA GCCTGGTTGA CAGAGTGAGA CTTTGTCTCA
 37251 AAATGAAACA AAAACACCGCA CAAAAAAAGG TCTAGTTCTT CAAAACCTCT
 37301 TTTCTGAAA TGTCAACCATG GTCTTATTAG ACAGGAAAAG CCTCTGTGGC
 37351 AGTTTATTTC CCACCCCTAGG TAACCATAAT ATAGCCCATA TTTCTTTCA
 37401 TACCATTATC TAAAAACAAAC AACAAAAAAAT AATAATGGAG ATAAACCTAA
 37451 ATGGATAAAAC TCCTTTTAA ACACTCATTT ACTGTTATTA TTTTGTGGGA
 37501 GAGGAGTGGG GTCTTGCTCT GTTACCCAGG CTGGAGTACA GTGGCGCGCT
 37551 CTCATAGCTC ACTGTAACCT CAAACTCCTG GGCTCAAGCT GTCTTCCAC
 37601 CTTAGTCTCC CAAGTAGCCA GGACTACGGG CACACACCAC CATGCCCTGGC
 37651 TTAATTCTCA AAGTTTTGT AGAGATGGAG TCTGGCTATG CTGGCCACAT
 37701 TTACTTAAGT ATATCTTTT ATTAAATTCA AATAACAGTTT AAATAAAAGG
 37751 GACAAATTAA GGGCCTTTGT AATTAGTAA CGGTTTGTGTT TTGTAAGTT
 37801 TTTCTACTGT TTTAAATGT GAGGTAAAGGT CATAATTGTC TTCAATTAG
 37851 GTGGGTCAA AAGTAATTGC AGATCTGCT CTGAAAAGTA CAAAATCTAT
 37901 TCGCTGTTAC GTTACGGCTC TATTTGATA GTTTATTTTT ATTTAGTAGT
 37951 AGTCTATGCG GCCTTCAAA CTGTTTAAG CATAATTATA CATAATTATG
 38001 TGCATCGCTC TGTGCTTTCT CACATTCA AAGTAGATAG GAAAACCTCA
 38051 TAGGCATCAA GTGTAACAGA AGGACTTTA GTTGAATTG TTGTGAAAT
 38101 TGGCACAAAT CTCATAATAG AACATTGGTT AATTATTAAT CTTACAAAT
 38151 GCTTATCTCA CTTTCCCTAA CTCAAGTTAT ACTCAAGAAA TACAAAGATA
 38201 ATTGAATTCT AATCTATGCT GACATAAAAC TTGCTGCAGA AATTAACACT
 38251 TAAAACCTGC AAATTATATT GTCTTAGCCC AGGCTGCTCA AACAAACATAC
 38301 CATAGACAGG GTGGCTTTAA CAAACAGACGA TTATTGAGT TCTGGAGGCT
 38351 GGCAAGTCCA CAGTCATGGT CCGGCTCTGG TGAGGACCT CTTGCTGGCT
 38401 CGCAGATCCC TCCCTTCTTG CTGTTATCCTC ACACGGCCAA GAGAACGAGT
 38451 TCTTGCTCTC TCTTCAACAG GTACAATCTC GTCATGGAGG TTTCTACCC
 38501 CATGACCTCA ATCTAAACT GATTATCTTC CAGAGACTCC ACCATCACAT
 38551 CTTGGGGGTAA AGGATTCAA CATAAGAATT TGAGGTGATG CAAACATTTA
 38601 GTTCATAACA CATATAAATT ATTTTTTTT ACTTTGCTCA TGAATTATTA
 38651 GTGCTACTGT TTTGACTAT TTTAAATGCA GAAAATGGGA ATTTAAATATA
 38701 TAGGATTTAA AACAAATGTT CAAGAAATTG AAGGTTATCT GATTCTCATG
 38751 CCATCGTGAC TTGTTAGTTC ATTATTGAA CAGGTAATTG TTGAACAACT
 38801 TAACTAGTTA TACATACCTG ATCTTAAGT GAATTGTTAT ATACATTAA
 38851 CACATACATAT GTATCAGTGA AACAAATAAA ATCTTTCTG TCATGGAAC
 38901 TAATGCTCTA GGTAATAAAA TAACATCTAT AAACACTTAAACATTATCA

FIGURE 3.

17/32

38951 CTAGCAAATG AAAACTTATT ATCTGGTAAT TTCTAGAATT GTCATGTTAA
 39001 ATTGCTTAA GTATGGAGCC AAAAGCACTA CAGGTTGAGT ATCCCTAATC
 39051 TGAAAATCT GAAATGCTCC AAAGTGAAAC TTTTGAGTG TCAGCATGAC
 39101 AGCACAAAGTG AATTCCACAC CTGACCCCAT GAAATGGGTG ACTGTCAAAAA
 39151 TTTGTTTCA TGCCACCAAT GACTGTATGA AATTACGTTG AGAGTATATA
 39201 TGGTGTGTG GAAACATAAA TGAATTGTTG GTTAAACTT GGATACCATC
 39251 CCCAAGACAT CTGAGTATGT ATATGCAAAT ATTCAAAAT CTGAAATCTG
 39301 AAACACITCT GGTCTTACCT TGGGACCAGC ATTTAGATA AGGGATACTC
 39351 AACCTGTATT GAATATAATA AGATGTATT GAAGTTGCCA TTTTAACCTT
 39401 CAGGAAAATT TTTAAATGGT AAAAGGTTAA TTAGATTCTG TGAAGTATGT
 39451 AAATTAATTC TGACTCTTAA AGTATACTGG GAGAGGCAAG GAGTTGTCTA
 39501 GAGATTGGG TTCCAGTACT GCTGTTAACT AGGTGCGGTG TGTCCTAAGT
 39551 TTTGGTATG TAACTGTTT ATGTCTTAGT GGTCTCTCTC AAACAATAAA
 39601 GATTGAGTC AATATATATT AACTACATT TATTAACAC TTGCTGTGTG
 39651 TCCCAGGTC TATGCCAAAC ATCTTACATA AAGGTTCCAT CAAGCTCTAA
 39701 AATTGTTAGGT ATGAATATTC CCTGTTAACCC TTTTGAGGAC ATTAATGTAT
 39751 TAATCTGAA TCATTGAAAT ATCTTGTGTC CCACCTCAGG TATATTATAA
 39801 AATTAGCTT AATTCCCTGG ACTTAAGCAG AGATGTGGGT TCTGTGTATT
 39851 TTCAACATC TGTCTTATAT AGTAAGATGA TGTTTGATAT TTTAAATAT
 39901 TTATCTCCC TGTCCTCCCG CTGCTTTTTT TTTTATACAG CTACCTGTAC
 39951 TACAGAAAACA TGGAAATAACC CATATAATAT GCATACGACA AAATATTGAA
 40001 GCAAACTTTA TTAAACCCAA CTTCAGCAG TTATTTAGGT AAGAATTATT
 40051 GCTATGATT GTAAACACT TAATGAAGTT TCATTCAGG TTTTGACCA
 40101 TCAGTTGTT CTGTACATAT CTAGTTGTA AAAATGGGT ATATAGTACA
 40151 TAGTTTTTA AAATAAATT TACTTAAAT ACTTAAATAA ATTATGCCA
 40201 TAATGCAGAA TTCTAAAGGT TCAAAAGAGT GTATATTGTC AAGAAGTTTC
 40251 TGGGAAAGTA AAAATAAAAA AGAATTTAAA AATAATGTAT ACTGAAAAAT
 40301 AGGTTTGTAGT GTACATTATT TTATCTCTG AAGGGATAAAG GAATTGAGTA
 40351 TCTAGGGGAT AGGTTAGGG AAACAGCATC TACTGTTACC TCTTTATGG
 40401 GTAGTTTTG AGTGTAGGT TAAATTATG AGCATAGTCT TATAGATAAA
 40451 TTTTTTTTA CATTGGCTTT CTTTTTTACT TTATTTTTT TGGAGATTGG
 40501 TTATATCGG TATGTATATC AACTGCTTA TTCTTTTAA GTTGATTTG
 40551 AATCCATTGT ATGGCTATAC TAAAATTAT TCAATTAGTC TGTTAGATAT
 40601 TTAGATTGTT TCTGGCCTTG TACTAATATG TATAGCATAT AGTGAATATC
 40651 ATTGTACATA TTACTCAATT TATATGTGAG CATATTGATA GGGCTTATTT
 40701 GCAGAATTGC TGGATATAAG AGTATGAACA TTTTAAATT TGATAGATGT
 40751 TGCAGATGT TTTCCAGTGC GTTGTATCAG TGTACATTCC CATTATCAAG
 40801 TATGTGAGAG TGACTCTTCC CTAGTATCT CTCCAAGACG GAATTGTGAA
 40851 ACATTTTAA TTCTCAAAG TCTAATGGAG TAAAATGGT ATCTCATTG
 40901 ATGTTCTTAT TTATCTGTA AGTTCACTTG AGCATGTAAT GGTTTTAAT
 40951 GTTCTTATT TTAACCTCAT TTTAAAATA GAGTATATTA CGCATGGTAC
 41001 AAAAGTAAA GGATATGTAAC ATATATATAA TGAAAGTAAC TCTACTTTT
 41051 CTCTTAACCC AAGCCACCTT GCTCCTATCC TGGGAGGCAG CTTCTCCCTT
 41101 CAATATCTAT GTAAAAGTAT ATATGTTAAA AATATTTAG GCCAGCACGG
 41151 TGGCTCACGC CTGTAATCCC AGCATTGGG GAGGCCGAGG TGGGCAGATC
 41201 ACCTGAGGTC AGGAGTTCGA GACCAGCTG GCCAACATGG CAAAACCCCA
 41251 TCTCTACTAA AAAAAAAATT ACCTGAGCGT GGTGGCAGAT GCCTGTAATC
 41301 CCAGCAGCTC AGGAGACTGA GGCAGGAGAA TTGCTTGAAC CCAGAAGGCA
 41351 GAGGTTACAG TGAGCCGAGA TCACACCCT GCACCTCCAGC CTGGGCAACA
 41401 GAGCAAGACA CCGCTCTAAA AAAAAACAA AAAAAACAA AAAAAAAACA
 41451 GTGCTGTGGC TTACACCTAT ATCCCAGTA CTTTGGGAGG CTGAGGGAGG
 41501 TGGATCACGA GGTGAGATT GAGACTGTCC TGGCCAACAC AGTGAGACCC
 41551 CGTCTCTACT AAAAATACAA AATATTATCTG GGCCTGGTGG CACATGCCTG
 41601 TAGTCCCAGC TACTCAGGAG GCTGAGGAG GAGAATCACT TGAACCTGGG
 41651 AGGCAGAGGT TTCACTGAGC CAAGATTGCC CCACCTGCACT CCAGCTGGC
 41701 GACAGAGCAA GACTCTGTCT CAAAAATAAA AAAAAAAATT TAATGCTCTG
 41751 CTTTATTTT ACAATGAAAC CAATCTATAA ATATCTGTAATACAGATA
 41801 CATACTCTAA AATACATTGT GTGAACATAT AATAGAATAC TATGTAACCA
 41851 TGAAAAAGAA TGAATATATG GTATGTGTTT GGATTTGGG TGATCTCAA
 41901 GATAATGCTATACATGAA AAGCAGGGTG TGGAAACATG TATATTTTG
 41951 CAATGTGTT AGTAAATATA TATATACATAC ATTCCATATA TTTATTCTTA
 42001 ATATATGCTATACAGAAAATTC TGGACCAAGA GGCTAGAAAC TTCACTAGTGA
 42051 TTGCTCTAA GAAGGAAAAT TCAGGGCCTG TGATGGTAGA GGGACGTATT
 42101 TTTCTTCGT TTTTAAATTGTTT GTTTTTTTT GTTGTGTTG TTTTTTTT
 42151 TTTTTGAGA TGGAGTCTCA CTCTGTCACC CAGGCTGGAG TGCAGTGGTG

FIGURE 3

18/32

42201 TGATCTGGC TCACTGCAAC CTCTGCCTCC TGGGTTCAAG CGATTCTCCT
 42251 GCCTCAGCCT CCTGAGTAGC TGGGATTACA GGCACTGTGCC ACCACACCCA
 42301 GCTAATTTTT TTTTTTTTTT TTTTTTTGGA CAGAGTTTCG CTCTGTTGCC
 42351 CAGGCTGGAG TGCAGTGGCA TGATCTCGGC TCACTGCATC CTCCGCCTCC
 42401 CAGGTTAAG CAACTCTCG CGTCAGGCCCT CTAAGTAGCT GAGATTACAG
 42451 GTGCCACCA CCACTCCCCAG ATAATTTTTT TTGTATTATT AGTAGAGACG
 42501 GGGTTTCAGC ATCTTGGCCA GCGTGTACCTT GAACCTCTGA CCTCTTGATC
 42551 CACCTGCCCTC AGCCTCCCAA AGCACTGGGA TTACAGGTGT GAGCCACCGC
 42601 ACCTGGCCTA ATTTTGAT TTTTAGTACA GACGGGGTTT CACCATGTTG
 42651 GCCAGGCTGG TCTCGAACTC CTGACCTCGT GATCTGCCCA CCTCGGCCCTC
 42701 CCAAAGCACT CGGATTTCACA CGCGTAAGCC ACTACGCTCA GCCGAGGGAC
 42751 ATATTTTCA TGTCACCCCTT GATATCCATG GGGGATTGCC TCCAGGAACC
 42801 CCCATGAATA ACAAAATCCT CAGATGCTCA AGTCCCTTAT ATAAACTGGT
 42851 GTAATATTG CATATAACCT GTGCACATTC TCTCATATAC ATAAATCAT
 42901 CTCTAGATTA CTTCTAATAC TTAGTACAGT GAAAGTGTG TGTGAATAGT
 42951 ATTGGATTTT ATTTTATAA TTTTTAGTGT TGTATTTAC CTTATTTTT
 43001 GTTAATGTTT TTTATTGTTG TCGGTTGAAT CCACAGGTAT GAAATTCTTG
 43051 GATATGGAGG GCTGACTCTT TACTTTGTA GTGTTTTTTT TTTACACCAT
 43101 ATTTAGTTA TTAAAGACTAG TTATTAAGAAA GGAATATCCC AAAACACTGA
 43151 TTTTTTTTTT TTTTTTTTGAG ACAGAGTCTC GCTCTGTAT
 43201 CCAGGCTAGA ATGCAGGGCT CACTGCAACC TCTGCCCTCC AAGTTCAAGGC
 43251 AATTCTCTG CCTCAGGCCCTC CGAGTAGCA GAGATTACAG GCATGTGCCA
 43301 CCACGCCCTGG CTAATTTTTG TATTTTTAGT AGAGACGGGG TTTCACCATG
 43351 TTGGTCAGGC TGGCTCTAAA CTCTGACCT CGTGATCCCC CTGCCCTGGC
 43401 CTCCCACAGT GCTGGGATTAA CAGGCCTGAG CCACTGCGCC CGGCCTGAAT
 43451 TTTTTATAAT TATGAAAGAA ATACTTTTTT TTTTTCAAA GATAGGATCT
 43501 TTCTCTGCTG CCCAGCCTGG ATTGCATTGG CATGATTCT GTTCATTGTA
 43551 GCTTGACCT CCCAGGCTCA AGCAATCTC CTGCTCAGC CTTCCAAGTA
 43601 GCTGGGACTA CAGGTGACC ACCGGATCGG GCTAATTTTT TTTTTTTTT
 43651 TCTAGAGATG GGGTTTTGCT GTGTTGCCA GGCTGTTCTT GAACCTCTGA
 43701 GCTTAAGCGA TCTACCCACC TCAGCCTCCC AAAGTGCTGG GGTTACAGGC
 43751 ATGAGCCACC ACACCTGGCC ATGAAACACT TATTCTTTAT AAGTACTTCG
 43801 GAAGGTATAG AATGACACCA AGAAAAATAT TAAATCATC TACAGTTCCA
 43851 CAATTCAAGG AAAACACTTT TGTAAACATT TGAATATT CCTTTAAAT
 43901 CGTTCTCTGT TGTGTATGT TATTTACGTA TATATGCATA GAATTATAA
 43951 AGAAAATGAG AATGTTGTAT TTAAAGATAT CAAACTATAT AAGGTGAAC
 44001 TAATCTTAAG AAAAACAAA AAAGCCAAA AATCATACTA TTCAATTCTA
 44051 ATGTGTACAG ACTTTTGTT TAAATTATA ATGTTGTTG TGCAAGTTCT
 44101 TTATCCTAAT GGAAGAACCA TTCTCTTAA AACTTTACAA ATACTAGCTT
 44151 CTTAGAGATT GATAAGTCTA CTAGCAGTGC TTGACACTGA AAATGTTATG
 44201 CGTTAAAATA TTTAATTCTA TTCTGAGTTA ACATTTTCC CCTGAAGCAT
 44251 TATTTTATGT AACTGGAAATA CCCAGTCACT TCAGGATACA GTCATTGTCG
 44301 AAATCCTGT AGGTAAATA TTGGATTTC CTCAGATCCT GAGGTTCAAGC
 44351 TTCTGTGTTT TTTTTGTTT GTTTTTGTTT TTGTTTTTGTGA
 44401 AACAGAGTCT TGCTGTTCA CCCAGGCTGG AGTGCAGTGG CACAATTGG
 44451 GCCCACTGCA ACCTCTGCTC CCCGGGTTA AGTGAATTCTC CTGCCCTCAGC
 44501 CTCTGAGTA GCTGGGATTAA CAGGTGTCGA CCACCATGCC TGCTAATT
 44551 TTATTTTTT AGTAGAGATG GGGTTTCACC ATGTTGCCA GGATGGCTTT
 44601 GAACTCCTGA CCTCAGGCCA TCCACCTGCC TCGGCTTCCC CAAGTGCTGG
 44651 GATTACAACG ATGAGCCACC ATGCTCAAGC TCAGCTTCTC TGTATTAAAG
 44701 TCTGTGTTT TTTGAAAGTTG TTACCACTTA AATGATCATT GAAAAACTGT
 44751 ATTTTTTGTG CAAAAATTGT TCTTAAACT AATTTAAATA CTTAGCTAAT
 44801 TGCTTATAGT TGTGTAAATA AACAGTGGTC TTAGAAACGC TTAGAAATGG
 44851 AAGTTTTTA CAAAAATAAG CTAACATATT TAAAATGCC TTAAAGTATT
 44901 TTGTAAGTG TAAAATTCAAG TACAGGTGCT CTCTCAGCTA TTGTTTTTT
 44951 TTTTTTTTTT TCCCCCTTA CTAAGATGAA GTTCAAAACAG TGAATGTTG
 45001 ACTCCCTGGTT CCATAGACCA TACCTCCGT TTTTATTTGT TCCTCTCTT
 45051 AGACTTTGGA CTTCTCTGTA AATGCTCTCT GTAGGTTCAT GAGCAGGAGT
 45101 CACAGGACCA CTTAGAGAAC AATCTCTGG TCTTAGAGAA ATTGGTAGAA
 45151 ATAAAAGAAT AACATAACGA TTACAGGTAC TTTTGTCTTT ATTTCTAGGT
 45201 CCACTCTAAT CTAGAGGAAT GTATCTTCCCT GCTTGTGATT TTTCTATTT
 45251 AACCAAGATGG TTCATTATAT GCAAATAAAA TATGTATTAA TTTTTGAGAT
 45301 AAGAATCTTG CTCTGTTACC CAGGCTGGAG TGCAAGTGGCC CAATCACAGC
 45351 TTACTATATC CTTGACTTCC AGGCTCACAC AGTTCTACCT CAGCCCCCTT
 45401 AGTAGCTGGG ACTATAAGTG CACACCACGA CACCCAGCTA ATTTTTAAT

FIGURE 3

19/32

45451 ATTCTGTAGA GATGGAGTCT CCCTCTGTTG CTCAGGCTGG TCTCGAATCC
 45501 CTGGGCTCAA GTGATCCTCC CACCTTGGCC TCCCAAAAGA GTTTCTTTT
 45551 GCTGGGATTA TAGGCATGAG CCCATTGTGC CCAGCCTGAT GGATTTTTA
 45601 AATACTTAAAT TATCAGAGAT GTAAACATGG TGTTTCAGGT TTTAATGCCT
 45651 TCAAGCAATG TAAAATCTAC CACACAGITC TTGGGAATAT GATACTTGA
 45701 AAGTTGTTTG GCATCTTGC CATGGTTAAC AAGAAATAAT GAGTTATTT
 45751 TTAAAGTAC CTTAAGTGTGTT TTAACCTAAAG TGTCCTATC ACAAATACT
 45801 CTATTTTCAG ATATTAGTC CTGGATATTG CAGATAATCC AGTTGAAAAT
 45851 ATAATACGTT TTTTCCCTAT GGTTAGGTACG AGTATTTTT AAATATCATT
 45901 TAAAATTAT TTATGATTTG ACTTCTTAGT TGTCCTTTT TTTTTTTTTT
 45951 TTTTTTTTTT TTTGAGACAA GAGTTTTACT CTTGTTGCC AGGCTGGAGT
 46001 GCAATGGCGC AATCTTGGCT CACCACAAAC TCTGCTTCCC GGGTTCAAGT
 46051 GATTTTCTG CCTCAGCCTC CCAAGTGGCT GGGATTACAG GCATGAGCCG
 46101 CCATGCCAG CTAATTTGT ATTTTAGTA GAGACGGGGT TTCTCCATGT
 46151 TGATCAGGCT GGTCTCAAAT TCTCGACCTC AGGTGATCTG CCTGCCTCAG
 46201 CCTCCCCAAAG TGCTGGCATT ACAGGCGTGA GCCACCGTGC CCAGCCCCTT
 46251 TAATTGTGCT TGAAAGCTT GCTACTTTA CTGGCTATG ACTGAAAATT
 46301 ATGTGATTGT GTTTTAAAAA GAATTATTTG TAGAAAATT TTTATGATCT
 46351 CCAGAAATTG GAGGAATCAT ATTGTGAATG TATTGGACTT AAATTAATT
 46401 TTGGCTCTT TAATTTTTT GGACTTGTAA TAGTTCTATT TATAGCATTT
 46451 TGGAAATTGG TGAATCAAAA TAATTTTTAT ACATATAAAT TAGGAAATTG
 46501 TTTCAATAG GTTCATTTT GTTCATTAT ATGCATTTAT TTTATGCTTA
 46551 CATTAAATCA CATGCTTTT GCCTCCAGAC TAAGGAATT ATTGATGGGA
 46601 GCTTACAAAT GGGAGGTAAA TAACATTTCC TTTCCCTAAC TAATGTTAT
 46651 ATTTGATTA TTTGTTAATT TTTAGTTGG TATTGTCTT AAATGCAGGA
 46701 TATGGAAGTT ACAATTATAT GTAGTAGCTT ACTCCAAAT TTGTATTTC
 46751 CCAATTACTT GTTTCATTTG GATAGGCTT CTGGAGTATC CCTGTAGACT
 46801 GTTTCAAAAT TCTCTGTAG CTTCACTTT CTTTAAATAAG AGTCTGCTAT
 46851 ATTCTCTACA CAGTGTATAA TAACAAATTG TAAAGATTG AAGATATCCA
 46901 AGTATTATAA GTATATAAAG AGTTACTTTA CTGTGGTTTC AATGTAGTT
 46951 AGCTACTGAC TCAGGGTGTG TTCTATTAGA ATAATGAATT CATGTTTTC
 47001 AGGAAAAGTT CTTGTGCATG GAAATGCAGG GATCTCCAGA AGGTATGAAG
 47051 TTAGAAATAA TCTTCTTT TATAACATT AATTAATGGG CTGTATTTTC
 47101 TGGTTGTTTT TAAAATTATT TCCCCCTCTT CAGTGCAGCC TTTGTTATTG
 47151 CATAACATTAT GGAAACATTG GGAAATGAAGT ACAGGTAAGA AAATACCTA
 47201 AAACCTAGAC ACAGTTAAA TTCTCATTA AATGAAACTT AATGGGAATA
 47251 GTTTGGAAGT TTGAAGTTCT TATTCCCTG ATTATTTTTC ATGTAGTCAT
 47301 GTTTGATTAG GCAGGCCCTT ATTCCATGAT TAGTCTTAAC CTAATTATC
 47351 TACTTGATA GATATGCATA GGCTAATATG GAAATCCTAT GGAAAACCTAC
 47401 TTACCTACCA CAAGGGAATT GGTTGGTAG AGTATAAAA CTCGTGACCA
 47451 CAAATGTTAG TGCTGCCTT ATTAAAGGG CTAATTATC ATGTTCTCCT
 47501 TTAACAATAG TTGGATGAAA AATTACCTAG GAATTGTTG CAGCATCTAT
 47551 TTACAATTCA GAGTAGTCCTT TCTTATCAA AATCATCTT TCCAAGCATT
 47601 CTGTATAGAT TTTTAAAGG ATAGGGGGTG GTAATGAGCT TCTTGCCCC
 47651 AAGACAAAGC AAAAGCCTGG GCCAGTGTAC AGTATTTCCCT TTCTCAGCTT
 47701 TTCTGTTCT CAAATATTAGA AATCTTATAG TAATCATGAG CACATCTTC
 47751 TATTCAGTC CCCTTTATA TCTAAATTAG AATGGATAAC TTTGCTTAAA
 47801 AATATCTATT CTTAAAGGAA TATTATTTGA ATACAAATAT TTATTTATTT
 47851 ATTTTGAGA CGGGCTCTG CTCTATTGGC AGGCTGGAGT GCAGTGGTGC
 47901 GATCTCAGCT CACTGCAACC CCCGCCTCCC AGATTCAAGC AATTCTCCTG
 47951 CCTCAGCCTC CCTAGTAAGT GAGACTACAG GTGCACACCA CCACGCCCTGG
 48001 CTAATTCTTG TATTCTTATT AGAGATGGGG TTTCACCATG TTGGCCAGGA
 48051 TGGTCTCGAT TTCTTGACCT TGTCATCCAC CTGCTCTGGC CTCCCAAGGT
 48101 GCTGGTATTAA CAGGGGTGAG CCACTGCAACC CAGCCAGAAT ACAAAATATT
 48151 AATTGAAAAA AGATTAACAA TGTTATTGAG GACTTTATGT TTATATATT
 48201 GTTTTATTA TTTCGAATT TGTCAGACCA TTAATGTTGG AAATAACTTG
 48251 TATTTATTGG GTCTCTGCTA TGAGCTCAGT ACTATTATAG GCACCTTAAG
 48301 CCTCATAACA AAAGTAAATA AACCTCTTA ACCAGTGATA GTATTTGAG
 48351 CTTGAACCTG TACTATATGC ACAAAATGCT TACATTTAT ATATTTATTT
 48401 TAGAGACAGG GTCTCTCTT GTTTCTCAGG CTGGAGTGTAGT GTGGCACAAT
 48451 CATAGCTCAC TGAGTCTCA GACTTGAGGA CTCAAGTAAT CCTCCCACCT
 48501 CAGCCTCTCA AGAAGCTGGG ACTATACAC ATCACTGTGC CTGGCTAATT
 48551 TTTAAGTTT TTGTAGAGAT GGGGTCTTAC TACATTGCC AGGCTGGTCT
 48601 CAAAGTCCTG GCTTCAGCA GTCCTCCTGT GTTGGCCTCT CAAAGGATTG
 48651 GGGTTACAGG CAAGAGCCAC TGCACCTGGC CACTTTACAC TTACCTCCTA

FIGURE 3

20/32

48701 TTCATAGTAG TTCCCCAAGG TAGGTTGTTAT TAGACTCTTC ATTTTACCAA
 48751 TGGACAAAAT AGAGCTTAGA GAAGTTGAGC AAGCTGCCGT AAGCATATAG
 48801 CTGGTGAGAA AAGGAATTGT GATATTTAAT CTCATCATGC TTTTCCATT
 48851 ACAACTCATT ACCCTCTCT ATTGCTAAGT TGATGATTA TGATTAATT
 48901 ATTAATAAT GCTATCACAT TAACACTCTT TTTCTGTTT CAGAGATGCT
 48951 TTTGCTTATG TTCAAGAAAG AGAGTTTGT ATTAATCCCA ATGCTGGATT
 49001 TGTCCATCAA CTTCAGGTAA CTTTCTTCC TCTTTAAGGC AATCAGAAGT
 49051 AAGATATAAA ATCTTTATA CATGTAATTG AGGTGTACAA TTTACTTGT
 49101 GAATACTTAA AATTGCCATA ATCTGACTAC TTGATGCTT TATTCAAGTT
 49151 TATATCTCTA TTTAGAAGTA TTTCTTGGC TGGGTGTGGT GGCTTATACC
 49201 TATAATCACA GCACTTTGGG AGAACAAAGGC ATTTGGATTG CTTGAGGCCA
 49251 GAAGTATGAG ATCACCTGTA GCAACAAAGT GAGACCCAAAT CTCTAAAAAA
 49301 TAAAAAATTAA AAAAAAAATT AGCCAGTCAT GGTGGTGCAT GGCTGTGGTC
 49351 CCAGCTACTC AGGGGCTGA GATGGGAGGA TTGCTTGAGC CCAGGAGTT
 49401 GAGGCTACAG TGAACAGTGT GTCTTGCAC TCCAGCCTGG CCCACAGAGT
 49451 GAGACCCCAT CCCAAAAAA TTAAAAAAAC TTTTTTTCT TAAAGGCTGG
 49501 CATTACCAAG AAAAAAGGGT TAAAGACACA TTATCAAATC TAAAGTAAAA
 49551 TAATTGCTGT TAGAAATGTC TGATTTTTT TTGTTGTICA TTTTGATCAC
 49601 ACAGACATA AGACAGTTT GATTCTAAGT ATACTAACTA TAACAGCTT
 49651 TTCTATTCTA TGTTTATCTT TTCCATGTTG TTTCATATT TGTGATGCC
 49701 TGGCAGATGCA CTGACAAAG ATGATAAGTC TATGAATTAA CCTAATTAGA
 49751 CCACGTGCT CAGTTTATTG CAAGAGGCAA AATCATAGGC TGCAGAAATG
 49801 GCTCTGCTA ATTACATCCA ATTATGTAGG AATAAAGCTC ATGTTTCAAC
 49851 ATCAAGATA TTTTATACAA ATATATTGT TATAGTTACC AAGGTTAAA
 49901 TTTTATTTA ATATTTAATT TACTTTTAAT TTTTACTACA TTCAAAAGAG
 49951 AAACAGTGTCA ATCTGTGTC AGCCTGTTCA TGTAATGTT TTGCTTCTA
 50001 ACTTTGTAAG TTTCTTGCC TTTTACCATG TTGAGAAAA CATTGTTTT
 50051 TTTCATTTT TTAAACTAT TTTTAAGCT TTTCTTTTT TTGTTGATAC
 50101 ATAGTAGGT AGCTTATTG ATACAGGCAT GCAATGTGTA ATAATCACAT
 50151 CATAAAAAA TAGAGTATCC ATCCCACCAA TCATTTATCC TTTGTGXXX
 50201 XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX XXXCCTCCCA AGTAGCTGGG
 50251 ATTACAGGCA CGTGCACCA CGCCCAAGGTG ATTTTGAT TTTTAATAGA
 50301 GATGGGATGG CCGGGTGTGG TGGCTCACGC CTGTAATCCC AACACTTGG
 50351 GAGGCTGAGG TGGGTGGATC ACCTGAGATC AGGAGTTGA GACCACCTG
 50401 GCCAACATCG TGAAACCTG TCTCTACTAA ATTACAAAAA ATTAGCCAGG
 50451 CGTGGTGGCA GGTGCCTGTA ATCCCAGCTA ACNNNNNNNN NNNNNNNNN
 50501 NNNNNNNNNN NNNNNNNNNN NNNNNNNNNN NNTGCTGGAAGGGATCACC
 50551 TGAGTATCAG GAGTTGAGA CCAGCCTGCC CAACATCGTG AAACCTGTC
 50601 TCTACTAAAA TTACAAAAAAAT TAGCCAGGCG TGGTGGCAGG TGCTGTAAAT
 50651 CCCAGCTACT TGGGAGGCTG AGGCAGGAGA ATTGCTTGAA CTCGGGAGGC
 50701 GGAGGTTGCA GTGAGCCGAG ATGGCCTCAT TGCACTCCAG CCTGCGAAC
 50751 AAGAGCAAGA CTCGTCACA AAAGAAAAAA AAAAATAGAG ATAGGTTTT
 50801 GCCATGTTGC CCAGGATGGT CTTGAACCTCC TGACCTCAGG TGATCCACCC
 50851 ACCTTGGCCT CTCAAAGTGC TGGATTACA GGCGTGAGCC ACCACTCCTG
 50901 GCCCAAAATG TTTCATTCAG ATTTCGTTGA TCATTTGTTG GTGTTCTCT
 50951 CACGGTTTG TAAGAGCTCT TTATATATA TGGAAATCTA TTTATAGCCT
 51001 ACCGATTGAT AATATCATT TTATTTTATA CCAAATTCTG ATATGTCCTT
 51051 TAGAAGTTTG AAGTTTCTT TTTTAAGGTG TTATGGAAT GGCTAGTTCT
 51101 AGTTTTGAA CCGTTAATAT GGTGACTTGA GTTACTGGAT CACATTAGAT
 51151 TGGATTCCCT AATATTGAAT CATCCTTTG GTCCAGCAAT GGATCCCAC
 51201 TGGTTATGAT AGACTGTTCT GTTAATGTAT TGCTGGATT TATTTGCTAA
 51251 TCTTTTGTGTT CAGGATTGTT GAATCAGTTA AATAGTAAAT TGGTTGTCT
 51301 TTCTTTTTT TTTCTGTACT ATCCCTTTCTT GGTTTACTA TCTCTGTCAC
 51351 AGTGTCTCA TTTTTAGTG GAAGCTTCC ATTTCTCTT GTGCCATGG
 51401 TCAATTAAA TTAGATTGGA GTTACTGTC TCTTAATGCA TTAGTATAG
 51451 GCACCTGTGA AATATCTGAC CATAATGTT TATCTAATTC AGTTATTCT
 51501 TATTCATTC ATTCAATATAT TTGACAATA GACCACTCT CAGACAAACAT
 51551 TCTTCATTTG GTGTATCGGT TTGATTTTTT CTTTTCTTCC TTTCTTCTT
 51601 TCTTTTTTTT TTTTTTTTTT TTTTTTTGAG GGCAGAGTCT TCTGCTCTGT
 51651 TCCCCAGGCT GGACTGCACT GTTGCACATCT CAACTCACTG CAACCTCTGC
 51701 CACCTGGGTT CAAGTGTATC TGCTGCCCTCA GCCTCCAAAAA TAGCTGGGAT
 51751 TTACAGGTGCA CTGCCACAC AACTGGCTAA TTGTTGTTTT TCAGTAGAGA
 51801 CGAGGTTTCA CCACATTGGC CAGGCTGGTC TCAAACCTCCT AACCTCTGGT
 51851 GATCCGCCCG CCTCGGCCCG CAGAGTGTG TGTTACAGA TGAGGCCAC
 51901 TGCTCCTGGC CTGGTTGAT TTTCTGATAC CCCTCAGGTC ACTTTGGATG

FIGURE 3

21/32

51951 TATTTATGAT CTTCTGTGTA ATCATTGATT TCATAAGAGT TCTACATAGA
 52001 ATTAAGGAAA ATAATATCTT GACTTTAAT ATCTTTGGT TCTATTATT
 52051 TTTTCTTCA TCTGGTTAGT CCATGTTGTT TTTCTGTATT CTAATTCTG
 52101 CTTCCCTGGT ACTTTGCTTT AGTGTGTT GCTGCTGCTG TTGTGAATT
 52151 CCTGAGTTGA AAACCTGGTT TCTTTTATT CTTTCAAAAAA TTCAAGGCTA
 52201 TTAATTATCC TCTTGCAATT GTGTTAGTCG CATGCTGCAG ATTCTCATCT
 52251 GCATTATTT TATGTTATAG CTTGATATTG TGTGATTCA GTTTGGTTT
 52301 CATTTTTAT CTAATATGTG TTGAGATTT TTTTATTGTA TAGGTGACTG
 52351 GGTTTAAAT TTTTATTGTT TGTTCATATT TAGTTTATT ACATTGAAAT
 52401 CACAGAATGT TTTGTTAGTAC TTGTTATTT TGATGTTTC TTTGTTGGTT
 52451 AATATGTTAGT TGTTTCATG AATTTTATGG GCATTTGAAA AGAAGATGCA
 52501 TTCTGTTTC AGGGGATAAA GTTAAATGTA TTTGTCACACT TGATCTGTCT
 52551 TGGGCTGAAA TCAGTGAATT GAAATCTTT ACTATATTGT GTTTATT
 52601 TCTTTATTTC CCCCCTTTTG GTTCTGCAAG TTTTTCTG TACTTAACTA
 52651 TTTGGTACAT AAAAATTCAA GTTAGGTTT TATTTTATT GTACCCCTGTT
 52701 TAAATTTCAG GTTGTGTTGTG TGTTGTTGTT GAGACAGAGT CTTGCTCTG
 52751 GGCCTCAGGT GGAGTGCAGT GGTGCGATCT CGGCTCACTG CAAACCTCTGC
 52801 CTCCTGGGTT CAAGTGAATT TCCTGCCTCA GCCTCCCAAG TAGCTGGGAT
 52851 TACAGGCATG CATCACCACG CCCCCTGAAAT TTTTGTATT TTAGTAGAGA
 52901 CGGGGTTTCAG CCATGTTGGC CAGGCTGGTC TCGAACTCCT GACCTCATGA
 52951 TCCTCCCAAC TCGGCCTCCC AAAGTGTGCGG GATTACAGGT GTGAGCCACT
 53001 GTGCTGGAC AAATTCGGT TATTTTACCT TGCACTTAAAC CTCGTTAAT
 53051 ATTGTGAATC CTACTCTTTCG TGTTCGCTTG CTACCTTTG AGTTTCCC
 53101 TTCTTTTCC TTCAAGCTTT CTAATACACT TGATTTAGA TGCTTTCC
 53151 CAGTGTAGTC TAGGATTGAG TTTTGTATT AGATTGGTA TCATTGTTTC
 53201 CTAATAGGTG AATTTAACCC ACTTTCATTT ACTGAAAATG ACAGATACAA
 53251 TCTTATCTAT TATTATTC TATTATGTT TCTGTTTAA ATGAATCCTT
 53301 TTTTAAACCT TCTGCTATAG TTAAAATTT TTTGGTGTGTT TTATGTTGTT
 53351 TACATAATT TTAAGGTTT ATTATTTAC TTTTCTTTT TTTTTTTT
 53401 TTTTTGAGT TAGAGTCTCA CACTCTGCC CAGGCTGGAG TACAGTGGTG
 53451 TGATCTCGGC TCACGTCAAC CTTTGCCTCC TGGGTTCAAG CGATTCAAC
 53501 ACCTCAGCCT CCCGAGTACG TGGGATTACA GACATATGTC ACCACATCCA
 53551 GCTAATTTCG GTATTTTGG TAGAGACGGG GTTTTGCCAT GTGGCCAGG
 53601 ATGGTCTCGA ATTCCTGAGA TCATGTGATC CACCCGCC CAGCATCCCGA
 53651 AGTGTGGGA TTACGGGCGT GAGCCACGGC GCCCAGCCCC TTAATCCTAC
 53701 ATTTAAATAG GGATTTCAGCC CAATCCTATT ACCTGTTCC AGGGTCTTT
 53751 ATTAACACTCT TGGACTTTAT TAAGAATAGT TTCAATGGAAA CTATATTCCC
 53801 AGGGAAAATC ATCCCTTGC ATATTGAAA AATATTTTC TTTTGCCTC
 53851 TATATTGAA TGACAGTGGC TAGATATAAA ATAGGTATT AATACTTTT
 53901 CCCTAGTGT TTTGTACACA GACCTGATAT TAAATATT TTTGTTGTT
 53951 TTTATTTTG GGAGATGGAG TCTCACTCTG TCGCCAGGC TGGATGAGT
 54001 GCAGTGGTAC AACTCTAGGCT CACTGCAATC TCCACCTCCC GAGTTCAAGT
 54051 GATTCTCCGC TTCAAGCCTCC TGATTAGCTG GGATTACAGG CACATGCCAC
 54101 CACACCCAGC TAATTTTATA TTTTTAGAAG AGATGGAATT TCACCATGTT
 54151 AGCTAGGCTG GTCTCAACT TCCGACCTCA GGATGATCTGC CCTCCTCGGC
 54201 CTCCCCAAAGT GTGGGATTAG CAGGTGTGAG CCACCGTGGC TGGCCTAAAT
 54251 ATTGTTTATG AGAAGTTGAGA AGGCAGACCA ATTAAAGAT TCCCCCTTA
 54301 GGTGAATTGA TTTGTATCAG GAGAAGGTTG TCTAGATCAG CAGTCTCAA
 54351 CCTTTTCAACCAAGGACC AGTTTCATGA AAGACAATT TTCCACGGAT
 54401 GGGGTGGCGG GGGAGATGGT TTCAGGACAA AACTGTTCTA TATCAGATCA
 54451 TCAGGCATTA GTTAAGGAGT GTGCAACCTA GATCCCTCGC ATACCATAGG
 54501 GAGGGATAGG TTACCATAG GTGTTGGCCT CCTGTGAGAC TCTAATGCTG
 54551 CTGTTGATCT GAGAGGAGGT GGTGCTCAGA TGTTAATGCT CCCTGGAGTG
 54601 CCACTCACCT CCTGCTGTG TGCTGGGTTCT CGACAGGGC ATGGACCGAT
 54651 TCTGGGCTCT GCAGTCCAGG GGTGGGGACCT CTCATCTAGA TGACCATAG
 54701 ATGCTTTATC AAGGGTGTATC CTGGTTTTTG ATGTTTTGTT TTTTGAGGG
 54751 GGTCTCGCAC TGTCACCCAG GCTACAGTGC AGTGGCGCGA TCATGGTTCA
 54801 CTGTTGCTT GACCTCCTGG GCTCAAGTGA TCTTCCCACC CTAGCTCC
 54851 AAGTAGCTGG GACCATGGGT GCACACTATC ACACCTGGCT AAGTTTTTG
 54901 TTTGTTGTTG TTGAGACAA AGTCTCACTC TGTTGCCAA GTTAGAGTGC
 54951 AATGGGGCAA TCTGGCTCA CTGCAACCTC TGCTCCCTGG GTTAAAGCGA
 55001 TTCTTCTGCA TCAGTCTCCC AAGTTGCCAG GATTACAGGC ATGTGCCACC
 55051 AAACCTGAGT AATTTTGTGTTTTGTAG AGAGACAGGG TTTCACCATG
 55101 TAAGCCAGGC TGGCTGAACTGCTGACCT CAGGTGATCT GCCTGCCTCG
 55151 GCCTCCAAA GTGCTGGGAT TACGACGTGA GACCACACAC CTGGCTTAGT

FIGURE 3

22/32

55201 TTTTTAAATT ATTTTGGTA GAGATGGGGT TTTGCCATAT TTTCCAGGTT
 55251 GGTCTCAAAC TCCTGGGCTC AAGCGATCCT CCCACCTGG CCTCACAAAGG
 55301 TGCTGGGATT ACAGGCATGA GCCACTATAT CCGGCCAAGA TGTATCTGT
 55351 TGATTGCTCT ACATCAGTTT TTTCTGAGT CACAGTGTGC CCTTACCACT
 55401 TGCAAATTCA AGCCTTCCCT GATTCAGGA AAGTTGTCTT CTATTGTGA
 55451 TTTACCTTT TGTTGTTCT GTTCTTCTT CTTTTACTA TACCCCTTAC
 55501 CCCGGTATAG TTTATGTTCC CTTTTCTTCTT TGTTATTGCT TATTCTCT
 55551 GTAATTATTT GCAGCTTGT TCTTTTTTTT TTTTCCACTT GATTCTCTC
 55601 ACCTTTGTTT TCCATGTCCC ATGCTGCATT GTTTCATTAA ATATTATTT
 55651 GGCATTGTT TAGTTAGGCA CTGACAGTAA AGCAGAGAAC AAAACAGACA
 55701 ATAATCCTTG ACCTCACGAA ACTTATTAG TGGGAGAAC AGACAACAAA
 55751 CAAAATGTTAG TAGGCCAGAA GTAATGAATC CAAGAAAAAT AAGGCCATGT
 55801 AAGGAAGGTG GGACGAGAAT TGATTTTTA GAAGGGTGGT CAGAAATGGG
 55851 CTTACTGAAAGTGTATTT GAGCAGAACCTAAGCTAAGAGAT GCACCTATTT
 55901 GGGGAAAAGC ATTTGAGGTA GAGGAATAAGS TGTAAGTGGT TTGAGGTGGG
 55951 AGCATAGTTC TTAGAAGGAT ACTCATTTCAGTCA TCATAGGGCC AGTCCTCTCA
 56001 TGACCTCATC CCAACTTAAT CACCTGCCAA AGTCCCCACA TTAAGTGT
 56051 GGACTTCAAC ATATGAATTA TGAGGGGAAT GCAAACATTC AATCCCTAA
 56101 CTGCATATT TTCTTGATT AATTGTTCA TAGTTTCAT CTGCTTCATG
 56151 GTATAAGTTT TATGGCATTTC TCTTTATGAC ATTTGGTTAT ACTCTTGCTT
 56201 TTCTGTTTTT GTTTGTTTTT GTTTGTTTTT TTCTTGCAAA ATCTTTGAGT
 56251 AAGACCTAAC TGGTCCCTC TTGATTATTG GTCATTTTG AACTGGAGGT
 56301 ATTCGCTTA GATCAGCTAT TTACCCAAGA ATAAAATTGT GGGAAAGGGG
 56351 CCAGAGGAGT GGTGGGGAA GGCTGACAGC TTGAATTTC CCAGGTTCC
 56401 TTGGTGGCAT GAATCAGTGA GTAAAGAAGCA GAGCTCCCTA TATCACAGGT
 56451 TTATTTGTT TAAATTGATA AACACTGATT CATATTAGAA TCACCTGGGG
 56501 AATCCTTACCATGCCAAATG AAATCAAAT CTGTGAGAGT GGGGCTTAGG
 56551 TATATAGGTT TAAAGTGCC TCAGGTGATT CTCTATGTATA TCCAGGCTAG
 56601 AATTGCTGAT TTAGCCTTTA CTTTTAGCTA TCCAAGATCA ACTGATGCTT
 56651 GGCTACATGC AACAAATTTC CACTTCCGCC TTACCATACT TAAACAGCCT
 56701 GCTGCTTCA AAAAATGGCA GGTTAGGTG TTCACTATTT CCTTAATATG
 56751 TCCCACCTTC CCCATAGGC CACTCATATT TTCTGACTTT GTCATACCAT
 56801 GCAAGGGCTT GTTGGTTTTA TTTTAGGTCA CTTTTTTAG CGAGCTATGA
 56851 ACTGTACCTA CTCTGGCCCA CAGAGGAGT ATCTGCTATG CCTAGCTTAG
 56901 GATGGTTCTA TTTTTTTGAA AAATTTATT GTGAAATTAT AATATAGAAA
 56951 ATGCATAAAA TGTAATAAA CATCCATGTA ACTATTGCCG AAGTATGGAA
 57001 ACAGAAATGTT TACCAAGGACA CCAAAAGCCT TTTTCATGCC GCTTCTCAGG
 57051 CCAAAATCTG TTTCTCCCTC TGAAAGTAA CCACTATCCT GACGTAGCTG
 57101 GTAAATCAAATT CTTTCTCCCCC TCATTCTCT CATTTCAGG GTAATGGATG
 57151 TTTCTAGTT TCATCAAATG TTTCTCTGT TTTCAGAAAAA GAGAGAAACA
 57201 AAAATGCCCT TATTCTTCTA TCTATAACTG GAAGCAGAGG ACTATTGAGA
 57251 TTGCCAATT AAGTTTTGG TGTTTTGG GGTTTTTTA AACAGATGAA
 57301 GTCAGAGATC ATTATAGCTA ATGCCATACT GACTGGCAGT TCAGCATGCA
 57351 GTACCCCTAGC ACAAACTATT AGCCGGGCTT GATTTATAGT TATCAGTAGT
 57401 TCTGAATTTA TGAGACAGGA ATTTAAACT TCCATTCTC TTCAAACAAAT
 57451 ATGGCACTAG ATTTCATCAAT ACAGATGAAG AATACCAACA GTGTATACAT
 57501 TAATCAGTAT TTGGGGTATC CAAGAATGTA ATATATAAT TAAGTTAATT
 57551 AACTTATTTT TTTTTAGGA ATATGAAGCC ATCTACCTAG CAAAATTAAC
 57601 AATACAGATC ATGTCACCAC TCCAGATAGA AAGGTCTTA TCTGTTCTT
 57651 CTGGTACCAAGGTAAGGAT TTTTTCTT TTGGAGAAAT TTGGGAAGAA
 57701 AGATAATGAA AGGTGGAGAA CTGCTACAA GTTACACTGA ACAATTAAA
 57751 TTGTTTAGAA AACTTGTAA ACTATTGAGC TAATTCCAGA AGGATTCTT
 57801 TTATAATGAA TAAATGTGTA CTATAATAAG CTAAAGTCTT TCAAGTAGTA
 57851 GTACATCCGT GTTGAAAGA TTAAAATAAT AGCAATCTGG AGAAGGGGCC
 57901 CTAAACACGC TTAGGTGATC TTATTTAAAG TAGAGGGCGG TTAAATACAGC
 57951 GTGTAGCATG GCTAATGTGA GCTTCTTCT CTTGCCATCA ATATTCAT
 58001 CCTTTCTCC CTCTGTTGCT ATTTCAGAAG TACCTAAGC CCCTTATTT
 58051 CAAAGTTAAT CCAAGCATGC TCTTAAATC TTCCCTTCCC AAGACCTG
 58101 TACCTGTGTT TATCACCTT GTTCTCTCC CAACAAAGCA CACAAGGCAT
 58151 TTTACTTTA TTTCAGTTT TTCCCTACCT GCAGTTCACT TCAATCTTG
 58201 AACCAACAGT TATATAAGGT AGTAAGAAC GCTTATATAC TTAGCACTGA
 58251 CCTGGAAATT GAGGAGAGT GATCTGATCC ACAAGTATAG AACTCTTGC
 58301 ACTCTACTGC ACTGCCCTA GTGAGTAATA TGACTGTATA TTCACTCCCCA
 58351 AGGCTCAACT TCCTAATTGT CATTGACTT TTCACTTCC TTGCCACATC
 58401 TGTCTAATAA TTGCTCTCCA CATCCTATAG GGTCCGTTT GTCACTATTG

FIGURE 3

23/32

58451 TTAACATTCC TTCTTTTT TAATAGTGAC CTTAATCTAG TTCAGGTCCG
 58501 GATTTGCCCT CTTTCCAAAC TCTTGTATT TGGTCTGTC TGTACATTGT
 58551 GGCCAGACTT ATCCCCATGA AAAGATATTC TAATATTGAT ATTTTCCCT
 58601 TGCCAAAGCC TCCTTGGCT TCATTCCCTAC AAAAGTTTAT AGAATGCCAT
 58651 ATGCCCTCT GATTTTTGG TTTCTTCTC TCATTGTTCT TCTTTATGTC
 58701 TGCATTTCAAG AAAACAACG CTGATGGTTT CCTGTGTGTC TCTTCTTTCT
 58751 CCCACCTAAA ATGCATCACA TTTAGTCTCC CTATTCTGG TTCATATGTC
 58801 ATCTCCCTAG GAAGACATGA TGATTAATGC ACTCTCCCTC TAACCCCTAG
 58851 TCATTTGGAG TTCCCATAGA AGCACAGCAC TTCACTGAA ACTTAATCAC
 58901 AGTATCTGGG TTTCAGCTGA GGGCTAGGAT ATTTTATCTC ATTCAATTGT
 58951 ATTGATGACTA TATTTTATC TTATGAAATT TTATAGTGAAC ACATTCTTC
 59001 ATTAGAATAT GCCCTCTGAA TTAAACATTAT TATTACCATG ATATAACAGT
 59051 CCTGTAGGGC ATAAGTTAA GGTCATGCCA TTGTTAGGCA AAAAACACAG
 59101 CAGACCTCT GCTGGTTAA CTGTTCCCTA AAGTTTCTC CCATTGAGAG
 59151 TCTAAATTTC TGATTTATAAC TTTTGGGGAT ACAGAGATAG CTTTGATTCT
 59201 ATGTGGGAGA TTTCAGTACT ACCAGATGCT GGTATGAAGA ATAGATAAAA
 59251 GAAAATCTCT TTATATGCTA CATGCCCTCC TTTCTCCCAA CCTAGACTTC
 59301 GATAGCTGA GTGGAAAAAT ATTTCAGCT GCTCTTCATA ACAGCCTCTG
 59351 TGAAAGCAAA AAGATTATCT ACAAAAAAATT ATACAAATAC AAGATTAATT
 59401 TCCTAAATTTC TATGCCCTAA GTCACATGTT TATGGTGCCT AAAAACAAAT
 59451 TAACTGATA ACTAAACATT TATGTATTAT CTCTTGAAA GGTCTATTTT
 59501 CACACTATTT CAAAAATTAT TTATTTATA TGCAATACCT AAGACATAAT
 59551 ACTTGAGAAG GAAAATATAT CCGTGTATGA AGATTAAGAAA GTTATAATAT
 59601 TTAGGTAATT TATCACAAAG GAATTTACTA AATTTTGCTA TATCAGTTGT
 59651 GGAATTCTCA TAGTGTATAC ATGATCCTT AATAACAAAA TTTTACTTGC
 59701 TGTAACCTTT TAAACATGAAT TTATTTAGT GCCCTTTAA TCTTCATGCA
 59751 ATAACCTTTA GGCAAGTTGA AGAGAACACA TGAAGAAGAG GATGATTG
 59801 GAACCATGCA AGTGGCAGCT GCACAGAATG GCTGACTTGA AGAGCAACAT
 59851 CATAGAGTGT GAATTCTAT TTGGGAAGGA GAAAATACAA GAGAAAATTA
 59901 TAATGTAAAA TGGTAAAAAC ATAAGTAGTT TTTTTTCAA TTACATGTTG
 59951 CTTCCAGACA TACTCTCTG CAACTTGTG AGCAACATT TAAGATGTTG
 60001 GACTCTGCA ATAGATGACA CTGATGGTT TACTCCTTT TTTAAAACA
 60051 CATGCGCGC CACACACACA TGTCTTACAA GTTTTATTAT AAACCAAGAA
 60101 TTTTGGACTT GCAAAAGAGGT ATTATTGCAA TAATGCACTT TTCATACTTG
 60151 AAATTTATTT GTATGATATA AAGTTTATTAC TTAAACAAAA ATGCAACTAT
 60201 GGGGGGATTG TTATATAAGT TTGGTAATT TATAACAAAA TTGCTAAGG
 60251 TTTGCTAAAA ATTCACTTTT CTGTTCTATA TATTACATT TTAACATAAT
 60301 TTACAGTTTCA AATTTTATGA TGGAGCCTCT TACAGAAACA TTAACAAAAT
 60351 GCAGGAATCTC GCCACATTTC TTTTTAGTA TAACTTAATA GCTTAATTAC
 60401 CATTTCATTTC TTATACCTTC TTCCATTATT AATCTTTAA TCATGATCCT
 60451 AATTAGCTGT CCTTACTTTA ACTTGATCTA ATTATTGCTT CCTTTCTTAT
 60501 TACTTTCTTA ATTTTCTAT ATTAAAAAAA CTACAGTTTC CATGATAAAA
 60551 GGAAAACGTT TTGATTTATA GTACCAAGTG CTTAAACACCA AGGATACTGT
 60601 TAGATTTCG AGTGAACCTTC CTTTTGCAT TTTTGGCAG TAAAAGCCAA
 60651 ACGTGTATT TGTTCTTTAG AGAGTTGTCC AGCCCTTTT TCCCTTGTCC
 60701 AAAATGATTC TAAATAGAAT CTAAATAAAC AATGTAGCAT TATTTTTTC
 60751 TAAATGAAAG CCCAAAAAAAG AAAAGTGCCT TGCATCATT AAAAAAATA
 60801 ATTAATACCT CATGCCCTCT AAAATTGAT GTAGAACACT GAAAAGTCT
 60851 TAAACATTTC GTGTAATTTC CTTCTTTTT AAACCATAAA TTAGTTAAA
 60901 CTGAAAGTAC GAGCCTGGAA GAATATTAG TAAATTTATT GGAATATAGA
 60951 ATGTTACTC TTCTTTTTA TGTTGTCTA ATGATTCTGT GAGATTGTT
 61001 CGGCTCAAAC AGAACCTTT CTTGGGGAA GGTGATTGTT GGGAGACTCT
 61051 AGTGTATTTC AAATTAGCAT TTAAATCCAT TCTTGACATT CAGTTAGTCC
 61101 AGATCTGCC CATAATTGTC TTAGTAAAG TCACTTTATG GATTTTGGC
 61151 TATGTTTAG TTGTGTGTA TAAAAGTCT AAGAAAACAT TTTGCTATT
 61201 TTAAAGTATGT AAGGGAAAGAG AGGAGTGTGTT TTAACCTTTT ATAGTTGATG
 61251 ACTTTAGGGG TAGCACAAC AAAACTCCCT TGTATCTAAC TTTTCTCAAT
 61301 CCTCTCTTGA GGTCTTTAC TAATGGGAAT GATTTCTGTA TGTTCCCTG
 61351 GTACCCAAGA GGTACTATGC AAAGTAACCT ATTACACCAA GTTACTTGCT
 61401 TTGCTTCCT CTCTATGATG TGATAATACA GTAAAAGCTT TCTTACCCAG
 61451 CATACTGGGA GAGTGGAGAT TAATTAAAT TGTTAATTAA GAGTTAATT
 61501 CTATTGACCC AGGTGATATT TCTCTCTGTA TTTCCTCTCC CTTCCCTCT
 61551 CTTATCTTAC CACTGTGAAAC ACAGCATATT GTTAATCTCG TTGTCGTC
 61601 GTATTCTGCT TTGTGATTAG CTCTTTGAT GTACAGTGGT CTAGTGGAGT
 61651 CAAGATTGCG ATTGGTTTT CTAAACATTCC AGTTGATAAA AGTTCCAGAT

FIGURE 3

24/32

61701 AACACAGCTT TCCTGTATAT AGATCACTAT TGGGCAGGTC AGCAAAGATC
 61751 TCTTACAGTG TAATAATAAT CTATGATGCT TCATTTAGCA GAAACTCTGC
 61801 TTAAAAGAAT CTTCATAATA GTAAGTTAG GTTTTAAAAA CTTGTTCAT
 61851 AAATATACAT ATATCCTCTC TAGTAGTCTG GCCAAAAGAA CAGATTTGT
 61901 TATTGATAAT TTGTAAGCTGG TAATTTTCCA CATTTCATC CCACTGTAAT
 61951 TTTTATGTTG TCACTGAAGT GCCTGCCAG TACTGTATAT TACAGTCCT
 62001 CACAAACACT GGGAAAAGGG ACTGTATCA TCTTGAGTAC TCTGTGTGA
 62051 TATATATATA TATAGATAGA TAGATTTTTT TTTTTTTTTT GAGACAGAGT
 62101 CTCTAATGTC ACCCAGGCTG GAGTACAGT GCACAACTT GGCTCACTGC
 62151 AACCTCCACC TCCTGGGTTA AAGTGAATTTC CCTGCCAG CCTCCCAAGT
 62201 AGCTGGGTT AGAGGCACAT GCCACCATGC CTGGCTAATT TTTGTAGTTT
 62251 TAGTAGAGAT GGGGTTTCAC CATGGGGCC AGGCTGGTCT CAAACTCCTG
 62301 ACCTCAAGTG ATCCACCCAC CTCGGCCTCC CAAAGTGCTG GGATTACAGG
 62351 CGTGAGGCCAC TGCGCCTGGC TGAGTACAAT ATTAAATGTAAC ACAACCATG
 62401 AAGTTTATTA TTCATATAA GAACATTACA GGTTTGTGTT TTCTTGATG
 62451 TCTGTCCACC TAATGTTAA GTAGTTCTGG TAGCTCTTC TATTCTTTAT
 62501 TCTATTGAT CTCATTTCTG TGATTCTTT ATTACCACTG ATGTTTGTG
 62551 ATAGTTAACT ATGATAAAATT TAACTGATCA TGATTATCT TCTAGAGTAT
 62601 TAAATAATG TATGAGTGAC CACCCAAATC CAACATTTAA AGTGTAACT
 62651 GGGCCCATAA TTTATAGTGA AATTGTATCA AAACATAGGG AAACGTATT
 62701 ACTGTCCATT TTGAAAATAT GAAACTTGAG TATTGAAAAT ATTCAACAT
 62751 CGAACATGGCAG TATTCTAATT TCAGTTAGTT GGTTCATGTT AATTCTTAC
 62801 CTGTTAGATG TTTAAACTG AGTGACCTTT ACTTGTATCT ACTCTGTGGT
 62851 GGAAATGTTA AACCATGATA CCTTTTGCTA CCAACTCAAC CACTTAACCT
 62901 TTAGAGCAGT TTTGGGGAGA GTTTATGCTT CATCTGAGTT TAGAAGTAAT
 62951 GTCAGAAAAT GTTAAGCATG TCTGTATTAA GAAAATATAA GGTTCTAAT
 63001 TGTCTTATTA ATATGGTAAT TCAAGTGAAT TAGAAATATT TAACTGCAAT
 63051 CTTGAATTAT AAAGTTGAGA TATATATATA TATGTATCAA GATCTCAACT
 63101 TGATGTAAG TAAATGAGCA GTTACCTGGC GGATTTTTT TTTTTAAAT
 63151 AACTGATTTA ATCCATAATC CCATAACAAA CATACTTCA CCTCAGTATT
 63201 TTCTTTCTT CTTTGTCAA CAGTGCTCCG ATAAGGAAAT GCTAGAAAAT
 63251 AGATGAGAAG TACTGAAAAG CCTTTTTTTT TAATTGATTA GAAAAGTAAG
 63301 TCTCTAGGGT CTTTGAATGC TGGAATTTTT TTTTTTTTT TTGCTTTCC
 63351 CATCTGTGGC AGCTAAAACA AAAATCACTC AAAATATTCA GGTTACATG
 63401 TTAGCTCTCT CTCATAGGGG GCTGCCATAC CTCACAGTTC AAAGTGTATT
 63451 CTATAGATCA GTAACATTAT ACTGACATGT AATTGCAATT TACTATGCAG
 63501 CAAAAATGAT TCAAGAAGAA AAATAACCTA CAGTGTCTGT ATACCTTGT
 63551 ATACACAAATT GCTTAAGTTA CTCTGCTTTT AACATTGTA CTTGGATAAA
 63601 ATGCTTATGT CTGTATAGGA ATGTCAAGT GCAAGATGCT GCTAGGCCAG
 63651 GCACAAAGTA TTTAAATTAT TTGTAAGAAGA TTGGTGGTTG TATTAACACT
 63701 GCTGTGCCAT TATACCTCAA AAATATTGAA AAGTCATTC ATACTGCTGC
 63751 TTATACCTCA AAACCTCTT ACTTAGATTG TTATCTGCTG GGAAAAGTA
 63801 ACCCAAATTT ACTCTGAGTT AAGAAGAGT GATGAACATT GAATGTTGAG
 63851 AAGCACTTAA GAGTATACTC TAAAACACTG TGGTTACACA CACACACAA
 63901 ATTATGGTCT GTAGTCCAGG CAAGCCTCAA ATTCCAGTC AAGTTTATT
 63951 TTAAGGATTA GTTGGAGCAAG TTGGAGTTG GAAGTGAGAG AATCTGTGTT
 64001 AAAGGAAAGG GTAGGTATC CACAGAACAG CTTCAGTC TTACAAAAAA
 64051 AAAATACATTC TTGCTTTTAT ATTACCATCT TCCCCCATTA GGCTTACCTG
 64101 CATACTGTGC TTCATCAAT CTAAGATCAC CTCACAACTA TACCATATT
 64151 TTAGGCCACCA CTAAAAGACA GTGTATTGCT AACAAAACCA TGATAAACCA
 64201 TTGATAATAT ATCCAGATT CAGAGATGTT ACAGTGCATC TTAGTTGATG
 64251 AAACAAAAAT ATACAAAACA TGAGACACAG TAAAATGAT AAGTACCAAC
 64301 TCATTATACC TTTCATCAAAG CAAATAGTGG CCAAAAGATGT GAACGCCAG
 64351 ACACGGTAGC CGACATATGT AATCCCGATG ACTCTGGAGG CTGAGGCAGA
 64401 GGATCACTTG AGCTCAGGAG TTGAGACCG GCTTGGGCAA TATAGTAAGA
 64451 CCCCCACAGAA AAATGTAAGG CCAGGTGTGA TGGCACACAC CTGAGTTCC
 64501 AGCTACTGGG GAGGCTGTGAG CAGGAGGGAT GGCTTGAACC CAGGAACCTGG
 64551 AGGATGCACT GAGCTATGAT CACACCACTG GACTCCAGGC TGGGTGATGG
 64601 AGTGGGACAG TGTCTCTTT AAAATGTGG GCCAGGTGCA GTGGCTCGCA
 64651 CCTGTCACTCC AAGCACTTTG GGAGGCTGAG GTGGGAGGAT CACTTGAGCC
 64701 TAGGAGTTAA GAGACCAAGC TGGGCAACAT AGACTCCACA CAAAAAAATT
 64751 TTTTAATTAG CTGGGTGTGG TGGCATGCAC CTATAGTCCC AGCCACATGG
 64801 GAGGCTGTGAG TGGAGGATC ATTGAGCCC AGGAGATTGA AGCGGCAGTG
 64851 TGTGGTGTGATT GTGCCCTGCTC GCTCTAGCTT GGGCAACACG GAGACCTTGT
 64901 CTCAACAAACA ACAACAAACAA AAGGCTATCT ATTGTGGGTA CACTGCCTAT

FIGURE 3

25/32

64951 GGGGTAGTCC TGCTCCACAA GGAGCAGTTT TTAAAAAAA AAAGTTAAC
 65001 AAGTGTGTTA TGAGCACTT TTTCATATT TACATTTACT CACCATATGG
 65051 CTTCAAAAT CATAAACATA CTCACACTAA ATTACAGATC ACCATTGTCC
 65101 TCAATGACAC AATTTTGTA TGGTGTACCT TACCTGTAAT TCTATTCT
 65151 ATGGGAGGAT TAAAGAGATA TCTTAGGAAC ACTATTTAA GGGATTTACT
 65201 GAAGTGCCTA CCTTGTGAAT GATTTTACCT CAAATTGTC AGTGGTAAGA
 65251 AAGGTAAATAA AGCATTAGT TGTGCCCTTA AGTAGGCTAA TTTTTTTGT
 65301 TTTGTGTTGA GATGGAGTCT CTCTCTGTCC CCAGGCTGGA GTGCAGTGGT
 65351 GTGATCTCAG CTCACGTCAA CCTTGGCTC CCGGGTTCAA GCGATTCTCT
 65401 CGCCTCAGCT TCCTGAGTAG CTGGGATTAC AGGCGCATGC CACCACGTCT
 65451 GGCTAATTTC TCCTTTTTT ACTAGAGACA GGGTTTCACC ATTTGGTCA
 65501 GGCTGGTCTC AAACCTCTGA CCTTGTGATC TGCCCACCTC AGCCTCCCAA
 65551 AGTGTGGGA TTACAGGCCTG GAGCCACTGC ACCCGGCCTT ACCAGGCTAA
 65601 TTTTAAAAA CATGCGTTT TAATTACAG GATTACCTG ATAAAACATAC
 65651 TCTTTGTCAA GGTGTGAGA CCTCTGAAAA GACAGAACTA GCTTTGTTGC
 65701 GTTTCACGAA GGACAGATCA GTTCGTCTGT ATAGGCTATA AGCAGGTAAG
 65751 TAGTGCCTC TATTGGTGA GGATTTCTGT TGTTTGAA AGCCAACATAT
 65801 AGCTGGCTGC ATGGAGGGAATC CAGATGACCT GGTGTGAGTC
 65851 ATGGGATGAAACACTGG TATTTTCTT ACAATTTCAT TTTACAAAGA
 65901 GCACATTAACTAAAATTTT ATGAATTATG ACTTAATCTA ATAGTCAAC
 65951 AGCAGACTCA AGAAAAGCAGATGTGATT CTAACAGAAAG ACTACTCATA
 66001 TAAACAGGTT TAATGCAACA TGGAATGCAA AAGATTAGAA CCATTAAAAT
 66051 ATTTAATTCT TCAACTTTAA AAAATTAAAT AAAATCAAA TAGGATAATG
 66101 ACCAGAAATAG TGCCATTATA ATCACATCAA AAAGCTTCCA TTAACATTTT
 66151 ATGAATTGG CAATCTAGTA CAATACATTA AGTATTGTGT TTCACTCAAT
 66201 TTTCGATAC TCCATTTTTG AAAAACCTTA GAGGCTTCAG ATACCCATGA
 66251 AAAGAAAAAATCAGGGTAG AAACACATAG GCTGAGGTT GCTAATTTCAC
 66301 TGTTTACAGA GGACCTTGA TGTCCCACTA TAATTGCTCT TAGGTATTT
 66351 TAACAAATGA ATAGTCATAA TTACAGAAA AGACAAGTGG TACTTTTTAT
 66401 CTACATAGAC TATACATAT AAAACTTCAG TAAACATTT AAATTGTTT
 66451 ACTTTAATC TTGTCAAGTA ATTTTCATT CTTCTACTTC AAAAGGTTGA
 66501 CCAGGGTTTGCTGTGGATCAAGC AATGTTGGAC TATACTATGT
 66551 TTAGTTATAA TAACTAATTG ATCCACCCCTG ACTTAATATG TGGGAAACAA
 66601 TACACCCCTA AGTGTATTGA GATGTTTCTT TGAAACAAAA ATATTAAATT
 66651 TTATGCATGT GATAAACAGC CTTATTCAAT GTATACTTT TTTAAATGAG
 66701 CAACACAGAT AGCAGACATA TAACTCCTTA TTACCCATAC TCTTGACTAC
 66751 CAAGAAAAGGA AGCCAAACTT TTAGAAAAAT ACAATGCAAG AAAAGATTCA
 66801 AGTTAAAAT ATATTCCTTT GGTTAAAAT CATCCCTT ATAATATTCA
 66851 TTGTGATCT AAATTACACAG CATGTCCAC CAGCCAAAG TAATCTTCTA
 66901 AATGTCTTAA TACTGTAGT ATTACATGT TTTTCAGTC CAGTATTAT
 66951 GGAGGTCACT CGGCTGCAGC AAAAAATTT TTCAACTCTA GGAAGAGTGT
 67001 AGCCTGTAG CATTAGCCCC TTTGACAATT TTCTTACAAG ATTTTACTT
 67051 TAGAAACCTC CGACACATGT AGTTTCTTC AGATACAGTA TATCCAAACT
 67101 TTTTATAGAA ACCAACATTT TGTGGTAGAC ATTCAAGGGT AATCTTGAA
 67151 CAGTTCAGTT TCTGCTTAG CAAAGTAAGG GTTGATAATA ACCTGAAATT
 67201 TAAAAAGGG GTAGGGTGAG GAGATAGCAT TTATTAAATAA AAATTGATT
 67251 TAGTACAAT ATGAAATTAT GTTATAAAAC TTAAGTTTCC TTAGAAACAG
 67301 GTTTAGATTA TGGCTTTCC CACTGCATTC ATGTAAGTGT ATAAGCATTT
 67351 AAATCACCCTA AGCATTTTTA CTTAGAGTCA AATATACTTT TATCTAGTAA
 67401 TCTCCAGCTC ACTAATAAAC AGGACAAATA CAAAACCTCAC CCTAACCCCT
 67451 CTTTAAAAT GAAATTAAAG GCTAGGTGCA GTGACTCTA CCTGTAATCC
 67501 TAGCACTCTG GGAAGCCGAG GCAGGCGATC GCTAGAGCCC AGGGGTTTGA
 67551 CACCAGCTG GGAAACACGG CAAAACCCCA TCTCTACAAA ATATAAAAAT
 67601 TAGTAGGGCA TGATGGCACA TGCCTAAAGT CGCAGCTACT CCAGAGGCTG
 67651 AGGGGGAAAG ATCACCTGAG CCCAGAGGAG TCAAGGCTGC GGTGAGTAGT
 67701 GATTGTGCCA CTGCACTCCA GCCTGGCAA CAGAGTGTAGT CTCTGCTTTG
 67751 AAAAGAAAAACGAATTTTA AGATGCATGT TAACACTAAA AACTCAACCT
 67801 TTAAAAAAAATGACCAA ATTATTTTG TAAAATTCT TTATTAAAT
 67851 CTATTAAAC AACTTCGGAG CAGTCGACAT ACCCCATCAA AATGAGTACA
 67901 TAATAGCTTT GCTCTTAAAT CATTTTAAA GCTACTTTAA TATTGTGAA
 67951 GGTGTGTATC AGATTAACCTC AAGATTGGTC TAATTAAAT GAAAGTGGAAA
 68001 CAAAGCAAGT CTACATCTAT ACAAATTTTC TTAATGAATC CAAACCCAGT
 68051 ATTAAGTGT GGATCTAAGT GCCTTAGGAGG ATAAAAACTA TAAAGATAT
 68101 ACAAAACTTGA AGGGTCTGCC CATGTTGAA CAGACTAAA AATCCTATT
 68151 TTAAAAAAAATGACCAA CAAAGACCT TGACTGAAGT ATGCCTGGCT GGTTGCAGTG

FIGURE 3

26/32

68201 GCTCATGCCT GTAAATTCCAG CACTTTAGGA GGCCAAGGAT CACTTGAGTC
 68251 CAGAAAGTCG AGACTAGCCA AAGCAACATA GCAAAACCCCT ATCTCTATAA
 68301 AAAATTAGCT GGGTGCAGCG GCATGCACCT GTAGTCCCGAG CTACTTGGGA
 68351 GGCTGAGGCG AGAGGCTCAC TTGAGCCCCA GAAATTCAAG GCTGCAGTGA
 68401 GCTGTGATCG TACCACTGTA TACTCCAGCC TGGGCAACAG AAAGAGATCC
 68451 CATCTCTTAA AAAAAAAA AAAAAAAA AAAAACATAA ATTATATAGA
 68501 CTAGAACACA AGAAATCGGT CTGTTTTGTT CACTGAGGTA TTCCAATAC
 68551 CTAGAACAGC ATCTGGTACA TAAGCAGGTA TTTAATATTT GTTAATTCC
 68601 TAAACCTAG AAGAGTTAGT GTAAAAAAGC AAGTTCTTGG GCCAGGCACA
 68651 GTGGCTCCCA CCTGTAATCC CAGCACTTTG GGAGGCCAAG GCAGGAGCAC
 68701 TGTGAGAC CAGCCTGAGC AACATGATGA GGCCCCATCT CTACAATTT
 68751 TTAAAAAATTA GCCAGGTGTG GCGTGTACCT GTAGTCCCGAG CTAATTGGGG
 68801 GGCTGAAGAG GATTGCTTGA GCCCAGGAGG CTGAGGCTGC AGTGAGCTGA
 68851 GATTGAGCCA CTGCAACCTCA GCCTGGGTGA CAGAGCTGTC AAAAACAGAC
 68901 CCTGCTCAA AACTAAAAA TTATAATAAA TAAGAACTAC AAGTTCTTAT
 68951 AAAATGGCAAA TAAATCAATA CCACTTATTT ATATTTATTT TAAATGATT
 69001 AGATATATAC AGTGAAGGCT GTTCAGTAT GTATTTCTAC AACTTATGAG
 69051 AATGAGAGAT CACAGAATAT TCTGTAATAG TTGAACATT CTTTGTTTT
 69101 TAAATATGAC AGAGAAGCTG AGGCAAATCC GATTAGCCCA AAAGTTTATC
 69151 TCCTACTAGG ACGAGAGCAT TACTATAAA AGTTAGTAAT TTAAAGATGT
 69201 TACTGCTCTGT AAAGAAGTAT GCTTCCAATT TTCAAACATT AAGGCAAAT
 69251 ATGTATAATA ATACTTTATT TCTTCATGAA ATTCACTCTA AACTATTAGA
 69301 GTGAGAATAA GTTCAGAATT AATGAAAGCCA AAAAGAACTT CAAACAAGTA
 69351 TCTTGTAAAG AACTAAATT GGAACCAAAAT TTATCCAGGG TTACCTTGT
 69401 TCTGCCTACT TACAATTTCG CAAAGCTGTT TCCTCTGCAT TCATCACTAA
 69451 CAAACACATC TTCTACTCTT CCTCTCTGAA AATATTACA ATGTTAAAG
 69501 GAGTAAGCAT TTACTTTGT TTTTAGCTAA AACGAGTGG TAAGATT
 69551 CTGATAATAA GTAGTATATT TTGTAACATT GAACTTAACA GAAATCAAAT
 69601 GCAAAATAA TTATACAGTG AAGGCTGTT CAGTATGTAT TTCTACA
 69651 TATGAGAAGG AGAGATCATA GAATAATTCTG TAATAGCTGA ACATTTCTT
 69701 TGTGTTAAAG TATGACAGAG AAGCTGGGGC AAATCTGATT AGCCCAAAG
 69751 TTGTTTCTCT ACTAGTATGA GAGTACTACT ATTAAAAGTT AATAATTAA
 69801 AGATGTTTTT ATTTTATTAGA GGGAAATAGTA TGAGTCAAGT TGTGACCTAA
 69851 ACTTGTGTTG GCTATGTCCC CAAACCTTCCC ACCCCATTGT CTTTAAACAA
 69901 ATATCAGGAT CAACATCACC AAAATGTAAC CTTTTCATGA ATATATCCAT
 69951 CATTCTACTC CTTGCTTACT AGCAAGTTAT TTTAGATATC CAAATAAAAT
 70001 TAATGCTCTAG TACAGAAACC CCACCGAAAT TCCTAAGTGT GACAGAACAC
 70051 ATCCCAGTG TTCCCTACCTT ATTCTCATTG AATTAAGGT TTCTCTCCCT
 70101 CTTTTTTAT TTACTATTAT ATGTGACTTA TTGAGGGATG AAAGGGCACT
 70151 ACATGCATTA GATGATCAT AATTAGAACG GAATAATCTG AACCTTAC
 70201 CATGTGAAA CAAATTATG CTAACGTGGT ATATTCAAGAG TTGTTTTT
 70251 TAAAAGAGTA ACATAGGGA TTTGTGCT TACTGCTAAG TTGTTGGTT
 70301 TCTCTATGCC TATACCAAAAT TGATCCACCT TACAGAACAA TTTAGCATA
 70351 CAATTCTACAC TGTTATACAT TTCTTTCTT AAAGCTCTCA GAACACACTG
 70401 GGAAAAGGGA TTCTAAGAG GCACTGAAAA TCAATGAGAA AACAGATTG
 70451 TCTAATGGAA ACTCAAAGTC AGTTGTGCTA GAAAACAGCT GTCCATT
 70501 TTATAGCA GCACATACCT TAGCACAGGA ATGGATGAAT TTATGTTCTA
 70551 TAATCAGAGT TGCGTAGCA ACAATCTGTC CTAGAGTCAC ATCTTCTACA
 70601 ACTGTAACAT AATAATCCC AGATTTCTTC ATATGCTCAA AAGATTCTGT
 70651 GGAAATTGGA TAACAAAGTG TTACATAGTA GACATTCAAT TTATGGGG
 70701 GCCAGAAAAA TATTAGGATT AGCTGACTTA ATTACTAAAT GTTTAAAGCT
 70751 GTTTTACCAT AGTAATTTC CTCCATTTC TAAAGAAAAT ATTACCAAGT
 70801 AGTTGAAATA TCAGCAATT TAATGCTAAAGT GAATATAACC TACACATTCA
 70851 AAATATCTGC TAGCAAATAA AAGACTAATA TAGCTATTT AGATGAACAA
 70901 CACTTAAAT ACAAGTAAAT GGCTGATGTT GCCACTTCCA TGACTAATGA
 70951 AAACCTCAAT TTCTCTATT ACCTTAAATA GATCTCTTTA ACTTTTATAC
 71001 TCAATAGATA TCTCAATATA ACCTTTGCAC ATTTTAACAA GAGCATGTT
 71051 ACATGGCTCA ATTCTAGAAT TTTAGTCTT TTGCTTCAA AATATT
 71101 CAAAATATAT TTAAATTTC CCTTTGTGAT GGAAAGTGT TTGTGATAAC
 71151 ATGACTTGCT CTTGTTGCT TTGAGAGCAC CTTGCAAGGA AGTAAAACAA
 71201 TATCTGTTTC CAAGTAACCT TTCCAAGTCA CATAGCAAAT AGGTGCAAAG
 71251 ATACTTCCC TCAATGGAT TTCACTGACT ATTGCTGAAA TAACATGGTT
 71301 TCTCATCTAA TTCATGTGCA TGCAAAGAAA AAATTCAAGGA ATAAAAATTG
 71351 AGGCTAATAG TCTCTCATAT TGGAATTTC CTATGGGCC TCATTCCAGA
 71401 TAGAGATCTA AAATGGGAAA AGAATTCA GTGAATGAAA ATAAACAATG

FIGURE 3

27/32

71451 AGTAATCAGT AATGATGGTC CTCATTCTCA GGAGGGTCAA ATAGCAATT
 71501 AATAACAAAT TCCCTTATTAT AAGGAAATGA AGAATTGTAA TTCCTCAGCT
 71551 ATTAATATT ACTAAATATT TAGTAATGAT AATAATACCT CATTTCCTT
 71601 ATAACAGGAA AAACAGTGG TAGAGCACTG GACAGAATTA AGGTTTTATT
 71651 CCTCACCGTA GCAATAACTA CCTGTGATCT TGGGCAAGTC TTTGGATCTC
 71701 TCTAAATTCC TATTTCTCC TATGTCTAAA AGAAGAGGGG CAGGGGACGG
 71751 GTGGACTAAC TCTTAAGATG CCTGCTAACCC TTAAACTTCA ATACAAATAA
 71801 ACCCCAAAAT AAATTAAAG CGTATAGTCT TGCTTTTTG ATTTGGTAAT
 71851 GAAATTCTG TAAAATAACCA CAGTAAGGGG AATACTACAA TAAAAAAACG
 71901 AAAAACCTCT AGAGCTAACCA CCTAGGTCCCT ATGGTACAAT AATTATCTAA
 71951 TAAAGTAGTC AGATAGTTG CAAAAACAAA GTTACTGGTA CATTGGATT
 72001 CTAGAACAAAC TCAGCCACAT TAAACATTTG TATAAAACAG CTAATTGTT
 72051 CTTTGAAATAA TTTCCAGCTA TTTGAACAAA AACAGAAGTG GGCACTGAAC
 72101 AGCTCTAAC AAAATGAAA TCATGTTCC CTTTATTCGA GGAAAAAGAG
 72151 GTTATGATAC TTACTCATAA ATTGTTCAAG GCTGACAATC CCAGTCTCTG
 72201 TTAGCTGACC CAAATACCTTA AAAAACCTA GTTGTGAAA ACAGATTCA
 72251 AATTACGAGA ATAGCAAAGA GAAGACAGTA TGAAAATAAG CAATATATA
 72301 AGCAGGTGGG CTTACAGGCA ATTATTTTT CAGAACTTTC TATAATCTT
 72351 TAATTATTAG AATAAGTGA ACCCTATTCT TCTATAATCA CTACATATAA
 72401 CAAATATAAC AGGTTTTAC AGTGCTTCTG CCTGCATAAG ATGTTTTAAA
 72451 TAGTGCTGAC CTTAATATCC AGTATTTATA GACCCAGAAC ATACATTCTT
 72501 CAATGTATTAA TATTTCATAT TAAGTCAAT GCAAAGGGTG CCAGATTTC
 72551 CAAATATGT GATTGGTTT TACTTAAAGG TGCAACATGG CTAATACAA
 72601 TATTCTAAA TAAAGTATA AGTAACACTG TTGAGATTAC ACTCTTTAAA
 72651 ATTGTAATTTC TAGTGAATT TCATTAGTGT TACCGGAAAT TGATGTGAA
 72701 AGTGCACTG GAATTTGAA AATCTTAAC TTCCCTACACT CAATAATTAG
 72751 GCCAAATTA GGCCCTTCAG GCTGTCTAGC AAAGAGATAA TTGTGAAAAG
 72801 GACAAAGTTG ACTTTTAATT ACCAAAGTTT AAGGAAGTTA ACTTGGAGAA
 72851 TTTAGATGTT AAAAAGAAA TAACTGTATA AAAACCTTT CAATTTATCC
 72901 AAGGAAAATT ATTCACCTT CATTCCCCA ACCAGCTTCT TAAGATCCCT
 72951 CCTTATGTG CATCACATAT GATAATTAA TTTTGTTTA TGAGAAATCT
 73001 TTTTGGCTTA ATTAGGAAGG AGTGATGTTG TATTAAAGTC ATTTTAAATA
 73051 TTTCACAGTA ATATTGGTC TTAGCCATGA CACACACTCA TTGGTATG
 73101 GTGTCCATCA CTTTAAAAAC TAAGTATTAT AAAAAAAATA GTCCAAAAGT
 73151 CAAATATTAA AAAAATTA TCTGCATCAT AATGTTAGA GAAAATGGA
 73201 AGGCTAACTC TAATTTACA CAGGATTTG TACATTACCT CTATTAAAGT
 73251 CAGCAGTACA AAGAGGCTC AAAACCAAGC CTTCTCCAGG ATGTGTTGG
 73301 GAAATGGCTG GAGAAAATGT AGCTGTATT TGACTCCAGT CCACCTCTT
 73351 GAGTAGACTT GGGTCAAACA TAGGAGTTTC ATCAGGTTTC ATTTTCTAG
 73401 TAAGGTCTAA AATAAAATT TGAAATTTAA GTCACTTTAT TTAATAGAAG
 73451 GAAAATTATG ATTGTTGAGA AAGTTAATAT AAATTATGCA AATTAGAAGC
 73501 ATTCTTACG ACATATGCGA GATATTTAC TGCAACCCAG CCTGAATCTA
 73551 ACATTAATT CCACAACTAC AGATAAATAG AAAAATCATG CCTACTATCA
 73601 GATAAAAAAA TGGCTAAGTG ACTAAATTAG TAAGTTTTAA ACTATAAAAT
 73651 CCCATTATT ATCAAGTCTT TTTTTTTTT TTTTTTCAG ACAGTCTCAC
 73701 TCTGTTGCC CAGCTGGAGT CGAGAGGCGT GATCCCCGCT CACTGCAACC
 73751 TCTGCCTTCT GGGTCAAAGT GATTCTCCTC TTTCAGCCTC CTGAGTATCT
 73801 GGGATTATAG GCACGTGACA CCACGCCCGG CTAATTTTTA TGATTTTA
 73851 ATAGAGACGG GATTGCGCG TGTAGGCCAG GCTGGTCTCA AACTCCCGAC
 73901 CTCAGGTGAT CTGCCGCCCT CGGCCTCCCA AAGTGTGGG ATTACAGGCG
 73951 TGAGCCACTG CGCCCGGCTA GTATCAGGTC TTTTAAACA TGTTTTCT
 74001 CTGGGTGGT GCTACTAAAT GAATAGTGA CTTTTCATGG GCTCTTAAT
 74051 TTTTACATT ATGTTCTGG ATTTTATTAT TGAGCCAAGA AGGCATCTGT
 74101 TTCAACAGGA AATTGCAAGG GGAAAAAAAT TTTTTTAAAA AAAGTAATCT
 74151 CTTAGTCTTA CTGGCAATA AAGAAAACCT TCAGCTGTGC ACGGTGGCTC
 74201 ACACCTGTAA TACCAACACT TTGGGAGGCC GAGGTGGCCA GATCACCTGA
 74251 GGTGGGGAGT TCGAGACCAG CCTGACCAAC ATGGAGAAAC CCCCACCTCT
 74301 ACTAAAAATA CAAAATTAGT CCGGGCGTGG GGGTATACCG CGTGTAAACT
 74351 TATTTCATCT ATGATGAA AAGTTAAGAA TATTCTGCC TACAGCATAC
 74401 TGTGACTTAT GAAATAAGGA ACAATTGGGG GTTGGTAT TGGGCAAATT
 74451 GGTCTCTCAT TAAAATATGG TTCTTTAAC TGGATATAGA AATAAGTGG
 74501 GGACTGCTTT TTTGGATCT CTAATCCAA AATCCAAAAC ACTCCAAAAT
 74551 TTGAAACTT TATTGAGGGG CCAACATGAT TGCCACAAGT GGAAAATCC
 74601 ACATCTGGTA TAATGGACAA AACTTTCC ATGCACAAA TTATTTAAA
 74651 ATATTGGGGT AAAATATTG GGCTATCTGG ATAAGATGTA TATGAAACAC

FIGURE 3

28/32

```

74701 AAATGGAATT TTGACTTTGG GTCCCCATCCC CAAGATATTTC TTCATTATGT
74751 ATATTGAAAA TATTCCCCAA ATCTGGAAAT ATATCCTATT TTTGAAATAC
74801 ATTATGTGTT TCCAAAACCT TGAAACATT TTTGGGCCA AACTTTGGA
74851 TAAGGAATAC TCAACTTTTA ATTTGTTGGG AAGCTTGTGTT TTTAAACAT
74901 TTTTGGGCTG GAAAAAAAGCC CCCTGGCCCC AAATTATCC CTTTGAATGA
74951 ATTGGTTTAT CC

```

FEATURES:

Start: 19364

```

Exon: 19364-19420
Intron: 19421-34110
Exon: 34111-34143
Intron: 34144-35683
Exon: 35684-35737
Intron: 35738-39940
Exon: 39941-40038
Intron: 40039-45810
Exon: 45811-45871
Intron: 45872-46578
Exon: 46579-46615
Intron: 46616-47002
Exon: 47003-47042
Intron: 47043-47133
Exon: 47134-47184
Intron: 47185-48943
Exon: 48944-49016
Intron: 49017-57568
Exon: 57569-57602
Intron: 57603-57761
Exon: 57762-59835
Stop: 59833

```

SNP's:

| Position | MMajor | MMinor | Context |
|----------|--------|--------|--|
| 3114 | G | A | <pre> AGGCTTTGTTATATGGACCACCAAGGTTGGTATTGAATTATTTCTACTCCACCAATAAG ATAAATGAATTAAAGGAATTAAAAAAAAGACAATTTTTATTTTATTTTGGAGA CACGGTCTCACTCTGTGGCAGGCTGTAGTCAGTGGCACAACTGGCTTAACTGCAAC CTCTGCCCCCTGGGCTCAAGTGTATTCTCCACCTCAGTCTCCACAGTAGCTGGACTGCA GGCGTGCATACCATGTCGTTAATTTGTATGTTAGAGAAGCAATTGGCCAT [T, A] TTGCTCAGGTATCTCAAACCTCTGACTCAAGGGATCTGCCACCTTAGCTCCAAAA TGTGGGATTAAAGCATAAAGCCTGGCTGGCCTGGGATAAGGTGGAAATTGTGGG AGTTCCAACCTCTCTCTTCAGAGTGAAGATAGAGATAGATTTATGCTACTGTT TTGAGGCATGCTAGTGCAATTGCTGCTCACAGTACATTTATCTAACAGGCCATGTGA TCTCACTGCAACAGTCTCAAATTGTTCAACAGACCCAGAGGTGCTTCATGGACTCT </pre> |
| 4004 | - | A | <pre> TCCAGCTGGCTGAGAGTGAAGCTCTCTCAAAAAAAAAAAAAAAAAAAATT TTTATATAAAGCAATGTACCTATAGCATACTGCTTGACATATGTAGCCCACAAATGAC ACAAAAACAAAAAAACTAAAAATGTTGCTGCTCTCCACTGTGTTGACATTGCTGATG GTGCAAGAGCACCAGGGAAAAATTAAATTAATCTGCACTGTAGTGTGAATCAGCATTAGT GGCATGAAACGGTGTAGTTAGTACGCCATTGCGTCTTGACTGCCACATACTTCAGTGT [-, A] AAAAAAAAAAAGTCAGTTCACTATAAAGCTTGGTGAACAGTAAAAATTATTAAT TTGTTAAATCTTCATCTTGGGTAATATTGTGTTCTCATGATAAAAGGGAAATAA ATATAAAGTACTGCTGCTATGAAATAAGATAGTGTGCTTAGGAAAGCACTGTGCG TTATTTAAGTGCAGCTGTAATTCTGTTTATGGAATACTTTTGCTGGAATGG ACCATTACAGATATGCTGTGATTATCAGACTGGTTATTGTTATTAGTTATTGATTACT </pre> |
| 4514 | T | G | <pre> TTTTATGGAAACTATTTTGCTGAAATGGACCATTTACAGATATGCTGTGATTATCAG ACTGGTTATTGGTTATTAGTTATTGATTACTCAAGACTGGTTTTGGTTATTGGCGCAC ATTTTCTCAAAAGCAACAAATTAAAGCTGTCATGTTAACAACTGACACCATCTATTG CATTGATAAAATGAAATGTCAGTGAAGTAAATTAGAATTGAAACATATATCTGGCA CTATGTTGAGCTGAAAGCTTTCTTTCTTTCTTTCTTTCTTTCTTTGATAAGG [T, G] GTTACTCTGTTACCCAGGCTGGAGTGCAGTGGCGTGATCATCCTGGCTCGCTGCAACTTC TGCCCTTGGCTCAGGTGATTCTCCACCTCAGCCTCTGAGTAGCTGGTACTACAGGT GTGTCGACCATGCCAGGCTAATTGTTGTTAGAGGGCAGGGTTTGCCATGTT GCCCAAGGCTGGCTTGAATTCTGGGCTCAAGCAACCCGCCACCTCAGCTCCAAAGT GCTGGGATTACAGGCATGAGCCACAATGTCCAGGCCACGGCAGCTTCTAATATTAATA </pre> |

FIGURE 3

29/32

| Position | MMajor | MMinor | Context |
|----------|--------|--------|--|
| 7570 | A | G | TAAATGTAAGAAGAACCTTTCCCTCTTAAATCTGAAATTGTGACTTGATGAAAGTAGA TACCAACATGAATCAGATGTTAGTTAACCAATTAAATAAAACCTTTCATGCCGGG TGTGGTGGCTCATGCGTAAATCCCAGCAGCTTGAGAGGCAAGGTGGCAGATCACCG GTCAGGAGATCGAGACCATCGGCCAACATGGTAAACCTGCTCTACTAAAGATCAA AAATTAGCTGGATGTGGTCACATGCCGTAATCCAGTACTGAGGAGGCTGAGGCAC [A, G] AGAATCGCTGAACCCAGGAGACGTAGGTTGCACTGAGGCCAGATCACACCACTGCAC CAGCCTGGCGACAGAGCAGACTCCGCTCAATAAAACCTTCACTTAACAAAATGA GAAAATTTACACCAAATCAAGCTAACTTGTCACTGAGATAATTCTGCTCTTAATTTC ATCTTAATGTTAACGCCACAGACTGTTATGTTCTTAAATGATGGTGTAGAG GAAAAGAGTAATGCAATAATTCCAAACTACTATCTAGGTGGTCGCGTTCTG 11672 C G CTGGAGGAAGGCAAGAGTCTGATGCTGAGGTTCTAGATAGTCAGGAA CTTGTGGAAAGTGTCTTTCTGAATGCTTCCTTCTCAGTGAAGTAGAATGCACTG AGAATGAAGATAGGGAAAGTCTTCTAGAGATTGAGGAAAGGAGAAAGGTATAAGTC TTATCTATGGAAGTGAGGGATTGGACTAGGGTCAGGCCAGTAAACATGGCTGTGAA CAAATCTGCTGCCCTGTGTTTCAAAACACACAAAGTTGTTGTAACCCAAGCATG [C, G] TCATTTATCTGTTCTATGGCTGCTTCTACTGGAATAGCTGAGTTGAATAGTTACAA CAGAAACCATATGGCTGCAAGCATACAGTATTACTCTGCCCCTTACATAAAAG TTTGTGACCTCCAGACTAGGGAAATCTAGTATAATTCCAGGCAGCCTAAAAACTCTT TAGAAGTTAAATGGTCCAGAAATGACAATAAGCTGTTGAAATTTCACATCTTCA GCCCTGTTAGAGAGTTTGTGAGCTGGAAAGCCAGTAACGAAACAAAGGATGTCA 11897 A C ACATGCCCTGAAACAAATTCTGCCCTGCCCTGTGTTTGGAAACACACAAAGTTGT TGTAAACCAAGCATGCTCATTTCTGTTCTATGGCTGCTTCTACTGGAATAGCTG AGTTGAATACTTAAACAGAAACCATATGCTTGCACAGCATACTGATTACTCTG CCCTTACATAAAAGTTGCTGACCTCCAGACTAGGGAAATCTAGTATAATTCCAGGC AGCCTAAAACCTTAAAGTAACTGCTGAGGAAATAGCTGATTGTTGAAATTTCACATCTTCA TTTCACTATCTCATTGCCCTGTAGAGAGTTTGAGCTGGAAAGACCGAACTGAACAA AGGAATGCAATGTTAGGTTCTCCACAAATAGCTGCTTAGATGCCAGAATCT GTGCTAGCCCTGGAAATCTCTGCTCAGGAGCTTACAATGAACTTAAACCTGATTAAA GACAATTCAAGAATATATGTTGATTTCAAAATAGAGAACGACATGCCCTATAATGCTG CCAAACGGTGCATCATCAAAGTATTCAAAACTGTTAGCTGCTGCTCTACTCTC 14523 T C GATTTAAATGTTAGTTCTTTAACTAGGGGACATTCAACATCTGGAAACATACTGAA ATTTTATCTCTTTAGTGAAGGTTTTGTTAACTGTTGAACTTTCGTAAGTTAAAT ACACTTGATTCACACTAGGCTCCCTGCTCAGGCTCTGACATTATCTCTTTGGAT TATAATACATCTTATTTTCTTTGAGACGGAGTCTCACTCTGCCCTGGCTG GAGTGCAGTGGCATGACTCTGCTCCCTGAGCCAGCTGATCATTCCTTATCT [T, C] CCAGTAGCTGGACTATAGGCTGCCAACACCCAGCTAATTGTTGATTTTGTA GAGACGGGTTTCACCATGTTGTCAGGCCTGGCTCAAATCCGGCCGGAGTAATCCAC CCACCTGGGCTCCAAAATGCTGGGATTACAGGCACAAGCTACCAGGCCGGCAGGCA TCTCTGTCAGATTACTTACTAAAGTGAATTGAAATAGCCATGTTGCAAGG TTACAAAAAAATACCTACCTAGTTCACTGTTGACTTCTAAACAAGTTGAAACTTGT 16586 C T AGCTTCACATTATTCATGAAATTATGTTCTTATATGAAACATATAATTCTATA TGTGATATATAGCACTGTTTATCTCTACAGGTATGTCGAATTGCTGCTGA TCATGATTTGTTGAGTACAGGAAGACTTCATGAAAGCAGTCAGAAAAGTGGCTGATTCTAA GAAGCTGGACTCTAAATTGGACTACAAACCTGTTGAAATTACTGTAAGATTGTTGATG TGCATGACAGATGTTGGCTTATGTAAAGTAAAGAAAATATGATGTTGATG [C, T] AATGATGTCATTAAGTATATGAAATAAAATGAGTAACATCATAAAAATTAGTAATT CAACTTTAAAGTACAGAAGAAATTGTTGTTGTTAAAGTGTGCAATTATGCAAG TTACAAAGGGAAAGTGTGAGCTTTCATATTGCTGCGTGAAGCATTGTAAGAAAATATT GAAACTGGTTGAGATAGTGGTATAAGAAGCATTCTTATGACTTATTGTTGATCATT GTTTCTCATCTAAAGTGTAAATAATGAGTAACATCATATAATTAGTA 16644 T C TATGTTGATATAGCAGTCATGTTGTTTATCTCTACAGGTATGTCGAATTGCTGCT GATCATGATTTGTTGAGTACAGGAAGACTTCATGAAAGCAGTCAGAAAAGTGGCTGATTCT AAGAAGCTGGAGTCTAAATTGGACTACAAACCTGTTGAAATTACTGTAAGATTGTTGATG GCTGCTGAGATGTTGGCTTATGTAAAGTAAAGTAAAGAAAATATGATGTT GGCAATGATGTCATTAAGTATATGAAATAAAATATGAGTAACATCATAAAAATTAGTA [T, C, A] TTCACACTTTAAAGTACAGAAGAAATTGTTGTTGAAAGTGTGCAATTGTCAGCA AGTTACAAAGGGAAAGTGTGAGCTTTCATATTGCTGCGTGAAGCATTGTTGAAATA TTGAAAGTGGTTGAGATAGTGGTATAAGAAGCATTCTTATGACTTATTGTTGATCAT TTGTTTCTCATCTAAAGTGTAAATAATGTTGTTGATTCAGTCTCCTACATATAT ATTCTGTCCTTCTGAGTATTTACTGTTGCTTGTAGGTTCTTAGCAAGTAAACTA |

FIGURE 3

30/32

| Position | MMajor | MMinor | Context |
|----------|--------|--------|--|
| 17969 | A | G | AATAGAAAATGGAGTGGTCAAGTTAGCCATCTCATCTCAAATTATTGTACAGTTCTAT TTCTATGTGTTGGCACTGCATTATGTGACAAAAGTAGAATGTAGGGGGAGGTTAAG TCAAATATCTATGTGATCTTCACTTATAATTGCATTAGTTAGTAAGGAGTGACTATCTT GCCTTTACCTTGTGCTGGGGTGTGTTAAAGAATCAATTGGTGTACAATCCTT TCTTCTTTTATTTGATTTTTGTGAGATGGAGTTCGCTTGTGCCCCAGGCT [A, G] TAGTGCCATTGCACTATCTAGCTATTGCAACCTCCGCCCTCCGGATTTAAGCGGGTTCT CCTGCCTCAGCCTCTAAGTAGCTGCGATTACTGGCATGCCACACCCAGCTAATT TTTGATTTTAGTAGAGACGGGGTTTCCATGTTGGTCAAGGCTGGTCTCAAACCTCCC ACCTCAGGTGATCCACACGCCCTCAGCCGCCAAAGTGCTGGGATTACAGCGTGGACCTC CGCGCCGCCAAATCTTTACCATGGGTTACAGGCATAACGCCACACCCAGGG |
| 18117 | C | T | TAATTGCAATTAGTTAGAGGAGTGACTATCTTGCCCTTACCTTGTGCTGGGGTGGTT TTTAAAGAATCAATTGGTACAATCCTTCTTCTTATTTTTGTGATTTTT TGAGATGGAGTTGCTCTTGTGCTCCAGGCTATAGTGCCATTGCACTATCTCAGCTCAT TGCAACCTCCGCCCTCCGGATTTAAGCGGGTCTCCTGCCCTCAGCTTCAAGTAGCTGG ATTACTGGCATGCGCACCACACCCAGTAATTGGTATTAGTAGAGACGGGGTT [C, T] TCCAATTGGTCAGGCTGGTCTAAACTCCCGACCTCAGGTGATCCACACGCCCTCAGCGG CCCAAAGTGCTGGGATTACAGCGTGGACCTCCGCCGCCAAATCTTTCACCATG GGTGTTACAGGCATAACGCCACCACCCAGGGATTAAATTGTTTTAGAGAGGGG GGTCTTACTATTGCTGCTGGCATAACTCTTTAAAGATATTGAAAGGCATCTGG TTTATTATTATTATCAAATAATAAATGGAGAAATTACAGTATTATATAACATT |
| 18518 | C | A | GCCAAATCTTACCATGGGTTACAGGCATAACGCCACCACCCAGGGAAATTAA AATTGTTTTAGAGAGGGGGTCTACTATTTGCTCAGGCTGGCAAACCTCTTTAA AGATATTGAAAGGCATCTGGTTTATTATTCAAAATAATAATGGAAGAAATT TTACAGTATTATATAACATTACTGAGTCAGCTATCAGTTCTTTCTGATTTTTCT AGTTGCCATTCTGATATTCTAGTAATCAAACGTAGGTGATTTCAGACTCTT [C, A] AAATACTTAAAAAATTAAATTGAGCGGTTAATTCTTGCTTAAAGGTGATGGGTAT TTATTTCTGATGGCACCTGGTATTAAATTGAACTCTCATTTATTAGTCATTTG GTTATAAACTCAGCATAGATTGCCAGAATTGAGGGGAGAAACTATAGCTTCCCT TCAGGATGCCACTGGGGTAGCCTGTTGCCCTGTTCTTATGTTAAAGAAGGGCTC TACGTCTGCTGGAAAGGGCGGAGCTGGCTCGGACGCCAACAGCTGCTTCCAGGACC |
| 19882 | G | A | TGAGTTGCTGCTCTCTCAGACCCCGCGGAGGGGACGGCTCTGGTGTACTTACATTGA GAAGAGGAAAGCAATCCCTAAGCTCCCTAGGCTGGCATCAGGACTGACCTGGAGTAAG GTTCCCTTTTATTGTCAGGAAACAGATTCAGGAGAGCTGGTTAGTCCTCTTGGAGGA ATATCTGTGGTGTAAACGATTCACTTGTCGGACACATGCCAACATGAAATAGACTC GGCGCTGAAGTTGGAGCGCGCCCTCGAAAGTTCCCAAAGTTTTGTTGTTT [G, A] GACAAGCTATGACCCGACAACAAAGTCTCRAAGCTAGCTCATCTTAACTGAGAAC TCTTAATCAGAAATCTTGACCTTGGAGAAAATTAAATTGAAAGTAAACATATAA CCTTTCTCTGGTTCTAATTGTCGCTTACTCCACCTTACATCCCTGCCGCT GTTTCTACTCTGGATTTCATCTGTTGCTAGTTAACATTACGGCATTGCAAGACT ACTAAATTAGAAATTCTGGAGGCTAAATAACAAGCAGAAGATACTCAGCTATACTTTA |
| 20988 | G | - | TAAGAGTAGAGACTTTGTTGTACTATCAGTGTGCAAATGAGTCAGTGGTGTGAT CTGGTTCACTGCACTGCAACTCCCATGCTCAAGCCATCTTCACTTCACTCAGCTCTGG AGTAGCTGGGACCATGCCGGCTAATTCTTCTTCTTCTTGTAGCGATGGGTTT TTCTCCAGGCTGGTCTGCAACTCTTGCCCTCAAGATCTCCCGCTCTCCGAAAGT GTGGGATTACAGGTGAGGCCACTGCACCTGCCAACAGAATATACTCATGGTTTTTTG [G, -, T] TTTTTTTTTTGTGACACAGAGTTCACTTGTGCCCCAGGCTGGAGTGCAGTGGCGCTGTCTCAGC GCTCTCTCAGGCCACCGCAGGCTCTGCCCTGGCTCCGGTCTCAACACAGTTCTCTGCCCTA AGCCTCCTGAGTAGCTGGGATTACAGGGCGCAGGCCAGGGCTGTTTTTTTTTTT TTTTTTTGAGACAGAGTCTCACTCTGTCGCCAGGCTGGAAATGATCTGCACTGGTGC ATCTGGGCTCACTGCAAGCTGCTGCCCTGGCAAGCTCAGCTCCGCCAGCTCC |
| 20999 | - | T | ACTTTGTTGTGACTATCAGTGTGCAAATGAGTCAGTGGTGTGATCTGGTTCACT GCAGCTCTGCAACTCCCATGCTCAAGCCATCTTCACTTCACTCAGCTCTGGAGTAGCTGGGA CCATGCCGGCTCTGCCCTGCCCTGGCTCAACACAGTTCTCTGCCCTAAGCCTCCTGAG GGCTCTGCACTCTGGCCCTCAAGATCTCCCGCTTGTCTCCGAAAGTGTGGGATTAC AGGTGTGAGGCCACTGCACCTGCCAACAGAATATACTCATGGTTTTTTGTTTTTTT [-, T] TTTTGACACAGAGTTCACTTGTGCCCCAGGCTGGAGTGCAGTGGCGCTGTCTCAGC CCACCGCAGCTCTGCCCTGCCCTGGCTCAACACAGTTCTCTGCCCTAAGCCTCCTGAG TAGCTGGGATTACAGGGCGCAGGCCAGGGCTGTTTTTTTTTTGAG ACAGAGTCTCACTCTGTCGCCAGGCTGGAAATGATCTGCACTGGTGCAGTGGCTCA CTGCAAGCTCTGCCCTGCCCTGGTACGCCATTCTCCGCCCTAGCCTCCGAGTAGCTGG |

FIGURE 3

31/32

| Position | MMajor | MMinor | Context |
|----------|--------|--------|---|
| 21465 | A | G | TTTTTTTTTGAGACAGAGTCTCACTCTGCGCCAGGCTGGAATGATCTGCAGTGG TCCGATCTGGCTCACTGCAAGCTGCGCTCCCGCTGTCACGCCATTCTCCGGCTCAGC CTCCGAGTAGCTGGACTGCAGGCACCCGCTACCAACACGGCTAATTTTTGATTT TTAGTAGAGACGGGGTTCACCATATTGGCAGATGGCTCAAACCTCTGACCTTG TCCGCTGGCTGGCTCCAAAGTCAGGAGTACAGGGCTGAGCTACCGCGCCGGCC [A, G] ATATACTCTAGAAAACAGGAGGTCAATTAGGCTAGTTATAAAAATGAATTATACTT AACATACAAATATGTAAGAGATATGCTTTATTATTTATTTGAGACG GAGTTCTACCTTGTGCCCAGGCTGGAATGCAGTGGCGATCTCGCTACTGCAAC TCCGCTCCACGTCAAAGATTCTCTGCCAGCCCTGAGTAGCTGGATTACAG GGCAGCCGCCACCACTCCGCTAATTTTGACTTTAGAGACGGGGTTTACCATG |
| 21625 | C | T | GGGCTAATTGGTATTAGTAGAGACGGGGTTTACCATATTGGCAGGATGGTC TCAACTCTGACCTTGATCCGGCTGGCTTGGCTCCTCCAAAGTCAGGAGATTACAGGC GTGAGCTACCGCGCCGGCAATATACTCTAGAAAACAGGAGGTCAATTAGGCTAGT TATAAAAATGAATTTATCTAACATACAATAATGTAATGAGAGTATGCTTTATTTA TTTATTATTAGGTTGAGACGGAGTTTACAGGGCTGAGGCTGGCAATGAGTGGCG [C, T] GATCTCGCTACTGCAACCTCCGCCCTCCACGTTCAAAGATTCTCTGCCAGCCGC CTGAGTAGCTGGGATTACAGGGCCGCCACACTCCGCTTAATTGGTACTTTAGT AGAGACGGGGTTTACCATGTTGGCCCTGCTGGCTGGAACCCAGACCTAAGTGATCC GCCCTGCCCTGGCTCCAAAGTGCTGGGATTACAGGGCTGAGGCAACCGCGAAGGGATATG CTTCAATCTCAAAATGTTAGCTAGTAATTCTGACTTAATGCAAGCAACCTTACAAA |
| 26291 | C | T | ATTTAGTATTGTATAGGATCAGCACTATCTCAATGATGAAACATATCCCTG TGGATAAGGGGGACTACTGTATTGAAAATTCTAATTTCATATTCAATGCAATAA GAATTATTATCTAATGTTACAGCTATCTCATTGATGTTTATTGAGGGTC TTGAACATTGTAACCTTCTCTATCCAAATGCACTTTATAGATCATTTATGGA AAGGAAGGAGATAATTGCGAAGGATGTTAACATGTTACTTCTACCTCATGTTGAT [C, T] GAAAGATTTCACTTGTGAATTAAATTGCTCAGAATCATGGTGGTCAAAATAGAGGGT TATTGGTTTATCTGGTGGCTTGGTTAATTGTTGAGCTGCTGGCTACTC ATAAGTTGGAAATTGATTCTACTAATTAACTAACATGAACTTAAATAGATCAT TGCTGGTATATGGAGATGCCCTTAATACCACGGTTCAAATGATGAGATTTCAGG AGTAGTGTGAGCGAGGATAAAGGATTAAGTGTGATAGTGGCAAGACTGGTTATTA |
| 28012 | T | C | AGTCAGCACACCCAGAACACTGACACAAGTATCATCTATTATTCAGGGCC CATTTATCTCTCCAGAATTGCTCTAAATTGCGTATAACCTCTACCCCATGCTA TATAAAGGGTATATAAACTCTAAATATCACTTTTTTTTGATACAGTTCTTT CCTGTGATACCCCATGCACATAATGAATCTGATACCTTTCTCCGTTAGTTTATTC ATAGACTGGTTGAAATATCACGGATTGTTGTTGGTATACACTTTTAAATAA [T, C] CACTTTTTTTGGTATACACTTTCTCTGTGATACTCCCATACACATAATAAA TTGATACATTTCTCCATTAGTTTATCTAGACTGTTATGCAATCTGATGGTAG AGGGAAACTCTCCCTGGCTTACACAAGTATTCCAGAAATATTTACACCATTCTTG ATATGTTGGCCCTGTTTTCTTAATTACACAAAATTAGTGTGATTTCACTTAGA TAAATTCAAAGTACGATTCTTTAATTGTTCTTCTTACAGCTGACAAGTGGCTCAGGAAGATAAGG |
| 28030 | T | G | ACAAACTGACACAAAGTATCATCTATTATTCAGGGCCATTATCTCTCCAGA ATTGTTCTCTAAATTGCGTGTACCTCTACCCCATGCTATATAAGGGTATATAAAC TCTCTAAATATCCTTTTTTTCTATACACGTTCTCTGATACCCCATGC ACATAATGAATCTGATACCTTTCTCGTTAGTTTATTCATAGACTGGTTGAAATA TCACGGATTGTTGTTGGTATACACTTTAAATATCCTTTTTGG [T, G] ATACACTTTCTCTCTGTGATACCCATACACATAATAAAATTGATACACTTTCTCC ATTAGTAGTTTATCTAGACTGTTATGCAATCTGATGGTAGAGGGAAAGTCTCCCTG CTTACACAAGTATTCCAGAAATATTTACACCCTCTGATATGTTGCCCTGTT TTTTCTTAATTACACAAAATTAGTGTGATTTCACCTTACAGATAATTCAAAGTACGCA TTCTTTAATTGTTCTTATCACAGCTGACAAGTGGCTCAGGAAGATAAGG |
| 33671 | A | C | CAGAGCTGGCTTTAGTCATTCGATTCTCATTCATTCACTACTATTTTTCT AAGTTAAAATTTTACCTTCTTACCATTTGTTGTTGTTTACAGCTTCTT TATATTGGCTGCTTCAACAGACAAATGAAGTCTCTTATGTTGTTGATGTTAA AATAATTGAACATAGACAAGAATGTTAGGCCAGTGGAGATAAGGGAAAGCTTCTT AGCATTGGCATTAGTACAGAGATGCCAGTACGATGACATAGCATTCTTTTAT [A, C] CATTTCAGATATTATGTTGATCAGACACTCTCTCTGCTTGGACCAACAGTGGT TTAGGATCTGCTGCTAGTGTGATCAGAGTGGCATGAGAACAAAAAAATCTATTGGCA TCTCTGACTTAAAGGATCAGTTGGGAGAATCTCTGGAAATCTATTCTATTCTTAAG TTAATGAGTAATTCTACCTTATGAAAGTACATAACAAATTCTGGAACCTAGTTAT TTAAGAATGCTTAAGCTTGTGACTTCAGATGTTGTGAAACCA |

FIGURE 3

32/32

| | | | |
|-------|---|---|---|
| 37703 | A | G | CCATTATCTAAAAACAACACAAAAATAATAATGGAGATAAACCTAAATGGATAAACTC CTTTTAACACTCATTACTGTTATTATTTGTGGGAGAGGAGTGGGGCTTGCTCTGT TACCCAGGCTGGACTACAGTGGCCGCTTCATAGCTACGTAAACCTCAAACCTCTGG CTCAAGCTGCTCCCACCTTAGTCTCCRAGTAGCCAGGACTACGGGACACACACCCA TGCTGGCTTAATTCTCAAAGTTTTGAGATGGAGTCTGGCTATGCTGGCACATT [A, G] CTTAAGTATACTTTTATAATTCAAAATACAGTTAAATAAAGGGACAAATTAGGG CCTTGTAAATTAGTAAACGGTTTGTAAAGTTTCTACTGTTTAAATGTGAG GTAAGTCATAATTGCTTCATATTAGTTGGTCAAAGTAATTGAGATCTGCCTCTG AAAAGTACAAAATCTATTGGCTGTACGTTAGGGCTTATTTGATAGTTATTATT TAGTAGTACTCTATTGGGCTTCAAAATGTTAACATATTACATAATTATGTGC |
| 39269 | C | G | AACCTATTATCTGGTAATTCTAGAATTGTCATGTTAAATTGCTTAAGTATGGAGCCAA AAGCACTACAGGTTGAGTATCCCTAAATCTGAAAAATCTGAAACTGCTCCAAAGTGAAACCT TTTGAGTGTAGCATGACAGCACAAAGTGAATTCCACACCTGACCCCATGTAATGGGTAC TGTCAAATTTGTTCATGCACCAAATGACTGTATGAAATTACGTTAGAGTATATAG GTGTGTGAAACATAATGAATTGTTAAACTGGATACCATCCCCAAGACATCT [C, G] AGTATGTATACTGCAAATATTCAAATCTGAAATCTGAAACACTCTGGCCTACCTGG GACCAGCATTTAGATAAGGGACTCAACCTGTATTGAAATAAAAGATGTCATTGAA GTTGCCATTAACTTCAGGAAAATTCAAATGGTAAAGGTTAATTAGTTGTGAA AGTATGTAAATTAACTGACTCTTAAAGTATACTGGAGAGGCAAGGAGTTGTCTAGAG ATTGGGTTCCAGTACTGCTGTTAACTAGGTGGTGTCAAGTATTGTAATGTAA |

| POSITION | Allele 1 | Allele 2 | |
|----------|----------|----------|-----------------|
| 3114 | G | A | Beyond ORF (5') |
| 4004 | - | A | Beyond ORF (5') |
| 4514 | T | G | Beyond ORF (5') |
| 7570 | A | G | Beyond ORF (5') |
| 11672 | C | G | Beyond ORF (5') |
| 11897 | A | C | Beyond ORF (5') |
| 14523 | T | C | Beyond ORF (5') |
| 16586 | C | T | Beyond ORF (5') |
| 16644 | T | C | Beyond ORF (5') |
| 17969 | A | G | Beyond ORF (5') |
| 18117 | C | T | Beyond ORF (5') |
| 18518 | C | A | Beyond ORF (5') |
| 19882 | G | A | Intron |
| 20988 | G | - | Intron |
| 20999 | - | T | Intron |
| 21465 | A | G | Intron |
| 21625 | C | T | Intron |
| 26291 | C | T | Intron |
| 28012 | T | C | Intron |
| 28030 | T | G | Intron |
| 33671 | A | C | Intron |
| 37703 | A | G | Intron |
| 39269 | C | G | Intron |

Map:

Bac accession number: AL139317.2

Human chromosome 14

FIGURE 3

SEQUENCE LISTING

<110> Wei, Ming-Hui
Sanders, Robert D.
Gilbert, Dennis A.
Beasley, Ellen
Bonazzi, Vivien R.

<120> ISOLATED HUMAN PHOSPHATASE PROTEINS,
NUCLEIC ACID MOLECULES ENCODING HUMAN PHOSPHATASE PROTEINS,
AND USES THEREOF

<130> CL000871PCT

<140> US 09/685,853
<141> 2000-10-11

<150> 60/182,194
<151> 2000-02-14

<160> 3

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 1218
<212> DNA
<213> HUMAN

<400> 1
aacaccacgc gtccggcage ggcatggcgg ccgggtgtaa gacgcccggac cctccttc 60
cctgtctcg cggccggcgc tgctggagtc actgggaccc tggatgtctgc gtgtgttagt 120
tgttaatcccg cggccctctgtc tcagccctc cgccggccgg gcccttccttc ctteccggc 180
cgccggcaggc cccggggctcg gccggctgtg taacacttc ccaccccccacc caccagccgg 240
cgccggcaggc ccatggagga cgtgaagtg gagttccctt cccttccaca gtgcaaggaa 300
gacggcgagg agtggacacta ccctatgaga cgagagatgc agggaaattttt acctggattt 360
ttcttaggcc catattcatc tgctatgaaa agcaagctac ctgtactaca gaaacatgaa 420
ataacccata taatatgcat acgacaaaat attgaagcaa actttattaa accaaactttt 480
cagcaggat tttagatattt agtcctggat attgcagata atccagttga aaatataata 540
cggtttttcc ctatgactaa ggaattttt gatgggagct tacaatggg aggaaaagttt 600
cttgcgtatg gaaatgcagg gatctccaga agtgcagcct ttgttattgc atacattatg 660
gaaacatttg gaatgaagta cagagatgt tttgtttatg ttcaagaaag aagattttgt 720
attaatccca atgctggatt tgcgtatcaa cttaggaat atgaagccat ctacctagca 780
aaatataacaa tacagatgtat gtcaccactc cagatagaaaa ggtcatttgc tggttatttc 840
ggtaccacag gcagttgaa gagaacacat gaagaagagg atgattttgg aaccatgca 900
gtggcactg cacagaatgg ctgacttggaa gagcaacatc atagagtgtt aatttttattt 960
tggaaaggag aaaatatacaag agaaaattat aatgtaaaat ggtaaaaaca taatgtttt 1020
ttttttcaat tacatgttgc ttccagacat acttctctgc aacttggatgaa gcaacattttt 1080
aagatgttgg acttctgcaat tagatgacac tggatgtttt actcctttttt tttaaaaaca 1140
catgcgcgcg cacacacacaca tgctttacaa- gtttattat aaaccaagaa ttttggactt 1200
gcaaaaaaaaaaaaaaaa 1218

<210> 2
<211> 223
<212> PRT
<213> HUMAN

<400> 2

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Glu | Asp | Val | Lys | Leu | Glu | Phe | Pro | Ser | Leu | Pro | Gln | Cys | Lys | Glu |
| 1 | | | | 5 | | | | | 10 | | | | | 15 | |
| Asp | Ala | Glu | Glu | Trp | Thr | Tyr | Pro | Met | Arg | Arg | Glu | Met | Gln | Glu | Ile |
| | | | | 20 | | | | 25 | | | | | | 30 | |
| Leu | Pro | Gly | Leu | Phe | Leu | Gly | Pro | Tyr | Ser | Ser | Ala | Met | Lys | Ser | Lys |
| | | | | 35 | | | | 40 | | | | | | 45 | |
| Ile | Pro | Val | Leu | Gln | Lys | His | Gly | Ile | Thr | His | Ile | Ile | Cys | Ile | Arg |
| | | | | 50 | | | | 55 | | | | | | 60 | |
| Gln | Asn | Ile | Glu | Ala | Asn | Phe | Ile | Lys | Pro | Asn | Phe | Gln | Gln | Leu | Phe |
| | | | | 65 | | | 70 | | | 75 | | | | 80 | |
| Arg | Tyr | Leu | Val | Leu | Asp | Ile | Ala | Asp | Asn | Pro | Val | Glu | Asn | Ile | Ile |
| | | | | 85 | | | | 90 | | | | | | 95 | |
| Arg | Phe | Phe | Pro | Met | Thr | Lys | Glu | Phe | Ile | Asp | Gly | Ser | Leu | Gln | Met |
| | | | | 100 | | | | 105 | | | | | | 110 | |
| Gly | Gly | Lys | Val | Leu | Val | His | Gly | Asn | Ala | Gly | Ile | Ser | Arg | Ser | Ala |
| | | | | 115 | | | | 120 | | | | | | 125 | |
| Ala | Phe | Val | Ile | Ala | Tyr | Ile | Met | Glu | Thr | Phe | Gly | Met | Lys | Tyr | Arg |
| | | | | 130 | | | | 135 | | | | | | 140 | |
| Asp | Ala | Phe | Ala | Tyr | Val | Gln | Glu | Arg | Arg | Phe | Cys | Ile | Asn | Pro | Asn |
| | | | | 145 | | | | 150 | | | 155 | | | 160 | |
| Ala | Gly | Phe | Val | His | Gln | Leu | Gln | Glu | Tyr | Glu | Ala | Ile | Tyr | Leu | Ala |
| | | | | 165 | | | | 170 | | | | | | 175 | |
| Lys | Leu | Thr | Ile | Gln | Met | Met | Ser | Pro | Leu | Gln | Ile | Glu | Arg | Ser | Leu |
| | | | | 180 | | | | 185 | | | | | | 190 | |
| Ser | Val | His | Ser | Gly | Thr | Thr | Gly | Ser | Leu | Lys | Arg | Thr | His | Glu | Glu |
| | | | | 195 | | | | 200 | | | | | | 205 | |
| Glu | Asp | Asp | Phe | Gly | Thr | Met | Gln | Val | Ala | Thr | Ala | Gln | Asn | Gly | |
| | | | | 210 | | | | 215 | | | | | | 220 | |

<210> 3

<211> 74962

<212> DNA

<213> HUMAN

<220>

<221> misc_feature

<222> (1)...(74962)

<223> n = A,T,C or G

<400> 3

| | | | | | | |
|--------------|--------------|--------------|-------------|-------------|-------------|------|
| ttgaaatcca | aaaatatatctg | aagctacatt | tggaccctgt | taaataatgt | aatgtataag | 60 |
| gattttcca | aaataaagtct | taatttcagt | tttcatatat | caacaaaaag | gtactattag | 120 |
| gagtacatag | ttgccacact | tgagacatat | tccaaatgc | tacacctaac | ggtactacta | 180 |
| ttacagaaca | gcacattcta | atccacatat | acacgagttt | taataaaattt | tagcaactatg | 240 |
| tctataatca | gaatgaatac | ctggaataca | tgtttctagc | aggaatattt | gttagcagct | 300 |
| ttaaggtact | tgaaatcacc | ataatcattt | ctatttttaa | tttaaattttc | actactgggg | 360 |
| taaatttccat | gagggaaagg | tgtggctatg | aatttttattt | tatttttttt | cttttggt | 420 |
| aaatatggag | aacttaccaa | atcttctata | tagcctggct | gtagatggca | atgcgaggaa | 480 |
| agaaaaagga | agcagaaaaga | aaaaaaaagg | caatcaaaa | aaatggcaac | gaagcaaaga | 540 |
| aaaagttgcg | gtcacctgc | aaccaaaaattt | ccagccaaaa | gtcatgcaaa | aaactacttt | 600 |
| aggtagaaaac | caagcaaaatgt | aaatgcaga | atggaaaaatg | aaaatgagga | agcagcaattt | 660 |
| actttccatt | tagaacactg | agaaaacactc | cacatttattt | tagaatgtt | aatgttgcta | 720 |
| aagaacctaa | gggttagaaat | ttgttagggag | aaagataaaaa | gagcaaatat | ttctttcccc | 780 |
| ctacatcg | tacccagtt | catcgatgt | ccagttctca | ccggtaagg | taaagccat | 840 |
| tattttagta | gaaaataaaa | agtatccaaa | agcctttaaa | gtcttctcag | atttagtcag | 900 |
| ataatatgtat | ccatgcactg | cttttcagaa | ataagaattt | gaaggcataa | aataagtgc | 960 |
| gtgcccacatct | gtttctttttt | ttacacaaga | aaagcaaacc | cctcagttac | catgtttttt | 1020 |
| ttgcacatc | tttcctggaa | gggaaaacaaa | agagatgcgc | tatactacat | gaggaatttc | 1080 |
| ggctttatgg | cattagtc | ttccatttag | attaacataa | atcaacataat | agaataattc | 1140 |

ttcaaaaattt aaaaatccag tttgagagtc atatttattt aaaaataccc acagcatgtt 1200
 tagttaatat atatataatt gaagggaaatt aaagtaggtt aaataacaaca gtttattttg 1260
 atagacccaa aagaaaacta cgagtctatg cccaggtagg gaagaatgtc cttgtggct 1320
 gcacatcttc ctacagcctc cagaacgcaa ctggatacag cttataattt actgagact 1380
 atgtccagtg tgactagtgt ggtatctgac acacagtagc aactaaactt ctgaatgtca 1440
 ctacttacta ggcaccaggg caataacatc atggcgta ttctctggaa acaattttt 1500
 tttctgacac ggagttcac tcttggcc caggtggag tgcaatggcg ccatcttggc 1560
 tcactgcaac ctccacctcc caggtacagg tgattctct gcctcagcc cccaaagtgc 1620
 tggcattata ggcgtgcacc accatgcctg gctaattttt gtatgttt tagagatggg 1680
 gtttacccat gtggccagg ctggctcga actcctgacc tcaggtgtt cactcaccc 1740
 ggcctcccta agtgctggg ttacaggtt gaggcaccgc acctagccca acacaactat 1800
 tcaatagaaa ttctctctc ggtcaggcat ggtggctcac gcctgtatc ccagactct 1860
 gggaggctga ggtgggtgga tcatctgagg tcaggagttc aagaccagcc tgccaatata 1920
 gtgaaacccc atcttctca aaagtacaaa aattagccag gtgtgggtt ggcgcctgta 1980
 gtcccagcta ctcaggaggg tgagacagga gaatcttgc taccggggag gcagagggtt 2040
 caatgagcca agatcatgcc attgcactcc agcctggca acagactctg tctcaaaaa 2100
 aaagaaaattt ctctttaag ttactggta tataagtaat ttaaatttggc ctttcagatc 2160
 ttcaatttct ctatctcata cttttctcc ttgaatcagt cttgagagca gaacatactg 2220
 ttctttaaaa gtcggcgtgg caaaatgcca acagataaaa attgtatata cttttctct 2280
 tggatgttg tcaaattccat cccccatttt agaattttt tggatgtt tttcaatgc 2340
 aaactagtat agatctttt agttgtt tttgttata tggttattt acttaactga 2400
 ttttttgg tataattttt tcatttggat ataatttacat taaaaaaatg tagattctt 2460
 agtgtacatt tcaaattatgt ttggacaagt tataatctg tggatgttcc accccaatca 2520
 agtgtgttgtt ttatttaaaa aacattttt gaaattttt agatgtt gatcttaat 2580
 ctacctggag caaaacctct taatataat ggttttaccc agcatggaa tcttaggtct 2640
 ttaagaatata tgatgtgtac acctaactaa ggtgatattt gacttagagt atttgaatgt 2700
 acattaaaaa tcttgactaa ctttttaaga aagatttaac ttctttctc ggtgatagaa 2760
 ttaccttta caaaccggca gtttatttccat ctttttttttccat ctttttttttccat 2820
 ttgttatatg gaccaccagg ttggatgtt attatttctt cttccacccat aagataatg 2880
 aattaaggaa tttttttttttaaa aagacattttt tttttttttt tttttttttt tttttttttt 2940
 tcactctgtt gcccaggctg tagtgcagtg gcacaatctg ggctaaactgc aacccctg 3000
 ttccgggctc aatgtatttccat ctttttttttccat ctttttttttccat 3060
 atcaccatgt ctggatattt tttgtatgtt ttgtatgtt gatgttccat ctttttttttccat 3120
 aggctatctc aaactcctgg actcaagcga tctggccacc tttagcccttccat 3180
 gattacaagc ataaaccact ggcctgccc ataaatgtt gatgttccat 3240
 aacttctctt ctcttccat gatgttccat ttttttttttccat 3300
 gcatgttag tgcattttgtt ctttttttttccat ctttttttttccat 3360
 tgcaacagtc ctcaatttttccat gatgttccat ttttttttttccat 3420
 tcaaaaactac ttataatccat gatgttccat ttttttttttccat 3480
 ccagacttc gggaggccga ggcaggcaga tcaccagagg ttttttttttccat 3540
 tggccaaacca acatgttccat gatgttccat ttttttttttccat 3600
 gtggcgtgca cttgtatccat gatgttccat ttttttttttccat 3660
 tggggggcag aggttgcagt gatgttccat ttttttttttccat 3720
 agtgagactc ctcttccat ttttttttttccat 3780
 gtacccatgtt gatgttccat ttttttttttccat 3840
 aatgttccat gatgttccat ttttttttttccat 3900
 gtaaaaattaa atacttgcat gatgttccat ttttttttttccat 3960
 gtttagtagcc attgccat gatgttccat ttttttttttccat 4020
 agtttccat taaagtcctt gatgttccat ttttttttttccat 4080
 ctttggtaa ttttttttttccat gatgttccat ttttttttttccat 4140
 catatttgcat ttttttttttccat gatgttccat ttttttttttccat 4200
 ctgaatttgcat ttttttttttccat gatgttccat ttttttttttccat 4260
 ctgtgatttgcat ttttttttttccat gatgttccat ttttttttttccat 4320
 ttatggcgccat ttttttttttccat gatgttccat ttttttttttccat 4380
 caccatctat ttttttttttccat gatgttccat ttttttttttccat 4440
 catatatctg gatgttccat ttttttttttccat gatgttccat ttttttttttccat 4500
 ttttttttttccat gatgttccat ttttttttttccat gatgttccat ttttttttttccat 4560
 ctcgtccat ttttttttttccat gatgttccat ttttttttttccat 4620
 ctggactac ttttttttttccat gatgttccat ttttttttttccat 4680
 gtttttttttccat gatgttccat ttttttttttccat gatgttccat ttttttttttccat 4740
 caccatctat ttttttttttccat gatgttccat ttttttttttccat 4800

ctaatatatt aatactaaa gactttctg atgagataag tggtagaaat aacaaaaatt 4860
 ttttataatg tgggtggaa aatgtcaaca tttgaaagat ttgcataact caaccatgg 4920
 tttccaaata atcaatgctt gatattaaa tattcataag taaaagatcc agtcagtgca 4980
 caggatagac caatgtatTT taatgtaca gaagttctg tcatagtcca tggtagaaat 5040
 agatagctat tataaaaaag aaaaaagttt ttgcaagatg tagagaaaaag agaaagaacc 5100
 cttgtacact actgggtggaa atgtaaatTT gcacagccat tttgaaaac atggaggTT 5160
 ctcaaaaaac taaaataga attaccatTT gattcagcaa tcccacttct gggtttat 5220
 ctaaaggaat taaaatcagt gtgtcagaga tagtgcact cccatgatta tttcacaata 5280
 gccaagatTT agaaacagcc taaaatgc ccatcaatgg atgaatggat aaagaaaaatg 5340
 tggtagccgg gtcagtgcc tcatacctgt agtccaaca ctttgggggg cggaggccgg 5400
 cgatcacct gagggtggaa gttcagacc accgtgacca acatggagaa accccgtctc 5460
 tgctgaaaat aaaaaattag ctgggtgtag tagtgcattc ctgtatccc agtactcgg 5520
 gaggcagagg caggagaatc acttgcaccc gggaggcaga gttcagtg agtgcagatc 5580
 atgcattgc actccagcct gggcaacaag agtggaaactc catctaaaa aaaaaagaaa 5640
 aagaaatgtg gtaaatacac acattggaaT actattcagc cttaaaaaag gaaactctgt 5700
 catttgcac aatatggatg aatctagagg atgttataact aagtggaaata agccagacac 5760
 agaaagacag ttaccacata atctcatttT catgtggaaT cttaaaaaat tgaactcgta 5820
 gaaaccaaga gtagaatggT gtttaccaga agttgtggT gtgtatgggg ataggggaga 5880
 tggtagtcaa agatataaa gttcacttag acaggaggaa taagttctag gtgacatatt 5940
 gcatagcatg gtgactataa ttaataatgt attagctatt tcaaaaattgc taaaagtaga 6000
 ttttaatgt tctaaccaca aagtaatgt aagcatgtga ggcgtatggat atgttgatt 6060
 gcctgattta atcattcttca aatataaca tttatcataa tttacccat aaatatacaa 6120
 tttatgtc aattttaaaT agattttaa aattataaca ttttgattaa aattttatg 6180
 ttgacacgac aagtacttttT gaattttttt tttttttt gaga cagagtctt 6240
 ctctgtcacc caggctggag tgcagtggcg agattataag ctcaactgcaaa ccccccaccc 6300
 ccggattcaa gcgattctcc tgcctcagcc tcccactgt gttggactac aggcgtgtc 6360
 caccacgctc agctaatttT ttgttatttt agtagagacg ggttttcaact gtgtttcgat 6420
 ctctgtaccc tttgtatctgc cccctcagc ctcccaaaatg gttgggattt caggtgtgag 6480
 ccaccacacc tggccaagta ctttggattt ttaatgaaa attctatTTT ggatttagct 6540
 ttcatTTTgg aaaaattact tgccaaacga ttatattttt aaaaaggattt taaaattttg 6600
 tttcacatag gcccgggtgcg gttgggttctg cctgtatcc cagcactttt ggaggctgaa 6660
 gtggcaggat caccgtggcc caagagtca agaccacat ggcacacac agagagaccc 6720
 cgtctgtgaa aaacaaaacag aaaaaacaaa aacttagctg tgcgtatgg cacatgcctg 6780
 tcatcccagc tacttgggg gctgggttgg gaaaatcgct taggtctggg aggtcaaggt 6840
 tgcagtggc tttgtatctgc ccacactccc agcctaggT acagatgtat gtcctgtctc 6900
 aaaaacaaatt ttttttctacc ttaccatcta attaagactt cttttgtcat tcttaggtac 6960
 gggaaaaaca ctcttggcac gagccgttgc tagccagctg gactgcattt tcttaaagg 7020
 aaagggaaaga ttatTTTgtt ctattgaaa ttatTTTtta ctgtattttt tttatattt 7080
 ctttactgtt ttccctttaa tcaggttgc tctgtatTTT ttgttagacaa gtacattgg 7140
 gaaagtggc tttgtatcgag aaaaaatttt aattatgtca gagatcatca accatgcac 7200
 atttttatgg atgaaataga tgcattttgtt aagaataaca cccttggta aagttttagg 7260
 acttttttttT aatgtaaaaa gaacctttt ccctcttta atctgtattt gtgacttgc 7320
 tgaagtagat accacaatga atcagatTTT agtttacca attttatTTT ataaccttc 7380
 atggccgggtt gttgggtggc tgcctgtaa tcccacact ttgagaggcc aagggtggca 7440
 gatcaccagg tcaggagatc gagaccatct gccaacatg gtggaaaccct gtctctacta 7500
 aaaaatccaaa aatttagctgg atgtgggtgc acatgcctgt aatcccagct actgaggagg 7560
 ctgaggcaccg agaatacgctt gaaacccagga gacgttaggtt gcaatggc gggatcacac 7620
 cactgcactc cagcctggcg acagagcgag actccgtctc aataaataac ctccacttt 7680
 aacaaaatgt aaaaatgtac accaaaatca agtctaactt tttgtatcgata attcttgc 7740
 tttatTTTtca tttatTTTgtt tttatTTTgtt tttatTTTgtt tttatTTTgtt 7800
 gttttagatg gaaaagatg atgtatTTTtca atttccaaat tttatTTTgtt tttatTTTgtt 7860
 cgggtttctg aggttacttc agtgcacaca gagattcaga gaaatggtaat ggaggtaata 7920
 tttgttggaaag ggggtttata aaaaacccaa tttttttttt atgaaatTTTtca atgaaatTTTtca 7980
 ttttggatag tcaaaaatata tagaacattt taaatgaaaat atgaaatTTTtca aaaaatTTTtca 8040
 caggaacaaa catgtttctc tttatTTTgtt tttatTTTgtt tttatTTTgtt tttatTTTgtt 8100
 ctatctggca aattccattt ggttataacc tttatTTTgtt tttatTTTgtt tttatTTTgtt 8160
 agtcattcat atatTTTtca tttatTTTgtt tttatTTTgtt tttatTTTgtt tttatTTTgtt 8220
 ttttggatag gtcatattaa gactgttggc aataaaatgtt tttatTTTgtt tttatTTTgtt 8280
 gctctaaaaaa ttatTTTgtt tttatTTTgtt tttatTTTgtt tttatTTTgtt tttatTTTgtt 8340
 ttgataatgg aagaggatag atgacagaat gaaagaatgc acataaagcc ttcctccagt 8400
 tttaccttcc cccactccaa attctgtgaa agtgcataca agatccaaa tacatTTTtca 8460

tgccctata tgcctgacca aacgggtcat catcaaagtt attcaaactg tagtagcctg 12180
 tgctgtctta ctctcttcc tattctgtat cagatccatt gttgtaccc caatccata 12240
 gctttgtat tcatgtctgt tatgtgggtg gatggagaac tcactttatt actgtacca 12300
 tagatctgtat acttcaccac ttgaatctt cacagaaacc agagaagcta gctaatgcat 12360
 gctgttagcat ttaaaaattt catgtgatac aattatgtat gattacattt cagttttgt 12420
 atacttata ttggcttgc atgatcaaag taaacaaagt aaattccatt gttataattt 12480
 gttttgagtg ttatagggtt attcaaatcc aagatttgc tacagttttg ataagagtca 12540
 cagcttaaca ggtatcttgc gttcacatgt gcatacttat ttcactgtat aaaaatagat 12600
 taagatattt tgagattttgc tgatatttgc ttgtttttaa agtttcaggg gtgtgtctaa 12660
 ttcttcttgc tgctggttta tttaacagaa gtcttagttt ttggatatta atattgttgc 12720
 aagtttaacag agctgtatgtc tagctgtatca aactcaaagt aagctctca gttttaaattt 12780
 tcgatgtggg cattaaatcaa gtaaaggctt aattttttaa actaatttcc agtattttttt 12840
 ctaaacagat tatgaagcaa ttgtgaagct ttcgatggc tttaatggag cagatctgag 12900
 aatgtttgtt actgaagcag gtaagggtt aaagtagt tttactattt attttgcattt 12960
 tttaaaatttgc ctgaaaactgtt ttgagtttgc tctgaaaagcg gacatagac ttgcaggaa 13020
 tttgggttca tgctgttctt ttaggaatcg attccaggaa ataggagaag cagggcaagt 13080
 gagatggaaa gagggaaagc taatatgagg gtcacccattt gaggtaggtt ctgttaggaaa 13140
 gggaggttag atctcagaga agcatacaga atgccttcca ggatcaccacca gctgaaagtt 13200
 gggagactag aacatttgatt taccgtact catccccat tggatgagat ttgtccttgc 13260
 tagtgttgc tcccttgcac ttctacccatc ctttagggcag aatgttgcag gagaggcatg 13320
 taatagaaca ctggcccccattt aaagtaatgc tgagttgtatca cagaatttgc taccacaccc 13380
 gtggctggaa ttagaatggg ccagcaccag aggtatctgc tgcaaaatgtt attgtgtatg 13440
 ttgtctaata ctgtctgtt agcagtgtt ttgaaagattt atttatgtat tatgtatca 13500
 tgccatttgtt gtaaaatgtt gatattttat ataatttctt gtggattgtt tgatactatt 13560
 ttttcactt ctacatgtt gtaaaaattt gtgtgtatgtt attttttttt ccagtagccaa 13620
 gtagctttaa tacccttacccat agaatttccat agtttttgc ttccatatacg aatctttaaa 13680
 tagaaaaaaat aaacttctac agtataatgtt ctgactttat aggtttagata ttttcttaag 13740
 tattagaata tggatttcc tcttgctttt catatcatgtt ttagcccttgc taaattcaac 13800
 acagtgtttt aagtggctgc tcaggggaggc cttctcagta caggtatctt catgggtatt 13860
 gggatgtctg tgagtctgtt tctgcacccat atatgcaggc cagatacttc tggcacgtc 13920
 tagaaatgtt gtcacatgca attagggtaa atcatgtatca cagagcgttca tcaataaact 13980
 aaacttatttta gaggtaaact gtcataatgc ttgaaacaagt tagagtaattt tatgacattt 14040
 tctttccaaa atgtaaaacca gaccaatttta ttatcagaag attgtttttgg ttagattgtt 14100
 atccaaatgc aagctgttgc gtgaacccat aggctgttgc tatccaaataa ttcgtttttt 14160
 ttccttacat attcttacccat atttacccat agtttttgc aatgagatctt aacttctgtt 14220
 tggataaaaa ttgtgttctt tttttaactt ggtggacat tccatctgg aaacatactg 14280
 aaatttttttcttcttctt gacttgaagg cttttttttt aacattttttt gtaagttaaa 14340
 atacacttgc ttcaactaca gttgccttc ctgttcaggc cttgcacattt tcttttttgg 14400
 attataatac atctcttattt tttttttctt tttgagacgg agtctactt tggcccaaggc 14460
 tggagtgtcag tggcatgtatca actgctccctt gtagcccaaga cttgtatctt ttcctttat 14520
 ctcccaatgtt ctggggactat aggcgtgcgc caccacaccc agttaattttt tttttttttt 14580
 gtagagacgg gtttccatcat gttgtccagg ctggcttcaaa attccctggc cccgagttatc 14640
 caccacccctt ggcctcccaa aatgtctggaa ttacaggcac aagcttccacccat gctggccag 14700
 gcatcttgc tgcatgttta ctatttactt aaagtgtttt gggaaatagc catgtgttgc 14760
 aggttttacaa aaataacttca ccttagttca ctgtatctt tttttttttt tttttttttt 14820
 tttttttttttaaaaatcttcat tttttttttt tttttttttt tttttttttt tttttttttt 14880
 ttccttacat agaaatcttcat aatgtttttt tttttttttt tttttttttt tttttttttt 14940
 attttttttttaaaaatcttcat agtggaaatcttcat aatgtttttt tttttttttt tttttttttt 15000
 taatttagtag atagcaataa acttacccat tttttttttt tttttttttt tttttttttt 15060
 aaatctggaa cccatataatca taacacaactt aatgtttttt aatgtttttt tttttttttt 15120
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 15180
 tgtagttgttcaataat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 15240
 aatttttttttaaaaatcttcat gacttccggat tttttttttt tttttttttt tttttttttt 15300
 tgatcccttcaacgt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 15360
 gatttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 15420
 acgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 15480
 attaaatgttcat agtggaaatcttcat aatgtttttt tttttttttt tttttttttt tttttttttt 15540
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 15600
 ctgcacccatc tggcccttccgg gttcaagcgat ttcttcccttgc tttttttttt tttttttttt 15660
 ggtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 15720
 ttaccatgttcat ggtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 15780

ctcccaaagt gttgggatta caggtgttag ccacccgtgcc cagccttga a ccggatgtta 15840
 aatattcata taatggtcat acctgtttt gttttagaac ataatcacaa caccgctatg 15900
 gatttttttt tttttttttt tttttagatg gggctcgct ctgttgcag gttggatgtc 15960
 agtgcacta tctcagctca ctgcaacctc cgcctctgg gttcaagcca ttctccctgcc 16020
 ttagccccc gagtagctgg gactacaggc gcgcgccacc atgcccagct aattttttt 16080
 tttttgtt ttttagtag agatggggtt tcacccgtt ggccaggatg gtcttaatct 16140
 cttgacattt caatctgccc atctggcct cctaaagtgt tgggattaca ggcgtgagcc 16200
 accgcacccg gcctgtggat ttttaattgaa aaaagatgt gtttttagc aaattacaac 16260
 tactggctca gaagtaataa atctaagctt cacatttatt ccatagaatt atattgttt 16320
 tcttataatg aacatataat tcataatgtt tatatacagc tcatgttgc ttattctcta 16380
 caggtatgtt cgcaattcgt gctgatcatg atttttagt acaggaagac ttcatgaaag 16440
 cagtcagaaa agtggctgtat tctaagaagc tggagtctaa atttttagt acaggaagac 16500
 aattttactgt aagattttt atggctgtat gacatgtt ggtttttgtt aaaaataaag 16560
 ttaaagaaaa taatgtatgtt atggcaatg atgtcattaa aagtatatga ataaaaatat 16620
 gagtaacatc ataaaaatattt gtaattcaac ttttaagata cagaagaaat ttgtatgtt 16680
 gttaaagttt catttattgc agcaaggatc aaagggaaag tttttagtgc ttcatattt 16740
 gctgcgtgag cattttgtaa aatattgaaat gtttttagtgc atagttgtt aagaaagcat 16800
 ttctttagtgc ttatttgtt tcattttgtt tcctcatcta aaaaatgtt aaaaatctgt 16860
 ttgattttagt tctccttacat atatatttgc ttcatatttgc agtataatttgc ttgtggcct 16920
 tttagttctt tagcaagttt actattttagt aaccaggatg gatttttagtgc tttagtgc 16980
 tattttaaaa tagtacacat acttaatgtt cataagatca tcttctttaaa taaaacatgg 17040
 atgtgtgggt atgtctgtac tcctcccttc agaaatgtt tacatatttgc tcatctactg 17100
 tgattaagct cattttgtgtt taattgaaaa tatacatgca catccataac tttttaaaga 17160
 gtatgattca acgttatttgc tgtaatatgc tgactgggtt ttcttgggtt atgttaagacg 17220
 ataggccctt gttggggatg tgaaggctgc gaccctttc cagaaaaat tctaacatac 17280
 aattttgcgt atactataat ttccggat ttttttttcc ccaagctcat ccaaggatc 17340
 ttttaggtatg ttttttttttgc agaaatgtt tacatatttgc tcatctactg 17400
 aaatgttcaaa acatgttgc ttgttacatc tacatgttgc ttatatttgc tggcaataaa 17460
 agcttataaca aagtttttttgc aggaatcatc attttttttgc aataatttgc aatgttgc 17520
 gtgaaaaaaa aagtttttttgc ctttttttttgc aacactaaat aacccaaaaat acatgttgc 17580
 gctaatttttta caataatttgc ttttttttttgc aacttccatc ctttttttttgc ttttttttttgc 17640
 tataatttttta agaaatgttgc acatgttgc ttttttttttgc aatgttgc aatgttgc 17700
 catactcaaa attatttgc agtttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 17760
 aaaatgttgc ttttttttttgc aatgttgc ttttttttttgc ttttttttttgc ttttttttttgc 17820
 ttgcatttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 17880
 aaagaatcaaa ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 17940
 atggagtttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 18000
 acctccgcctt ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 18060
 ctggcatgcgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 18120
 atgttggtca ggttggcctt ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 18180
 aaatgttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 18240
 ttacaggcat ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 18300
 cttaacttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 18360
 attatttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 18420
 tgagtcaatc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 18480
 aggttaatc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 18540
 ttgagccgtt ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 18600
 gtgattttaa attttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 18660
 cgcagaattt ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 18720
 ctgttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 18780
 gagctggctt ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 18840
 agcccccctt ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 18900
 cccacccccc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 18960
 cttggggcg ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 19020
 cgggtggagg ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 19080
 atccctggcg ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 19140
 gcccgggtt ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 19200
 cactggggacc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 19260
 ccgcctccccc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 19320
 gtaacactt ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 19380
 ggagtccctt ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 19440

tcctttgtt acttaggcgt ggaaagtttag ggtttccct tcaagttagt tctggaaagt 23160
 cgggtgaaa cagcctaga ttccctgcct ccagacccta ttcacctgcc tcactagcac 23220
 ctccagtgtt ttcatccaga agctcaacaa atcttattca acggttttta tagaactca 23280
 tctccatccc ctccataga ggtgtgttg tggtgaggc tgagagttca acccttctgt 23340
 cacatggctt ttctggtgac tggcccccacc ctaaatcaact tcattagcat aatcagggtt 23400
 gatcaaaaat agtggctcat aaataacca agacactcct attagaaaat tccaagagtt 23460
 ttaggaggac tggacagga actggagaga aagaccatgt atttcatatt atatcacagg 23520
 gacagaggta atggtaaag ctagtgata atgatgcaag tattgtctgc tgaaggccaa 23580
 ttcgtccgt atttcttaat attgcattt tggtatctt tggttgcaag caacaaaaac 23640
 gaatttaaga aaaagaagaa gtaattaaat ccggccgggc gcggggcctc acgcctgtaa 23700
 tcccacact gtgggaggcc gaggcggacg gatcacgagg tcaggagatc aagaccatcc 23760
 tggctaacac ggtaaaaccc cgtctctact taaaaaaaaa ttagcttagt atgggtggcgg 23820
 gcgcctgttag tcccagctac ttgggaggct gaggcaggag aatggcatga accccgggagg 23880
 cggagcttgc agtgagccga gatctggca ctgcactcca gcctggaga cagacgaga 23940
 ctccatctca aaaaaaaaaa aagaattaa atccagaagg gtagtggtgc agctagttc 24000
 aaggatttga ccaaaccac gtttataaa gcatcagaac tgccttgc tctcatgagt 24060
 tcttatctct actttctctc agagtctctg ctttctctc ggcttctcca agatgtgaag 24120
 cttggccatc tgggttcaca ctttatgag cttgttatt gaggataaaa actgaacact 24180
 tccagttct gtgtttgaaa tctagagaa ttgccaatt taattcatgt tcccacactt 24240
 tggatcagtc actgttagcca ggaaaggca gatacaatga gggggcccat ctaggtcata 24300
 tccctaattc ctggctaga ggagtgaatg ttattgttg tagccctccc accaaaaacca 24360
 taggaacatt tccacaggtt gagggtactt tctggctga taaaactata catagggcc 24420
 acataaataa actattaaat aggagcatat agttattcat aataaactga ctaataagca 24480
 ctgttaattt tctaattctcc agtgagataa tgtaaagtgt caaatggctc taagtagtta 24540
 gagtgatcag ccagcattgt ttcttgcaca caggagcac tacctggaaa tccaaattac 24600
 agaccaaatt taataaaaaac ggaattcaag cagaggttc agggaaatgct ttaatgtta 24660
 atgtgatcaa gctatgtat gttgtatgatt ctgtcacctc tacaagaata ttactttcac 24720
 gtttcttgcata atattggat tctttgtata ggacagtgtc aacaaaaatt tagatcagtc 24780
 agtttgcata aagattgtta cttttttgtt ttaaaacttt ttcatgaatt tccattgttt 24840
 tgaagatgaa atttaaaccctt tgacattat ttccagggtc ctgtatggtc tgacatctgc 24900
 atacctctc aaccttcattat tgactactc ttctgtctcc ttctctgtta agccctagcc 24960
 atatttatct tcttcattgtt cctggatgc ttaatttcc acccccccgc ttcaagaccc 25020
 ttatgttgc tattttcccc tgccttgct gccagcacct tccttacccct caccataatt 25080
 actgttacc ctgggtttag atcccaattt aggcaacatt tcttcagaga agcttttcc 25140
 gtttgcaggat ttctctact ctttccctca tcctctagac tggttcaatt ccccaactac 25200
 tatggcactt ggtactttaa tacttaccc ttgtacattt aacaattttt ggtcattgtc 25260
 tattttccat ttagactgaa ctttcataa gagagcttag atatttagaa gaaggagtag 25320
 ctgatagtagc caatttttaa gcaattttgt tgtagctggc gctattttgtt ttataattta 25380
 aaagttaatg ttttatcttc tcttcatttca gaaagtggaa tattttttt cattgcagtt 25440
 tagcaacttt ccatgtttcc ctttccattt ttcttgaa tccctgtgtc caggatcaaa 25500
 gataggaatt attaacata catggctgag gattcccttt ctatctccctt tatttagaaat 25560
 ggtgtttttt aacccttact ctagagtaag gaatttttaaaaactgtga tgcctggacc 25620
 ctaccagcac ctattgttagt ttaatttac tgaatgttgc tagatgttcc taatgtttag 25680
 tcaggtttaa aaattgtctgg tttagaaat atcttgatgtt ctcttctgc cctccagttc 25740
 ctgcccaccc tctttttttt ttgagtgaa acattttctt ttctccctttt atttaaagca 25800
 agctcaagct tgggtgtggaa atgaaagaa aaggactttg gagggtttaa ctttattttt 25860
 cttaggagaga aagtgtcaata ctaacttttgc tgggtgtggaa atgtcccag tgcaagtct 25920
 gtattctgtat gttttttttt ttcccccaac tggggccccc caccctccagc ctatgtacaa 25980
 ttgtgtttt atttttagtat tggatataa ggattcagca ctatctcaa atgtatgttca 26040
 atatcccctg tggataaggg gggactactg tattttttttaa agttcatatt tcatttttca 26100
 atgcataataa gaattttttt atctaattgt tacagtctat atcccttccattt gatgtgttt 26160
 ttgtgttttcc ttgtttttttt ttgtttttttt ttgtttttttt ttatagatca 26220
 tttttatggaa aaggaaggag ataattccgtt aggtttttt aacatgtggt actttctacc 26280
 tcatttttttcc tcaatttttttcc ttgtttttttt ttgtttttttt ttatagatca 26340
 caatagagggtt tttttttttt ttatctgttgc tgccttgggtt tggtttaatgtt ggttgaactg 26400
 cttggctact cataaaagttt gggaaatgtt tttttttttt tttttttttt ttatagatca 26460
 aaatagatca ttgtgtttttt ttgtttttttt ttgtttttttt ttatagatca 26520
 tagatttttttcc tcaatttttttcc ttgtttttttt ttgtttttttt ttatagatca 26580
 ctgggttttcc ttgtttttttt ttgtttttttt ttgtttttttt ttatagatca 26640
 acttttttttttcc tcaatttttttcc ttgtttttttt ttgtttttttt ttatagatca 26700
 ttttaacagg ttggagtgca gttttttttt ttgtttttttt ttatagatca 26760

ttcacgccc ttcctgcct cagcctccc agtagctggg actacaggcg cccgccacca 26820
 tgccggcta atttttgtt tttttggtag agacggggtgc tcaaccatgt tagccagat 26880
 ggtctcgatc tccgtaccc tgcgtccacc ctcctggcc tcccaaagtgc ctgggattac 26940
 aggcgtgagc cactgtgccc gccaacagg caggttaag gtttggtag taggtggtaa 27000
 tctgggttag ggcagcaaaag aagggtggat ctgagatcag catctgatga taacaccagg 27060
 aatagttcca aatgaacttt tctgtgagag aaagctttt aggtttcaaa ggatccata 27120
 ctattgcagt aattactaat gtctctgaa gaagggttct tatctgtcct gtgacttagga 27180
 ataatttttc attccttcct actatacaac ttgctttcc ctcttataat atcttccata 27240
 tatatatata tctcaagaga gtcttcatg ttgttattaca tataacctt tggaaagctc 27300
 aaaaggttct tgaagcctc tgggtgtca aaagggtcag gtaaattttt cattctatcc 27360
 catatgtgcc tgggtgtttt aatataaaaa ttgtttaat tagtaaccag tgaaaataact 27420
 gtttccctt aaagaatttt ttgataaaaa ttgataacttc agtggctttt agtgtcttt 27480
 ggcatattgc caaatgaagg tggaggaa atgcactcc aaaatatgac accttgat 27540
 attgattact ttaagttgga aacactgca aagtagcaaa tgcaagaaaa cactttctc 27600
 gaactcctgt tacctaccta aggacagatc ctccaaaaga agtcaattt gctcctaggg 27660
 agtttgcata accagggaaat ttgtctt atcactggag aggagagtaa aagtcaagcac 27720
 cacacccaga caaactgaca caaagtatca tctatttata ttctaaaggc ccatttatct 27780
 ttctccagaa ttgttcttctt aaattgcctg tatacccttata ccccatgtct atataaaagg 27840
 tatataaaact cctaaatatc actttttttt tttttgtata cacgtttctt tcctgtata 27900
 ccccatgca cataatgaat ctgtataacctt ttctccgtt tagtttattt catagactgg 27960
 tttgaaatat cacggattttt gtttgggtttt ggtatacact tttttttttt atcactttt 28020
 tttttttgtt atacactttt ctttccgtg atactcccat acacataata aatttgcata 28080
 catttctcc atttagtttta tttcatagac tggatcgaa tccgtatggt agagggaaag 28140
 tcttccttgc ctacacaag tatttcccg aatatttttta caccatttctt tgatatgtgt 28200
 tgccctgttt ttttttctt aattacacaa aattttgtga ttctacttta gataaattca 28260
 aaagtacgca ttcttttaat tgattttctt ctttatcaca gctctgacaa gttgcttcag 28320
 gaagataagg ctggctgtt gactacttga gaatctttttaaaaagaaaaa agtcaataac 28380
 attttagtgc gtagatctt gaaatgcatttattttgtc ttattttgtg tcaggcactg 28440
 tgcttatcat taggggtacc atgactaaaa agatcttttgcctaaaggc tttaaaaact 28500
 gttttttttt tccttttttctt ctttttttttt tttttttttt tttcgtttagt atagggtctg 28560
 tctctgtgc ccaggctggaa gtgcataatggc accatgtatgc ctcaactgcag cctcgaccc 28620
 ccaagcccgaa gtgatcttcc tgcctcagcc tcccaagtag cttaggaccc agtcatgcac 28680
 caccacgcg cctggctaat tttttttttt tttttagatgatgggttccctt tatatttgc 28740
 aggctgtct tgaactcggg ctcaagcttat cctcttgcggc cagcttccaa aagggtctgg 28800
 attgccagggt tgacttacca tacctggctt aaaaatcat atataaaaag attaccataa 28860
 cacatgttta agttaaagaa tctaggctgg ggcgggtggc tcatgtctgt aatcccagca 28920
 ctttgagagg ccgaggcagg tggatcatga ggtcaggatg tcaagacccaa cctggccaag 28980
 atgggtaaac cccatctcta cttttttttttaat tttttagatgatgggttccctt tatatttgc 29040
 tgtaatccca gctactcagg aggctgaggc agataatttgc ttgaacctgg gaaagccgagg 29100
 ttgcagttagt ctgagatctt gccactgcatttgcactccag ccttagggcagc agagcgagac 29160
 tccgttcaa aaagaaaaaaa aaagtatcta gtaaacaattt acattttccctt cattgttgc 29220
 ttagaaattt catgttttat ttctattctt ttaatatttca taaatttagtca attattttttt 29280
 gcagccaaata ttgtttaat tgtaactgtt tgggttgcgtt aaagtttatttctt cttacatgt 29340
 aagactgtat agtataatttgc ttcaagaaat gaaactctggg ttcaagactt ctggatccaa 29400
 aatcaagttt cttaggttctt ctatgactaa aatagacagt gatagttatcc ttcttcaaa 29460
 gaacatttttta actttttttcc tttaaagata tttttccggcatatatttctt taatttacag 29520
 ttgtttttgtt cctggccacta tgaatgttattt attttgcatttctt gttcatgc 29580
 ttgagaagttt agtgtccatc tgattgtctt tcctttgtt gtaatgttgc ttgttgc 29640
 ttgatctttt ttaataaaagg taaaattttt atatgttataat gtaaaaaatag taagtgtca 29700
 gttcatttgatgatgaa ctttttttttccat ctttttttttccat ctttttttttccat 29760
 ttagcataga agtttacatc tttttccagg cttttccctt ctttttttttccat aataggaaac 29820
 cagatttctt tcaacataga ttagtttcc ttgttgcatttgc acttgcataa aatggaaatca 29880
 tgcaatggaa ctcttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 29940
 ccatgttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 30000
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 30060
 aatatttctt tataatgttctt ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 30120
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 30180
 ttaccatttttcc attttacatttcc cccacccagca atgtgtgaga gtttttttttgc ttttttttttgc 30240
 tcaccacatc ttgttgcatttcc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 30300
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 30360
 ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc ttttttttttgc 30420

aaataaaaagg gacaaattta gggccttgc aatttagtaaa cggttgcgtt ttgttaaagg 37800
tttctactgt ttttaaatgt gaggttaaggt cataaattgc ttcatattag gtgggtgcaa 37860
aagaattgc agatcgcc ctgaaaagta caaaatctat tcgctgttac gttagggctc 37920
tattttgata gtttattttt atttagtagt agtctattgg gccttcaaaa ctgtttaag 37980
catatttata cataattatg tgcatcgct tgcgttct cacattcata aagtagatag 38040
gaaaactcca taggcatcaa gtgtaaacga aggacttaat gttgaatttg ttgtggaaat 38100
tggcacaaat ctcaatatac aacattgggt aattttaat cttaccaaata gcttatctca 38160
cttccctaa ctcaagttt actcaagaaa tacaaagata attgaattct aatctatgtc 38220
gacataaaaac ttgctgcaga aattaacact taaaacttgc aaattatatt gtcttagccc 38280
aggctgctca aacaaaatac catagacagg gtggcttaaa caacagacga ttatggtagt 38340
tctggaggt ggcagttca cagtcattgt ccggctctgg tgaggaccct ttgtctgg 38400
cgcagatccc tcccttcttgc ctgtatccctc acacggccaa gagaacgagt ttgtccct 38460
tcttacaagg gtacaatccgtt gtcattgggg tttctaccct catgacccca aactaaaact 38520
gattatcttc cagagactcc accatcacat ctgggggtt aggatttcaaa cataagaatt 38580
tgaggtgatg caaacattta gttcataaca catataaattt atttttttt attttgc 38640
tgaatttata gtgtactgt ttgtactat taaaatgc gaaaatggga attaaatata 38700
taggattttaa aacaatgtgt caaggaaattt aaggttatct gatttcattg ccatcggtac 38760
ttgttagttc atttattgtt caggtaattt ttgacaaact taacttagttt tacatactt 38820
atacttaagt gaatttgtt atacattttt cacaactat gtatcgttca acaaataaaa 38880
atctttctg tcatggact taatgtctca ggttataaaa taacatctat aacttcaact 38940
aaacttatac cttagaaatg aaaacttattt atctggtaat ttctagaattt gtcattttt 39000
attgctttaa gtatggagcc aaaagcacta caggttgggtt atcccttaatc tgaaaatct 39060
gaaatgcctt aaagtggaaac tttttgggtt tcgatgttcc agcacaatgtt aattccacac 39120
ctgaccctt gtaatgggtc actgtcaaaa ttttgggttca tgccaccaat gactgtatg 39180
aattacgttca agatgtatata ttgtgtgtgt gaaacataaa tgaattttgtt gttttttttt 39240
ggataccatc cccaaagacat ctgagttatgt atatgc 39300
aaacacttctt ggtccctaccc tgggaccaggc attttagata aggataactc aacctgtatt 39360
gaatataata agatgttattt gaaatggccca tttttttttt cagggaaattt tttttttttt 39420
aaaagggttaa tttagattctg tgaagttatgtt aaattttttt tttttttttt tttttttttt 39480
gagaggcaag gagttgtctt gatgtttttt tttttttttt tttttttttt tttttttttt 39540
tgtccaaatgtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 39600
gattgcgttcc aatataatattt aactaccattt tttttttttt tttttttttt tttttttttt 39660
tatgcacccat atcttacata aaggttccat tttttttttt tttttttttt tttttttttt 39720
ccgtttaacc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 39780
ccacttcagg tatattttttt tttttttttt tttttttttt tttttttttt tttttttttt 39840
tctgtgttattt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 39900
ttatcttccc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 39960
tggaaataacc catataatattt tttttttttt tttttttttt tttttttttt tttttttttt 40020
cttttcagg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 40080
tcattttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 40140
atatagttaca tagttttttt tttttttttt tttttttttt tttttttttt tttttttttt 40200
taatgcagaa ttctaaagggt tttttttttt tttttttttt tttttttttt tttttttttt 40260
aaaataaaaaa agaattttaaa aataatgtat tttttttttt tttttttttt tttttttttt 40320
ttatcttccg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 40380
tactgttacc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 40440
tatagataaa tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 40500
tttatatccg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 40560
atggcttatac tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 40620
tactaatatgt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 40680
catattgtata gggcttattt tttttttttt tttttttttt tttttttttt tttttttttt 40740
tgatagatgt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 40800
tatgttggag tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 40860
tttctcaag tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 40920
agttcagg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 40980
gagtttattt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 41040
tctactttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 41100
caaatatctat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 41160
ctgtatcc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 41220
gaccagccctg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 41280
ggtggccat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 41340
ccagaaggca gggccat tttttttttt tttttttttt tttttttttt tttttttttt 41400

gagcaagaca ccgtctcaa aacaaaacaa aacaaaacaa aaaaaaaaaca gtgctgtggc 41460
 ttacacatat aatcccagta ctggggagg ctgaggaggg tggatcacga ggtcgagatt 41520
 gagactgtcc tggccaacac agtgagaccc cgtctctact aaaaatacaa aaattatctg 41580
 ggcgtgggg cacatgcctg tagtcccagc tactcaggag gctgaggcag gagaatact 41640
 tgaacctggg aggcagaggt ttcagtgagc caagattgcc ccactgcact ccagcctggc 41700
 gacagagcaa gactctgtct caaaaataaa aaaaaaatt taatgtctg ctttatttt 41760
 acaatgaaac caatctataa atatctgtaa atacaagata catactctaa aatacattgt 41820
 gtgaacatata aatagaatac tatgtaaacc taaaaaagaa taaaatataat gtatgtttt 41880
 ggatttggg tgatctccaa gataatgcata tacatgaata aagcagggtg tggacaatg 41940
 tatatattttt caatgtgtt agtaaatata tatatactac attccatata tttattctt 42000
 atatatgcata agaaaatttc tggaccaaga ggctagaaac ttcatagtga ttgcttcaa 42060
 gaaggaaaat tcagggctg tgatggtaga gggacgtatt tttcttctgt ttttaatttt 42120
 gttttttttt gttgttggg tttttttttt ttttttggaa tggagtctca ctctgtcacc 42180
 caggctggag tgcagtggtg tgatcttgc tcactgcaac ctctgcctcc tgggttcaag 42240
 cgattctctt gcctcagccct cctgagtagc tgggattaca gcatgtgccc accacaccca 42300
 gctaattttt tttttttttt ttttttggaa cagagttcg ctctgttgc caggctggag 42360
 tgcagtgca tgatctcgcc tcactgcata ctccgcctcc caggtttaag caattctctg 42420
 cgtcagcctt ctaagtagct gagattacag gtgcccacca ccactcccag ataatttttt 42480
 ttgttattttt agtagagacg gggtttcagc atcttgccca ggctgatctt gaactcctga 42540
 cctcttgatc cacctgcctc agccctccaa agcactggg ttacagggtt gaggcaccgc 42600
 acctggcta atttttgat ttttagtaca gacgggggtt caccatgtt gccaggctgg 42660
 tctcgaaactc ctgacctcgat gatctgccta cctccgcctc ccaaagcact gggatttaca 42720
 ggcgtaaagcc actacgctca gccgaggac atattttca tggtaccctt gatatccatg 42780
 ggggatttgc tccaggaacc cccatgaata acaaaatccct cagatgctca agtcccttat 42840
 ataaaactggt gtaatattttg catataacct gtgcacattc ttcataatac attaaatcat 42900
 ctcttagatta ctctaaatac ttagtacagt gtaagtgtt gttgaatagt attggatttt 42960
 atttttattttt ttttttagt gttttttttt gttaatgttt ttattttgtt 43020
 tcggttgaat ccacaggat gaaattttt gatatggagg gctgactt tacttttga 43080
 gtgtttttttt ttacaccat atttagttt tttttttttt gttttttttt ggaatattttt 43140
 aaaacactga tttttttttt tttttttttt tttttttttt gttttttttt gttttttttt 43200
 ccaggctaga atgcagggtt cactgcaacc tctgcctccc aagttcaggc aatttttctg 43260
 cctcagcctc ctgagtagca gagattacag gcatgtgcca ccacgcctgg ctaattttt 43320
 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt gttttttttt 43380
 cgtgatccgc ctgccttggc ctcccacagt gctgggattt caggcgttag ccactgcgc 43440
 cggcctgaat ttttttataat tatgaaagaa atactttttt tttttttttt gataggatct 43500
 ttctctgtt cccagcctgg attgcattttt catgattttt gttcattttt gttttttttt 43560
 cccaggctca agcaatcttc ctgcctcagc cttccaaagta gctgggacta caggcgcacc 43620
 accggatcgg gctaattttt tttttttttt tttttttttt tttttttttt gttttttttt 43680
 ggctgttctt gaactcctga gcttaagcga tctacccacc tcagcctccc aaagtgttgg 43740
 gtttacagggc atgagccacc acacctggcc atgaaacact tattttttt aagtacttcg 43800
 gaaggatata gatgacacacca agaaaaatata tttttttttt tttttttttt tttttttttt 43860
 aaaacacttt ttgttaacatt tttttttttt tttttttttt tttttttttt tttttttttt 43920
 tattttacgtt tatatgcata tttttttttt tttttttttt tttttttttt tttttttttt 43980
 caaaactatata aaggtgaaac tttttttttt tttttttttt tttttttttt tttttttttt 44040
 ttcatcttata atgtgtacag tttttttttt tttttttttt tttttttttt tttttttttt 44100
 ttatcttaat ggaagaacca tttttttttt tttttttttt tttttttttt tttttttttt 44160
 gatagttctt cttagcagtgc tttttttttt tttttttttt tttttttttt tttttttttt 44220
 ttctgagttt acatcttcc tttttttttt tttttttttt tttttttttt tttttttttt 44280
 tcaggatata gtcatttttgc tttttttttt tttttttttt tttttttttt tttttttttt 44340
 gaggttcaggc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 44400
 aacagagtct tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 44460
 acctctgcct cccgggtttt tttttttttt tttttttttt tttttttttt tttttttttt 44520
 cagggtgtca cccacccatgccc tttttttttt tttttttttt tttttttttt tttttttttt 44580
 atgtttggcca ggtatggtctt gttttttttt tttttttttt tttttttttt tttttttttt 44640
 caagtgttgg gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 44700
 tcctgttggc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 44760
 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 44820
 aacagtggtc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 44880
 taaaatgcct tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 44940
 gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 45000
 actcttgcgtt ccatagacca tttttttttt tttttttttt tttttttttt tttttttttt 45060

ttttgtctt atttcttagt ccactcta at ttagggat gtatcttct gtttgtatt 45240
tttctat tttt aaccatgg ttcattat gcaaataaaa tatgtat tttttagat 45300
aagaatctt ctctgttacc caggctggag tgca gtttgc caatcacagc ttactat 45360
cttgacttcc aggctcacac agttctacct cagccccctt agtagctggg actataa 45420
cacaccacga caccagcta at tttttaat attctgtaga gatggagtct ccctctgtt 45480
ctcaggctgg ttcgaatcc ctgggctcaa gtgatcttcc cacccggcc tcccaaa 45540
gtttctttt gctggattt taggcattgag cccattgtc ccagctgat ggat 45600
aatactaaa ttcagat gttacatgg ttttcagg tttatgcct tcaagcaatg 45660
taaaatctac cacacagttc ttgggatata gatacttga aagttttt gattcttgc 45720
catggtaac aagaataat gatgtat tttaaagtagt cttaaatgtt ttacttaaa 45780
tgtgcitac acaaaaactt ctat ttcag atat ttagtgc tggatattt cagataatcc 45840
agttgaaaat ataatacgtt tttccctat ggttagtacc agtattttt aatatcatt 45900
taaaattat ttatgattt ac ttcttagt tttgtctttt tttttttt tttttttt 45960
ttttagacaa gagtttact ctgttgc caggctggat gcaatggcgc aatcttggct 46020
caccacaacc tctgttccc gggttcaagt gat ttttctg cctcagcc ccaagttggct 46080
gggattacag gcatgagccg ccatgcccag ctaat ttttgc at tttttagt gaga cgggg 46140
ttctccatgt tgatcaggct ggtctcaat ttcgaccc aggtgatctg ctcgcctca 46200
cctcccaaaag tgc tggcatt acaggcgtga gccacccgtc ccagccccctt taatttgc 46260
tgtaaagtt gctactttt tttgtctatg actgaaaatt atgtgattt gttttttt 46320
gaattattt tagaaaattt ttatgatctt ccagaaattt gaggaaatcat at tttgtat 46380
tattggactt aaattttaattt ttggcttctt taattttttt ggacttgc tttttttt 46440
tata gcatttt tggaaat tgg tgaatcaaaa taattttat acatataaaat taggaaattt 46500
tttcaatag gtttcaat tttgttattt atgcattt tttatgttca cttatca 46560
catgtctttt gctccagac taaggaaattt atgtatggg gcttacaaaat gggaggtaaa 46620
taacatttcc tttcccaac taatgtttt attttgcattt tttgttattt ttttagttgg 46680
tattgtctt aaatgcagga tatggaaat ttttgcattt acaattat ttttagtctt ac tcccaat 46740
ttgttatttcc ccaatttactt gtttcaattt gataggctt ctggagttt cctgttagact 46800
gttttcaat tctctgtgag ctttcagttt cttaat aag agtctgctt at tctctaca 46860
cagttgat taaaatttgc taaaatttgc aagatatcca agt gattata gatataa 46920
agttacttta ctgtggttt aatgtat ttttgcactt ac tttactgac tcagggtttt ttcttattt 46980
ataatgaattt catgtttttt agggaaat ttttgcattt gaaatgcagg gatctccaga 47040
aggtatgaag tttagaaat ttttgcattt tataacattt aat tttatggg ctgtat ttttgc 47100
tgggtt ttttgcattt ttttgcattt cagtgccat ttttgcattt catacattt 47160
ggaaacattt ggaatgaaat ttttgcattt aat tttatggg aaatccctt aacccatcc 47220
ttcttatttca aatggaaat ttttgcattt gtttgcattt ttgaaat ttttgcattt 47280
attat ttttgcattt atgtatcat ttttgcattt gcaaggccctt attccatgat tagtctt 47340
ctaaatttac tacttgcata gatatgcata ggcataat ttttgcattt gaaaactac 47400
ttaccttacca caagggaaat ttttgcattt agtataaaa ctcgtgacca caaatgtt 47460
tgcttgcctt at ttttgcattt ttttgcattt atgttctt ttttgcattt 47520
aattacccat ttttgcattt gtttgcattt ttacaatca gtttgcattt ttttgcattt 47580
aatcatctt tccaaagcatt ctgtat gat ttttgcattt ttttgcattt 47640
tcttgcctt aagacaatgc aaaaaggcttcc gcaaggcttcc agtatttctt ttcttgcattt 47700
ttcttgcattt acaatttgc ttttgcattt taatcatgat ttttgcattt 47760
ccctttata ttttgcattt aatggataac ttttgcattt aat tttatgcattt 47820
tatttttgcattt atacaat ttttgcattt aat tttatgcattt 47880
aggctggat ttttgcattt gtttgcattt gtttgcattt cactgcaacc cccgcctccc 47940
aattctccctt ctcgtgacca ctttgcattt gtttgcattt gtttgcattt 48000
ctaaatttgcattt ttttgcattt aatggataac ttttgcattt 48060
ttcttgcattt ttttgcattt gtttgcattt ttttgcattt 48120
ccacttgcattt ctttgcattt ttttgcattt 48180
gactttatgt ttttgcattt gtttgcattt ttttgcattt 48240
aaataactt ttttgcattt gtttgcattt ttttgcattt 48300
ccttgcattt aatggataac ttttgcattt 48360
tactat ttttgcattt 48420
gttttgcattt ttttgcattt 48480
ctcaagttt ttttgcattt 48540
ctggcttattt ttttgcattt 48600
caaagtccctt gtttgcattt 48660
caagagccat ttttgcattt 48720

tagtttatt acattgtaat cacagaatgt tttgttagtac ttgtattttt tgatgtttc 52440
 tttgtggtt aatatgtagt tgtttcatg aattttatgg qcatttggaaa agaagatgca 52500
 ttctgtttc agggataaaa gttaaatgtt tttgtccact tgatctgtct tgggctgaaa 52560
 tcagtgaaatt gaaatctttt actatattgt gtttattttt tctttatttc ccctttttg 52620
 gttctgcaag ttttttctg tacttaacta ttgggtacat aaaaattcaa gttaggttt 52680
 tatttttagtt gtaccctgtt taaatttcag gttttttgt tttgttggtt gagacagagt 52740
 cttgcctctgt ggcccaggct ggagtgcagt ggtgcgatct cgctcaactg caacctctgc 52800
 ctctgggtt caagtgattc tcctgcctca gcctcccaag tagctggat tacaggcatg 52860
 catcaccacg cccgctaat ttttgttattt ttagtagaga cggggttca ccatgttgc 52920
 caggctggc tcgaactcct gacccatga tcctccacc tcggcctccc aaagtgtgg 52980
 gattacaggt gtgagccact gtgcctggac aaatttgcgt tattttacct tgcatgttaac 53040
 ctctgtttaat attgtgaatc ctactcttc tgttcgcttg ctacctttt agtttccca 53100
 ttccctttcc ttcaagctttt ctaaatcaact tgattttaga tgcttttctt cagtgttagt 53160
 taggatttag ttttgcattt agatttggta tcattgtttc ctaataggtg aatttaaccc 53220
 actttcattt actgaaaatg acagatacaa tcttatctat tattatttca tattatgttt 53280
 tctgttttaa atgaatcctt ttttaacct tctgtatag tttaaaaattt ttgggtgtgt 53340
 ttatgtttgt tacat.zattt ttaagggtttt atttatttac ttttcctttt tttttttttt 53400
 ttttttgagt tagagtctca cactcttgc caggctggag tacagtgttg tgatctcggc 53460
 tcactgcaac ctgtgcctcc tgggttcaag cgattcacac acctcagcct cccgagtagc 53520
 tgggattaca gacatatgtc accacatcca gctaattttt gtatttttgg tagagacggg 53580
 gttttgccat gtggccagg atggtctcgat ttccctgaga tcatgtgatc caccgcctc 53640
 agcatcccgaa agtgctggaa ttacggggtt gaggccacggc gcccagcccc ttaatcctac 53700
 atttaaatag ggattcagcc caatcctattt acctgtttcc aggggttctt attaaactct 53760
 tggactttat taagaatagt ttcatggaaa ctatattccc agggaaaact atcccttgc 53820
 atatttggaaa aatatttttc ttttgcctt tatatttga tgacagtggc tagatataaa 53880
 ataggattttt aatactttttt ccctagtgtat ttgtacaca gacctgatataaattttt 53940
 ttgtttgtttt ttatattttt ggagatggag ttcactctg tcgcccaggc tggaatgagt 54000
 gcagtggtac aatcttaggtt cactgcaat tccacccccc gaggtaagt gattctcgc 54060
 ttccgcctcc ttgatttagctg ggattacagg cacatggccac cacacccaggc taattttata 54120
 tttttagaaag agatggaaattt tcaccatgtt agctaggctg gtctcaact tccgacctca 54180
 ggtgatctgc ctccctcgcc tccccaaatg gttgggattt cagggtgttag ccaccgtgcc 54240
 tggccctaaat ttgttttagt agaagtttga aggccagacca attttaagat tccccccctta 54300
 ggtgaatttga ttgttatcag gagaagggtt tcttagatcag cagtctccaa ctttttcac 54360
 accaaggacc agtttcatga aagaçaattt ttccacggat ggggtggccgg gggagatggt 54420
 ttcaaggacaa aactgttctt tattcagatca tcaggcatttta gtaaggagttt gtcacacta 54480
 gatccctcgcc ataccatagg gaggatagg ttaccatag gtttgcgtct cctgtgagac 54540
 tctaattgtt ctgttgatct gagaggaggtt ggtgtcaga tgtaatgtct ccctggagtg 54600
 ccactcacct ctgtgtgtt ggcctggcctt ctgacaggcgat tctggggct 54660
 gcagtgccagg ggtggggacc ctcatctaga tgaccataag atgctttatc aagggtgtatc 54720
 ctgggtttttt atgtttttgtt ttttgaggg ggtctcgac tgcacccag gctacagtgc 54780
 agtggcgca tcatgttca ctgttagcctt gaccccttgg gtcacagtga tcttccacc 54840
 cttagcttctt aatgtatgttgg gaccatgggtt gcacactatc acacctggctt aagtttttg 54900
 ttgtttgttgg ttgagacaa agtctactc tgggtcccaa gtttagagtgc aatggggcaa 54960
 tcttggctca ctgcaacccctc tgcctccctt gttaaagcga ttcttctgccc tcagtctccc 55020
 aagttgccag gattacaggc atgtgccacc aaactcagttt aatttttggta ttttttggtag 55080
 agagacaggg ttccaccatg taagccaggc tgggtggaa ctgtgtgacctt cagggtatct 55140
 gcctgcctcg gcctcccaaa gtgctggat tacgacgtga gaccacacac ctggcttagt 55200
 tttttaattt atttttggta gatgggggtt ttggccatattt tttccaggtt ggtctcaac 55260
 tcctggctca aagcgatctt cccaccccttgg ctcacaaagg tgctgggattt acaggcatga 55320
 gccactatcc cccgccaaga tgcattctgt tgattgtctt acatcagttt ttttctgagt 55380
 cacagtgtgc ctccatccact tgcacaaatca agccctccctt gatttcagga aagttgtctt 55440
 ctattttgttta ttaccctttt tgggtgttctt gttttttttt cttttttagta tacccttac 55500
 cccggatata tttatgttcc cttttttctt tgggttttttgc tttttcttctt gtaattttt 55560
 gcagctttgtt tttttttttt tttccactt gatttttctt acgtttttttt tccatgtccc 55620
 atgtgtcattt gtttccattt aatattttt ggcattttttt tagttaggca ctgacagtaa 55680
 agcagagaac aaaacagaca ataattccctt acctcacgaa atttatttag tgggagaatc 55740
 agacaacaaa caaaatgttag taggcccggaa gtaatgttca agaaaaat aaggccatgt 55800
 aaggaagggtt ggacgagaat ttttttttta gaagggtggt cagaatgggg cttactgaaa 55860
 agtgtatattt gaccaagac ctaaagagat gcacgttattt gggggaaaagc attttaggta 55920
 gaggaaataag tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 55980
 tcataggccctt ctgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt 56040

ttaagtgttt ggacttcaac atatgaatta tgagggaat gcaaaccattc aatcccataa 56100
ctgccatatt ttcttgatt aatttgtca tagtttcat ctgttccatg gtataagtt 56160
tatggcattt ctttatgac atttggttat actcttgc ttctgtttt gtttgtttt 56220
gtttgtttt ttcttgc当地 atcttgc当地 aagacctaac tggtccctc ttgatttattt 56280
gtcatcttgc aactggaggt attcgtcttgc gatcagctat ttacccaaga ataaaattgt 56340
ggaaaggaa ccagaggaggt ggttggggaa ggctgacagc ttgaattttc ccaggttcc 56400
tttgtggcat gaatcgtga gtaagaagca gagtccttgc tatcacagggt ttatgtt 56460
taaattgata aacactgatt catattagaa tcacccggg aatcccttacc catgccaatg 56520
aaatcaaaaat ctgtgagagt ggggcctagg tatatagggtt ttaaagtgc tcagggtatt 56580
ctcatgtata tccaggctag aatigctgtat ttaccccttgc cttttagcttgc tccaagatca 56640
actgatgctt ggctacatgca accaaaattt cacttccgccc ttaccatact taaacagcc 56700
gtctgttgc aaaaatggca ggtttaggtt ttcacatttt ccttaatatg tcccaccc 56760
tcccatagggc cactcatatt tcctgacttgc gtcataccat gcaagggttgc ttgggtttt 56820
tttaggtca ctcttttagt cgagctatgacttgc actgtaccta ctctggccca cagaggaggt 56880
atctgtatgc cttagcttagt gatggttctat ttcttttga aatttttattt gtgaattat 56940
aatatagaaaa atgcataaaaa tgtaaataaa catccatgtacttgc aatattggc 57000
acagaatgtt taccaggaca cccaaaagcctt ttttcatgtcc gtttcttcagg cacaatctg 57060
tttctccctc tgtaaagtaa ccactatcctt gacgttagctt gtaatcaattt cttttccccc 57120
tcattcttc cattttcagg gtaatggatgtt tttcttgc tctcaatgtt ttttcttgc 57180
tttcagaaaaa gagagaaaca aaaaatgcctt tattcttgc tctataatgc gaagcagagg 57240
actattggata ttgccaattt aagttttgg ttttttttttgg gttttttttttaa aacagatgaa 57300
gtcagagatc attatagcttgc atgcctactt gactggcagg tcatgtgc gtaacccttgc 57360
acaaaacttgc agccgggtt gattttatgtt tatttttttttgc tctgttttttgc 57420
attttttttttgc tccatttctc ttccaaacaaat ttttttttttgc ttttttttttgc 57480
aataccaaaca gtgttacatc taatcactat ttttttttttgc ttttttttttgc 57540
taagtttaattt aacttattttt ttttttttttgc ttttttttttgc 57600
aatacagatc atgtcaccac tccagataga aaggtcatttttgc tctgttttttgc 57660
aggtaaggat ttttttttttgc ttggagaaaat ttttttttttgc ttttttttttgc 57720
cttgctacaa gtttacactgacttgc acaatttttttgc ttttttttttgc 57780
taattccaga aggatttgc ttataatgaa taaaatgttgc ctataataatgacttgc 57840
tcaagttagtgc gtacatccgtt gtttgc ttttttttttgc 57900
ctaaacacgc ttaggttgc ttatttttttgc ttttttttttgc 57960
gctaatgttgc gtttttttttgc ttttttttttgc 58020
atttcagaag tacccttgc cccttgc ttttttttttgc 58080
ttcttttccca aagacccatc tacctgttgc ttttttttttgc 58140
cacaaggcat ttttttttgc ttttttttttgc 58200
accaacatgttgc ttttttttttgc 58260
gaggacaggtt gatctgtatcc accaaatgttgc aactcttgc actctactgc 58320
gttggatataa ttttttttttgc ttttttttttgc 58380
ttcatttttttgc ttttttttttgc 58440
gtcagtttttgc ttttttttttgc 58500
gatttgccttcc ttttttttttgc 58560
atccccatgttgc aagatatttttgc ttttttttttgc 58620
tcatttttttgc ttttttttttgc 58680
tcatttttttgc ttttttttttgc 58740
tcttttttttgc ttttttttttgc 58800
atcttccatgttgc gaagacatgttgc ttttttttttgc 58860
ttcccatgttgc ttttttttttgc 58920
gggcttaggtt ttttttttttgc 58980
ttatagtttttgc ttttttttttgc 59040
atataacatgttgc ttttttttttgc 59100
cagacccttgc ttttttttttgc 59160
tgattataac ttttttttttgc 59220
acagatgttgc ggtatgttgc ttttttttttgc 59280
tttctccatgttgc ttttttttttgc 59340
acagcccttgc ttttttttttgc 59400
tccttaatgttgc ttttttttttgc 59460
actaaacatttgc ttttttttttgc 59520
ttatgttgc ttttttttttgc 59580
agatttttttgc ttttttttttgc 59640
tatcgttgc ttttttttttgc 59700

gacattcaat tttaggggaa gccagaaaaa tatttagatt agctgactta attactaaat 70740
gtttaaagct gtttaccat agtaatttc cttccatttc taaaagaaaat attaccaagt 70800
agttgaaata tcagcaatta gtatcaattt gaatataacc tacacattca aaatatctgc 70860
tagcaaaaata aagactaata tagctatttt agatgaacaa cacttaaaaat acaagtaaat 70920
ggctgatgtt gccacttcca tgactaatga aaacttcaat ttcttcattt actttaaata 70980
gatctctta acttttatac tcaatagata ttcaaatata accttgcac attttaccaa 71040
gagcatgtt acatggctca attctagaat tttagtctt ttgcttcaa aatattttt 71100
caaaaatata ttaattttc ctttgcattt ggaaagtgtt ttgtgataac atgacttgc 71160
cttgcgttgc ttgagagcac cttgcaagga agtaaaaaca tatctgttc caagtaactt 71220
ttccaagtca catagcaaat aggtgcaag atacttcccc tcaaatggat ttctcgtact 71280
attgctgaaa taacatggtt tctcatctaa ttcatgtca tgcaaagaaa aaattcaggaa 71340
ataaaaaattt aggctaatacg tctctcataat tggttaattt ctaggggccc tcattccaga 71400
tagagatcta aatgggaaa aagaatatica gtgaatgaaa ataaacaatg agtaatcagt 71460
aatgatgtc ctcattctca ggagggtcaa atagcaattc aataaaaaat tccctattat 71520
aaggaaatga agaattgtaa ttccctcagct attaaatatt actaaatatt tagtaatgat 71580
aataatactt cattccctt ataacaggaa aaagcagtgg tagagactg gacagaattt 71640
aggttttatt cctcaccgtt gcaataacta cctgtatct tggcaagtc tttggatctc 71700
tctaaatcc tattttctcc tatgtctaaa agaagagggg caggggacgg gtggactaac 71760
tcttaagatg cctgtatcc taaaacttca atacaatata accccaaaat aaattttaaag 71820
cgtatgtct tgcttttttgg atttggtaat gaaatttctg taataatacc caagtaaggaa 71880
aataacttca taaaacccgtt aataacttca agagctaaca ccttagtctt atggtacaat 71940
aattatctaa taaaatgtc agatagttt caaaaacaaa gttactggta cattttggatt 72000
ctagaacaac tcagccacat taaacatttgc tataaaaacag ctaatattttt ctttgaataa 72060
tttccagctt tttgaacaaa aacagaagtg ggcactgaac agctttaaac aaaaatgaaa 72120
tcatgtttcc ctttatttca ggaaaaagag gttatagtac ttactcataa attttcagg 72180
gctgacaact ccagtctctg ttagctgacc caataccctt aaaaaaccta gttttgaaaa 72240
acagatttca aattacgaga atagcaaaag gaagacagta tgaaaataag caataattttt 72300
agcagggtggg cttacaggca attttttt cagaacttcc tataatctt taatttattt 72360
aataaaatgtt accctatttct tctataatca ctacatataa caaaaataac aggttttacc 72420
agtgcgttctg cctgcataag atgtttttaaa tagtgcgtac cttaatatcc agtattttata 72480
gaccgcggaaat atacatttctt caatgttattt tattttacat taagttcaat gcaaaagggt 72540
ccagattttc ccaaataatgtt gattttgggg tacttaaagg tgcaacatgg ctaataacaa 72600
tattcgtaaa ttaaagtata agtaacactg ttgagattac actttttttt attgttaattt 72660
ctagtgaatt tcatttagtgc taccggaaat tgatgtgaac agtgcacccgtt gaattttgaa 72720
aatcttaact ttcctacact caataatttgc gccaaaattt ggccttcag gctgtctagc 72780
aaagagataa ttgtgaaaag gacaaatgtt acttttttattt accaaatgtt aaggaagttt 72840
acttgggaaat tttagatgtt aaaaagaaaa taactgtata aaaaacccctt caattttatcc 72900
aaggaaaattt atttccaccc tcaattttttca accagtttctt taagatccct ctttatgtgt 72960
catcatacat gataattttt tttttgttta tgagaaatct tttttggctta attaggaagg 73020
agtgcgttgc tattttaaat tttcacatgtt atattttggc tttagccatgtt 73080
cacacactca ttggattttga gtgtccatca cttttttttttaaactttaat aaaaaatata 73140
gtccaaaatgtaaaat tttttttttttaaactttaat tttttttttttaaactttaat aaaaaatgaa 73200
aggcttaactt tttttttttttaaactttaat cttttttttttaaactttaat aaaaaatgaa 73260
aaggaggccctt aaaaaccaagg cttctccagg atgtgttggg gaaatggctg gaaaaatgt 73320
agctgttatttgc ttagtgcgttccacttccattt gatatttttgc tttttttttttaaactttaat aaaaaatgaa 73380
atcaggtttgc tttttttttttaaactttaat tttttttttttaaactttaat aaaaaatgaa 73440
tttaatggatgtt gaaaatttttgc tttttttttttaaactttaat aaaaaatgaa 73500
attttttttttaaactttaat tttttttttttaaactttaat aaaaaatgaa 73560
ccacacactca tttttttttttaaactttaat aaaaaatgaa 73620
actaaatttttgc tttttttttttaaactttaat aaaaaatgaa 73680
ttttttttttaaactttaat tttttttttttaaactttaat aaaaaatgaa 73740
caacttccatca tttttttttttaaactttaat aaaaaatgaa 73800
gggattttttttaaactttaat tttttttttttaaactttaat aaaaaatgaa 73860
gatttgcggcc tttttttttttaaactttaat aaaaaatgaa 73920
cgccctccca aagtgcgttggg attacaggcg tgagccactg cggccggctt gatcagggtt 73980
ttttttttttaaactttaat tttttttttttaaactttaat aaaaaatgaa 74040
gctttttttttaaactttaat tttttttttttaaactttaat aaaaaatgaa 74100
ttcaacagggaaat tttttttttttaaactttaat aaaaaatgaa 74160
ttttttttttaaactttaat tttttttttttaaactttaat aaaaaatgaa 74220
ttttttttttaaactttaat tttttttttttaaactttaat aaaaaatgaa 74280
atggagaaat ccccatctt tttttttttttaaactttaat aaaaaatgaa 74340

cgtgtaaaact tattttccat ctatgatgaa aagttaagaa tattctgcc tacagcatac 74400
tgtgacttat gaaataagga acaattgggg gtaggttat tggcaaatt ggtctctat 74460
taaaatatgg tttcttaac tggatataga aataagttgg ggactgctt tttggatct 74520
ctaatccaaa aatccaaaac actccaaaat tttgaaactt tattgagggg ccaacatgat 74580
tgccacaagt gaaaaattcc acatctggta taatggacaa aaactttcc atgcacaaaa 74640
ttatTTaaa atattgggtt aaaaatatttgg ggcattctgg ataagatgta tatgaaacac 74700
aaatggaatt ttgactttgg gtcccatccc caagatattc ttcatatgt atattgaaaa 74760
tattcccaa atctggaaat atatccatt tttgaaatac attatgtgtt tccaaaacct 74820
tgaacattt tttggccca aacttttggta taaggaatac tcaactttta atttggggg 74880
aagctttgtt tttaaacat tttgggctg gaaaaagcc ccctggcccc aaatttatcc 74940
ctttaatga attggttat cc 74962